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This thesis focuses on developing SF5-substituted biologically active compounds or building blocks, 
often using microwave synthesis. SF5 is a fluorine containing functional group that has only recently 
been explored in medicinal chemistry due to lack of commercially available building blocks. 
Exploring its biological activities as well as expanding the repertoire of SF5 chemistry appeared 
necessary.  
 
Chapter 2 explores the scope of SF5 in medicinal chemistry by incorporating it into known drugs, 
teriflunomide and leflunomide, HDHODH inhibitors. Affinity of the SF5 analogues towards 
HDHODH will be discussed and compared with the parent drugs’ affinity. In addition their potential 
as SARS-CoV-2 antivirals will be presented.  
 
Chapter 3 contains a brief description of the development of a small library consisting of 3 and 4-
SF5-substituted phenyl rings that are bonded to heterocycles including morpholine, piperidine, 
piperazine, and pyridine via an amide bond. Small libraries of novel compounds consisting of SF5, 
which is a bioisostere of the familiar trifluoromethyl group (CF3) and halogens, have been developed 
to improve commercial availability of SF5-containing building blocks. SF5 is often compared to the 
trifluoromethyl group and even dubbed as a ‘super trifluoromethyl group’ due to its superior 
lipophilicity, bulkiness, electronegativity, electron withdrawing properties, etc. A few compounds 
from this library have been contributed to the COVID Moonshot program, which is an initiative to 
accelerate the development of a COVID antiviral. 
 
Chapter 4 describes the synthesis of a series of SF5 substituted oxindoles. Included in the series are 
two SF5 cognates of Semaxanib. Using molecular modelling and a radioactive kinase assay we 
compared activities of Semaxanib and its SF5 counterparts in the VEGFR2 binding site. 
 
Chapter 5 explores SF5 as a bioisostere in 1,4 diazepines. We synthesised and compared bioisoteres 
of SF5- and the known Cl-analogues of diazepam and nordiazepam. 
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Chapter 1.0 Introduction 
1.1 LabFact 
 
LabFact is a project that involves 6 institutes within the France (Channel) England (FCE) region, 
(Universities of Sussex, Southampton, Rouen, Caen, ENSICAEN and CNRS) and an industrial 
partner (Pareon Chemicals) that brings together expertise in environmentally friendly chemistry. 
LabFact aims to bridge the gap between laboratories and factories by training small and medium 
enterprises in the Channel region to use environmentally friendly techniques to develop fine 
chemicals. A major goal of LabFact is to produce 1000 novel scaffolds between the institutes using 
non-conventional techniques such as flow, microwave, mechanochemistry, etc., to reduce the amount 
of waste generated. All novel scaffolds are acquired by the industry partner, Pareon Chemicals, to be 
commercialised. These scaffolds are hoped to act as building blocks or biologically active molecules 
and accelerate the production of next generation medicines and agrochemicals.1,2 
This thesis commenced under project LabFact and focused on developing pentafluorosulfanyl (SF5) 
containing biologically active compounds and building blocks while using microwave and 
mechanochemistry as the environmentally friendly alternatives whenever possible. 
 
1.2 Fluorination in medicinal chemistry 
Traditional medicinal chemistry depended on natural products or related derivatives to develop 
drugs. Therefore, fluorinated compounds in medicinal chemistry remained under-developed until the 
1950s as organofluorine compounds are almost absent in natural compounds.3,4 An example of 
organofluorine in natural compounds is Fluoroacetate (FA). FA refers to a series of compounds with 
the general formula CH2FCOOR. It is found in a range of plant species such as Dichapetalum, 
Gastrolobium, Oxylobium, Acacia, and Palicourea, and are highly toxic towards humans and other 
mammals upon ingestion. 5 
In 1954, initial work carried out by Fried and Sabo on fluorinated cortisone and hydrocortisone 
derivatives revealed enhancement of biological property of the parent drug following fluorination.6 
Since the synthesis and evaluation of the antimetabolite drug, 5-fluorouracil in 19577, fluorine 
substitution became a common practice in contemporary medicinal chemistry to improve metabolic 
stability, bioavailability, enable antimetabolite use and for protein-ligand interactions.4 Fluorine can 
provide unique protein-ligand interactions as the highly electronegative fluorine atom allows C-F 
bonds to form dipolar and multipolar interactions with protein backbone or side-chain amide groups.3 
One of the major effects of fluorination is the modulation of acidity and basicity of a parent 
compound leading to a strong influence on binding affinity, pharmacokinetic properties, and 
bioavailability of a given drug candidate.8 Introducing a fluorine or a fluorine-containing compound 
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such as trifluoromethyl group (CF3), trifluoromethoxy group (OCF3) or trifluoromethylthio group 
(SCF3) can modulate the lipophilicity of a compound.9,10 Lipophilic compounds are more susceptible 
to oxidative metabolic degradation by the enzyme cytochrome P450 monooxygenase. Introducing a 
fluorine atom can slow down drug metabolism by altering the rate, route or extent of metabolism. 
Moreover, a C-F bond is less susceptible to attack by cytochrome P450 due to the enhanced polarity. 
Replacing a hydrogen for fluorine brings only minor steric alterations.11  
New fluorinating reagents and fluorination processes have increased the range of synthetic 
fluorinated building blocks. The success of fluorine substitution in drug design is portrayed by the 
production of some of the key drugs available on the market.12 
Approximately one third of the top-performing drugs in the market contain fluorine atoms in their 
structure. For example, Lipitor (Atorvastatin), used for the treatment of high cholesterol and 
triglyceride levels and prevention of heart attacks and strokes was registered as the best-selling drug 
globally in 2008, Lansoprazole, a gastric acid secretion regulating drug, and Prozac, an 
antidepressant, are a few of the drugs that make the list of top-selling fluorinated drugs (Figure 1.1).11  
 
 
Figure 1.1 Top selling fluorinated drugs 
 
The incorporation of fluorine into organic molecules is commonly done by direct fluorination, using 
fluorinating reagents or by adding fluorinated functional groups on both aromatic rings and aliphatic 
chains. The latter is generally achieved using a CF3 group and it is one of the most accustomed 
fluorine moieties to be explored in medicinal chemistry.13 Selective incorporation of a CF3 group in 
a compound of pharmacological relevance usually results in significant enhancement of its 
lipophilicity, binding selectivity, and metabolic stability.14  
As the role of fluorine is very valuable in medicinal chemistry, the search for new fluorine containing 
functional groups is all the more important.  
 
In recent years, agrochemical, materials science and pharmaceutical industries have been 
investigating the potential benefits of highly fluorinated, yet rigid pentafluorosulfanyl (SF5) 





























1.3 The pentafluorosulfanyl (SF5) group 
Synthesis of aryl pentafluorosulfanyl compounds and their unique physiochemical properties were 
first reported in 1960 by W.A. Sheppard.15 The synthesis required hazardous reagents and specialised 
equipment such as Teflon containers. Hence, SF5 chemistry was not explored adequately until after 
40 years of its discovery. 
Sheppard reported the SF5 group to be highly electronegative as well as meta directing towards 
electrophilic aromatic substitutions. By virtue of having two extra fluorine atoms, larger size, higher 
hydrolytic stability, enhanced lipophilicity and electronegativity, the SF5 group is superior to the CF3 
group. The electronegativity of SF5 is estimated to be approximately 3.65, versus 3.36 for CF3. The 
Hammett substituent constants (σp and σm, Table 1.1) are also a reflection of the SF5 moiety’s 
enhanced electronegativity.16 The Hammett substituent constant, σ, represents the relative strength 
of a substituted benzoic acid compared to a non-substituted benzoic acid, by measuring the rate at 
which they dissociate in water at 25 °C. σ is therefore dependant on the nature and position of the 
substituent. σ value of benzoic acid is 0. More electron withdrawing a substituent is, the greater the 
σ value. Electron donating groups give negative σ values meaning they are acid weakening. σm and 
σp represent resonance effect of the substituent at meta and para positions while σi represents the 
inductive effect. Using the Hammett free-energy relationship, the resonance and inductive 
parameters of SF5 substituted benzoic acids were calculated and compared with the parameters of 
CF3 group by Sheppard (Table 1.1).17 
 
Hammett parameters SF5 CF3 
σI 0.55 0.39 
σR 0.11 0.12 
σp 0.68 0.53 
σm 0.61 0.41 
Table 1.1: Comparison of σ-parameters of SF5 and CF3 groups 
The data demonstrate the strong inductive effect exerted by SF5 (σI = 0.55) in comparison to CF3 (σI 
= 0.39) as well as a similar resonance influence of SF5 (σR = 0.11) and CF3 (σR = 0.12) groups. 
Scheme 1.1 shows that resonance effects are possible with SF5 and CF3 groups due to negative 
hyperconjugation and their ability to adopt “no-bond resonance” forms.12 The scheme also portrays 
the meta directing characteristic of CF3 and SF5 groups, to electrophilic aromatic substitutions. 





Scheme 1.1: “No-bond” resonance in a) CF3 & b) SF5-substituted arenes 
 
SF5’s peculiar and superior physiochemical properties, in comparison to the CF3 group, were also 
reported by Sheppard in a separate paper.18 Upon analysing (pentafluoro‐l6‐sulfanyl)benzene, 
Sheppard reported it to be a colourless liquid with a pleasant aromatic odour, unlike other aromatic 
sulfur compounds. He stated that the compound is chemically and thermally stable compared to 
trifluoromethyl benzene. When refluxed in a solution of sodium hydroxide in aqueous ethanol, 
(pentafluoro‐l6‐sulfanyl)benzene was recovered unchanged. It was also inert to concentrated sulfuric 
acid at moderate temperature but was hydrolysed to phenylsulfonyl fluoride when heated at 100 °C 
in 100% sulfuric acid; whereas, trifluoromethylbenzene degrades at 90 °C under the same conditions. 
Only a small amount of degradation occurs to the (pentafluoro‐l6‐sulfanyl)benzene, when heated at 
400 °C for several hours in a sealed glass tube (Scheme 1.2).18 Catalytic hydrogenation of meta- and 
para- nitrophenyl(pentafluorosulfanyl)benzene afforded the corresponding 
aminophenyl(pentafluorosulfanyl)benzene in over 90% yield (Scheme 1.3). This is a further 
demonstration of the stability of the SF5 group. Pentafluorosulfanyl groups are however, sensitive 
towards strong Lewis acids, alkali metals and organolithiums.18 
 
 
































Scheme 1.3: Hydrogenation of meta- and para- nitrophenyl(pentafluorosulfanyl)benzene 
Infrared examination of SF5-arenes showed very strong absorption in the 820 to 880 cm-1 region.20 
However, many substituted aromatic compounds possess strong absorption in this region due to C-
H deformation.  
The water solubilities of SF5 and CF3 compounds were analysed by Jackson and Mabury.15 Analyses 
were performed on SF5 and CF3 substituted meta- and p-anilines, p-benzoic acids, and p-phenols at 
24 ºC. Due to their bulky nature, SF5 substituted compounds were hypothesised to be less water 
soluble than their CF3 substituted analogues. Although, SF5 compounds are predicted to be less 
favourable to dissolve in water due to the larger entropic costs, C-F bonds are shorter and less 
polarizable than SF5 and so enthalpic costs maybe low for SF5 compounds. The water solubility (Sw) 
values of SF5 compounds were much lower than their CF3 counterparts which proves the concept 
that steric effects play a bigger role than polarizability in determining water solubility. 
Fluorine (19F) NMR of SF5 is highly characteristic (Figure 1.2).16 The chemical shifts of SF5-
compounds appear in the positive region indicating downfield shifts compared to the CF3 group’s 
chemical shifts which appear in the negative region (Figure 1.3).17 SF5 fluorine atoms appear 
typically in the range of d = 55 – 90 ppm while the CF3 fluorine atoms appear in the range of d = -
60 to -80 ppm. As the SF5 group contains fluorine atoms in two different magnetic environments, 
one axial fluorine and four equatorial fluorine atoms, it is represented by a doublet (d) integrating to 
four fluorine atoms and a pentet/quintet (p) integrating to one fluorine atom. The pentet is usually 
observed downfield to the doublet in SF5-arenes. The two-bond, F-F coupling constant in the SF5 










   
Figure 1.2: 19F NMR of SF5-substituted arene16 
 
 
Figure 1.3: 19F NMR of CF3-substituted arene 
The 13C NMR spectra of SF5-arenes are distinguishable like the 13C NMR of CF3-arenes. Figure 1.4 
shows an example of the 13C carbon of an SF5-arene (structure shown in the figure). The carbon 
bearing the SF5 group appears as a pentet (p) between d = 161.3 and 162.2 ppm with a coupling 
constant, 2JFC = 17.7 Hz and the two allylic carbons appear as a multiplet between d = 130.6 and 
134.9 ppm with a coupling constant 3JFC = 4.6 Hz. The appearance of these peaks can differ 
depending on the concentration of the NMR sample. Concentrated samples often show these peaks 
as pentets. Unlike the carbon signals stemmed from the CF3 group, SF5 derived carbon signals are 
easy to spot. 13C chemical shifts of CF3 groups appear in the range, d = 107- 128 ppm. The 
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trifluoromethyl carbon as well as other neighbouring carbons in vicinity are all split into quartets by 
the fluorine atoms. 1JFC splits in the range of 275 – 285 Hz, 2JFC usually split in the range of 2JFC = 
25 – 35 Hz, while three bond (3JFC) couplings are observed with values in the range of 2 – 3 Hz.18 A 
combination of weak signal and multiple couplings make these carbon signals difficult to be 
identified. The quartets with large coupling constants appear as individual singlets whereas the 
quartets that splits in the J = 2 – 3 Hz range can be very small and difficult to spot.18  
 
 
Figure 1.4: 13C NMR of an SF5-arene16 
Other properties that outline the superiority of SF5 in comparison to CF3 are enhanced lipophilicity 
demonstrated by Hansch hydrophobicity constants, π = 1.51 for SF5 and π = 1.09 for CF3.19 SF5 group 
has an octahedral geometry while CF3 has a tetrahedral geometry (Figure 1.5). The 4 equatorial 
fluorine atoms and 1 axial fluorine result in a square pyramidal array of fluorine atoms. This in effect 
achieves a reduced barrier of rotation giving SF5 the ability to optimize receptor interactions 
effectively. Steric hindrance of SF5 can be compared and contrasted with both tert-butyl group and 
the CF3 group. A tert-butyl group is often substituted in drugs due to its large volume, providing 
steric hindrance although, it is prone to oxidative metabolism.20 SF5 has a slightly smaller volume 






Figure 1.5 SF5 and CF3 geometry 
All these superior characteristics earned SF5 its nickname, “super-trifluoromethyl group”. Their 
thermal and chemical stability along with high electronegativity and remarkable lipophilicity make 
them an attractive moiety for drug design and development.22 Other than in medicinal chemistry, SF5 
is of interest in the agrochemical industry and new materials chemistry. 
 
1.4 Synthesis of aryl pentafluorosulfanyls 
As mentioned before, large scale synthesis of aryl-SF5 compounds requires dangerous and expensive 
reagents. Consequently, there is a lack of commercially available pentafluorosulfanyl benzenes that 
can be used as building blocks while available SF5-arenes are high-priced. The initial synthesis of 
pentafluorosulfanyl benzenes were accomplished by reacting aryl disulfides or arylsulfur trifluorides 
with silver fluoride at 120 ºC for several hours in a copper autoclave to afford meta- and para-
nitrophenyl(pentafluorosulfanyl)benzene in moderate yields (Scheme 1.4). This procedure was 




Scheme 1.4: First synthesis of arylsulfur pentafluorides 
 
In 1997, a reliable synthetic protocol was developed by F2 Chemicals Ltd leading to the commercial 
development of p- and m-nitrophenyl(pentafluorosulfanyl)benzenes. Direct fluorination of 
bis(nitrophenyl)disulfides enabled multigram production of 
nitrophenyl(pentafluorosulfanyl)benzenes in moderate yields (Scheme 1.5). This method can only be 
employed to make pentafluorosulfanyl benzenes with an electron withdrawing substituent.23 Strongly 
electron withdrawing groups on the aromatic ring are necessary to avoid ring fluorination. Attempted 
synthesis of o-nitrophenyl(pentafluorosulfanyl)benzene using this method failed due to the formation 
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specialised equipment like Teflon is required as molecular fluorine reacts with glass. Most other 
commercially available  SF5-aromatics and heteroaromatics are derived from 
nitro(pentafluorosulfanyl)benzenes.25,26 
.  
Scheme 1.5: Industrial synthesis of nitrophenyl(pentafluorosulfanyl)benzenes 
Not long after Sheppard’s and F2 Chemicals Ltd’s publications, Janzen et al. introduced a method 
which replaced silver (II) fluoride (AgF2) with Xenon difluoride (XeF2) and tetraethyl ammonium 
chloride to convert phenyl disulfides to ArSF5 via ArSF3 as an intermediate.27 Limitations of this 
protocol include poor yields (ca. 25%) as well as the use of an expensive reagent, XeF2. 
An alternative route to aromatic SF5 compounds was via cycloaddition of 
pentafluorosulfanylacetylene to butadiene to form an intermediate (1.1) that can be aromatized under 
extreme temperatures to afford the desired product (Scheme 1.6).28 
 
Scheme 1.6: SF5-arene via cycloaddition 
In 2008, Umemoto et al. published and patented a new synthetic pathway to SF5-arenes.29 The 
method converts thiols to SF5 via a tetrafluoro-λ6-sulfanyl chloride (–SF4Cl) intermediate (Scheme 
1.7). Initially, an aromatic thiol (ArSH) is treated with potassium fluoride (KF) and chlorine gas to 
give ArSF4Cl. In the next step, ArSF4Cl undergoes Cl-F exchange in the presence of ZnF2 to yield 
ArSF5. 
 




























Using this method, Umemoto was successful in producing non-substituted and substituted SF5-
arenes. Few examples include F at para and ortho positions, Br at para and meta positions, Cl at 
para position, CH3 at para position and NO2 at para position in excellent yields. For example, the p-
nitro(pentafluorosulfanyl)benzene was synthesised at 89% yield. Numerous SF5-containing building 
blocks have been developed and commercialised since this method was published. A downside of 
this route is the use of elemental chlorine gas that is hazardous. Although, recent developments in 
ArSF5 synthesis revealed Cl2 gas can be substituted with trichloroisocyanuric acid.30,31 
 
Kanishchev and Dolbier Jr. took advantage of Umemoto’s method to synthesise a series of 2-SF5-
pyridine derivatives. Treating 2,2’-dipyridyl disulfide which is a relatively inexpensive and readily 
available starting material, in the same manner as the thiol in Scheme 1.7, they obtained 2-
pyridylsulfur chlorotetrafluoride (Scheme 1.8).25 
 
 
Scheme 1.8:Synthesis of 2-pyridylsulfur chlorotetrafluoride 
Product 1h was reported to be a viscous liquid that is extremely sensitive to moisture, fuming in the 
presence of air and extremely reactive with water. It also reacts with glass particularly at high 
temperatures. 
1h was fluorinated using 2 equivalence of silver (I) fluoride (AgF) without any solvent under inert 




Scheme 1.9 Synthesis of 2-SF5-pyridine 
Functionalisation of pentafluorosulfanyl arenes can be achieved by SNAr reactions where the arene 
nucleus is activated by the SF5 group. For example, m- and p-nitro-(pentafluorosulfanyl)benzenes 
when treated with alkoxides generate a range of 3- and 4-(pentafluorosulfanyl) benzenes in a single 
step reaction. Scheme 1.10 shows p-nitro-(pentafluorosulfanyl)benzene reacting with alkoxides at 

























Scheme 1.10: SNAr reaction of SF5 arenes 
As the synthesis of aryl-SF5 compounds progresses mostly via aryl-SF4Cl intermediates, Togni et al. 
recently published a gas-free method towards their synthesis. Trichloroisocyanuric acid (TCICA), 
which is an inexpensive, and bench-stable solid was reacted with potassium fluoride as well as 
catalytic amount of acid under inert conditions to form the desired intermediates (eg: Scheme 1.11).31 
 
 
Scheme 1.11: Aryl-SF4Cl synthesis 
On account of these constructive developments, diverse SF5-containing building blocks are 
becoming more and more commercialised. Tokyo Chemical Industry, SpiroChem, and Fluorochem 
Ltd are a few providers of SF5-containing building blocks. Increased availability of SF5-compounds 
has seen a surge in research involving SF5-chemistry.32  
 
1.5 SF5 as a bioisosteric replacement  
1.5.1 Replacing the CF3 group 
The unique properties of SF5 make it an attractive substituent in medicinal chemistry. Recent years 
have seen applications of pentafluorosulfanylated compounds in known drugs with the aim of 
studying the effect of SF5 on drug activity. Such studies commonly substitute antecedent functional 
groups like CF3, NO2 or halogen atoms with SF5 as a bioisostere. 
 
Mefloquine (Figure 1.6) is an active antimalarial drug as well as a prophylaxis with long half-life (2-
3 weeks). It is associated with serious side effects including dizziness, diarrhoea, anxiety, depression, 
and central nervous system problems, among others.33 Mefloquine’s ability to inhibit P-glycoprotein 
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Figure 1.6: Antimalarial drug, mefloquine 
With the aim of reducing Mefloquine’s drawbacks, Wipf and co-workers re-engineered its structure 
by replacing CF3 groups with SF5 to “probe slight perturbations of the electron density” of the 
molecule.34 Their new compound was hoped to exhibit fewer neurological effects while retaining its 
antimalarial efficacy.34 
Initially Wipf et al. were unable to substitute position 8 of mefloquine with SF5, as the building block 
required (ortho-SF5 aniline) was not readily accessible. Functionalising positions 6 and 7 with SF5 
was accomplished by using meta and para-SF5 anilines as starting materials.  
SF5 and CF3 mefloquine analogues were synthesised and evaluated for their antimalarial activity 
(Figure 1.7 & Scheme 1.12). Compounds 1.2(a-d) were compared to mefloquine against four drug 
resistant strains of the parasite Plasmodium falciparum (Table 1.2). SF5 substituted compounds 1.2a 
and 1.2c exhibited similar inhibitory activities to compounds 1.2b, 1.2d and mefloquine. Compound 
1.2a was however slightly more active than its CF3 congener, 1.2b, against all strains. 
  
Figure 1.7: SF5 and CF3 analogues of Mefloquine 
Analogue Pf W2 Pf D6 Pf C235 Pf C2A 
Mefloquine 2.5 8.0 18 22 
1.2a 3.3 9.2 9.8 14 
1.2b 5.0 17 53 21 
1.2c 3.3 12 10 16 
1.2d 3.0 12 30 13 














a) R1= SF5; R2 = H
b) R1 = CF3; R2 = H
c) R1 = H; R2 = SF5




Scheme 1.12: SF5-Mefloquine synthesis 
A year later, in 2010, Wipf and co-workers published the preparation of novel ortho-SF5 aniline from 
commercially available 3-SF5 phenol (1.3, Scheme 1.13). 35 Compound 1.3 led to the synthesis of 
SF5-mefloquine where position 8 is substituted with the SF5 group. Although, its activity with respect 
to Mefloquine was not reported. 
 
 
Scheme 1.13: Synthesis of ortho-SF5 aniline 
Fluoxetine or Prozac (Figure 1.8) was the first selective serotonin reuptake inhibitor (SSRI) to be 






























1.2a; 6-SF5; a = HCl, 42%






























inhibition of 5-HT2c receptors results in activation syndrome and weight loss. Welch and Lim were 




Figure 1.8: Fluoxetine or Prozac 
  
Scheme 1.14: Synthesis of SF5-Prozac 
 
 The pentafluorosulfanyl analogue selectively inhibited binding of the 5-HT receptors. At 10 µM 
concentration, 97.3% of 5-HT2a, 75.8% of 5-HT2c and 77.8% of 5-HT1e were inhibited. However, in 
contrast to the Mefloquine study, this example shows a reduction in affinity for 5-HT receptors by 
compound 1.4d compared to Prozac.36  
 
1.5.2 Replacing the nitro group 
The nitro group which is significantly smaller in size in relation to the SF5 group has an 
electronegativity of 3.4 and a similar electronic effect. Plenty of examples on the bioisosteric 
replacement of CF3 with SF5 can be found in the literature. However, there are only a handful 
examples studying the replacement of the NO2 group with SF5.  
Wipf and colleagues investigated the effect of SF5-indole inhibitors on the AAA ATPase p97 while 
comparing it to its nitro analogue. p97 is an ATPase of the AAA family (ATPases associated with 
diverse cellular activities) which is involved in homotopic membrane fusion. The ATPase (AAA) 
p97 is essential to regulate processes including endoplasmic reticulum associated degradation, 
mitochondrial associated degradation, autophagy, etc.37 Interchanging the C5 nitro on the indole with 
SF5 reduced its potency (Figure 1.9). Even though, SF5 and NO2 are similar electronically, SF5’s 





























Figure 1.9: SF5 and NO2  AAA ATPase p97 inhibitors 
1.5.3 Replacing halogens 
Halogens have been used commonly in drug design to block metabolic sites, alter electronic and 
lipophilic properties as well as steric interactions. The SF5 group possesses a bulky steric volume 
and demonstrates greater hydrophobicity and electronegativity. Due to these differences, SF5 is 
regarded as a viable alternative to halogens. Much like the  nitro group, only a few comparisons 
between halogens and SF5 have been reported. 
The parasite Plasmodium falciparum possess Plasmodium falciparum dihydroorotate dehydrogenase 
(PfDHODH) enzyme in its de novo pyrimidine biosynthetic pathway. Inhibition of PfDHODH 
blocks the parasite’s pyrimidine nucleotide synthesis. Hence, PfDHODH is an ideal target for 
antimalarial treatment. A lead-optimisation study by Coteron et al, on triazolopyrimide based SF5 
CF3, and Cl derivatives as PfDHODH inhibitors demonstrate similar potency for all the analogues 
(Figure 1.10).39  
 
 
Figure 1.10: SF5, CF3, & Cl based PfDHODH inhibitors 
More than 100 triazolopyrimide analogues were evaluated and the SF5 derivative (1.6b) was chosen 
to be carried forward into clinical studies because of its oral bioavailability, metabolic stability and 
in vivo efficacy. 
 








a) R = NO2; IC50 = 0.05 µM








1.6a; R1 = CF2CH3; R2 = Cl; IC50 = 38 nM
1.6b; R1 = CF2CH3; R2 = SF5; IC50 = 33 nM
1.6c; R1 = CF2CH3; R2 = CF3; IC50 = 38 nM
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Benzoyl guanidine HOE 694 is a Na+/H+ exchanger inhibitor (Figure 1.11). Na+/H+ exchanger 
inhibitors protect the cardiac tissue during heart attack, chemotherapy, and organ transplant.40 
Structure-activity studies revealed that insertion of lipophilic and bulky groups at the 4-position of 
the benzene ring of HOE 694 could enhance its activity. Inserting SF5 at position 4 resulted in a first-
generation derivative (HOE 694-a) that showed an improved Na+/H+ exchanger inhibition activity. 
By increasing the bulk at position 4, a second generation of compounds were developed, of which 
HOE 694-b had 7-fold more potency than HOE 694-a. In both generations, insertion of an SF5 group 
increased the NHE inhibition activity, improved bioavailability and in vivo half-life.41   
 
 
Figure 1.11:NHE inhibitors 
Parasites of the family trypanosomatid are responsible for three human diseases; sleeping sickness, 
Chagas’ disease, and leishmaniasis.42 These parasites use trypanothione for the maintenance of their 
thiol-redox potential to protect them from oxidative and chemical stress. Function of trypanothione 
is regulated by two enzymes; trypanothione reductase (TR) and trypanothione peroxidase.43 TR has 
become a popular target for the treatment of diseases caused by trypanosomatidae. 
Stump et al. synthesised a series of TR inhibitors (TRI), bearing either a SF5, CF3, or tert-butyl group 
(C(CH3)3) targeting the parasite T.cruzi that is responsible for Chagas’ disease (Figure 1.12).44 
Compounds TRI(a-c) were screened against T.cruzi TR. The SF5 derivative, TRIb (Kic =  28 µM), 
competitively inhibited T.cruzi TR similar to the CF3 compound, TRIa (Kic = 24 µM), and  illustrated 
threefold improvement compared to TRIc (Kic = 84 µM) (Figure 1.12). 
 
 

























TRIa; R = CF3
TRIb; R = SF5







Inhibition mode of compounds TRI(a-c) were analysed through molecular modelling studies which 
revealed that the changes in binding affinity are a consequence of different steric and electronic 
properties of the groups CF3, SF5, and C(CH3)3. Bulkiness of the tert-butyl group leads to loss of 
important interactions as TRIc is unable to efficiently occupy the binding site. Although, the size of 
SF5 is relatively large, TRIb showed a similar binding affinity to its CF3 counterpart due to the strong 
electron-withdrawing nature of the SF5 group, that may strengthen the interaction of TRIb with the 
electron-rich residues of the TR active site. 
 
1.7 SF5 in materials science 
In material chemistry, SF5 was first employed by Kirsch and co-workers in the synthesis of  liquid 
crystal displays (LCD) in 1999.45 The late 90s saw the rapid growth of LCDs towards becoming the 
major technology for flat panel displays. Available LCD technology predominantly depended on the 
electrical and optical properties of nematic liquid crystalline molecules. Design of nematic liquid 
crystals has been based on cyanated biphenyls and phenylcyclohexane derivatives. A disadvantage 
of nitrile based liquid crystals are that they mobilise and solvate ionic impurities in devices resulting 
in a low voltage holding ratio. Another popular choice in liquid crystal design is the use of fluorinated 
aromatic rings primarily due to the unusual combination of high polarity and low polarizability 
imparted on the molecule by the fluorine atom (Figure 1.13).32  
 
 
Figure 1.13: Cyano- and fluoro-substituted nematic liquid crystal molecules 
The high demand for display panels led to mass production. In order to reduce the cost, the driving 
voltage of the active matrix LCD was lowered. This meant nematic liquid crystals with a higher 
dielectric anisotropy were required to obtain an electro-optical response. The most efficient way to 
increase dielectric anisotropy when designing a liquid crystal is to use a polar terminal group with 
the maximum possible dipole moment. Unfortunately, the overall molecular dipole moments 
provided by the fluorinated molecules were insufficient for certain LCD applications. Kirsch’s search 
for a new and more polar terminal group that would bring about an acceptably high dielectric 
anisotropy led him to the discovery of SF5 group. They synthesised a series of SF5 based liquid crystal 















Figure 1.14: SF5-substituted nematic liquid crystal molecules. 
Liquid crystals are merely one example where SF5 was found to be applicable in material science. 
Others include molecular superconductors, triboluminescent materials, luminescent transition metal 
complexes etc., among others. 
 
1.8 SF5 in agricultural chemistry 
An initial utility of SF5 in life sciences was chiefly as pesticides in the form of herbicides, fungicides, 
parasiticides, and insecticides. Trifluralin is an exemplar pesticide where the herbicidal activities of 
SF5 and CF3 congeners were compared (Figure 1.15). 
Trifluralin is a dinitroaniline herbicide used to control pre-emergence of annual grasses and some 
dicotyledon weeds in cotton, soybean, wheat and oilseed crops. 
To compare the relative efficacy of CF3 and SF5 in dinitroaniline herbicides, Lim et al.46 prepared 
the SF5 analogue of trifluralin and tested it alongside the parent compound. 
 
Figure 1.15: Trifluralin & its SF5 analogue 
Application of 1.9a in place of trifluralin did not show any advantage in post-emergence applications. 
However, when used in pre-emergence applications, 1.9a proved to be a superior herbicide than 
trifluralin as assessed by visual injury estimation. In pre-emergence applications, crop injury and 
growth inhibition were relatively low for 1.9a as opposed to trifluralin meaning that the crops are 
more tolerant to 1.9a than trifluralin. 
 
1.9 Microwave Chemistry 
Towards the end of World War-II, in 1946, Percy LeBaron Spencer discovered the use of low-density 
microwave energy as a method of heating while making magnetrons. Spencer noticed the melted 




















signals.47 Led by his curiosity, he tested other food items like popcorn and egg and observed fast 
cooking of these items. In 1947, Raytheon Corporation where Spencer was an engineer, built first 
commercially available microwave oven costing approximately US $5000 each.48 It wasn’t until the 
late 70s, the first microwave laboratory instrument was developed by CEM Corporation to analyse 
moisture in solids. Towards mid 80s, microwave energy saw its use in chemical synthesis, explored 
by Gedye et al. who published papers relating to microwave mediated reactions.49 Since then 
microwave has been used widely in synthetic chemistry to reduce reaction time and increase product 
yield. A number of microwave reactor models of different specifications have been available in the 
market since 2000. Major producers of microwave technology include CEM, Biotage, Anton Paar 
etc.50  
Microwaves are electromagnetic waves in the frequency range of 0.3 to 300 GHz. All microwave 
reactors operate at a frequency of 2.45 GHz to avoid interference with telecommunication and mobile 
phone frequencies. At this frequency, microwave photons, on their own, are not capable of inducing 
chemical reactions. The dielectric properties of a material govern its heating characteristics under 
microwave irradiation conditions. The ability of a specific substance to convert electromagnetic 
energy into heat at a given frequency and temperature is determined by a parameter called loss 
tangent, tan d.  
Microwaves consist of an electric and a magnetic field component. The electric component is 
responsible for the heating of the material. Two main mechanisms involved in heating are dipolar 
polarization and ionic conduction.51,52 
To generate heat, the substance being irradiated with microwaves must possess a dipole moment that 
aligns in the applied electric field. The dielectric constant describes the ability of molecules to be 
polarized by the electric field. Oscillation of the applied field causes the dipole of the sample to 
realign with the alternating electric field.51 Energy is lost in the form of heat during the process. The 
amount of heat generated is directly linked to the ability of the matrix to align itself with the 
frequency of the applied field. In essence, field energy is transferred to the medium and electric 
energy is converted into either kinetic or thermal energy and eventually into heat energy. Reaction 
mediums with high loss tangent (tan d) are required for efficient absorption of microwave energy 
and for rapid heating. High microwave absorbing solvents have a tan d > 0.5 and when tan d < 0.1, 
the solvent is classed as low absorbing. The tan d for ethanol = 0.941 in comparison to water, tan d 
= 0.123. Examples of poor microwave absorbing solvents are hexane (tan d = 0.020), toluene (tan d 
= 0.040), dichloromethane (tan d = 0.042), etc.  
Ionic conduction occurs when ions in the sample oscillate back and forth under the influence of 
microwave field and collide with the neighbouring atoms. The collision generates heat.53  
Traditional conductive heating makes use of external heating sources like a heating mantle or oil bath 
to perform synthesis. These methods depend on thermal energy and convection current to transfer 
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heat energy to the matrix, hence, are inefficient and comparatively slow. Moreover, temperature of 
the reaction vessels is higher than that of the reaction. And occasionally local overheating of the 
reaction mixture can develop which may result in degradation of reactants as well as product. 
Microwave irradiation on the other hand can produce efficient and uniform heating by direct coupling 
of microwave energy with the matrix. Figure 1.16 illustrates the difference in heating profiles of 
microwave vs conventional heating method. Microwave irradiation (left) raises the temperature of 
the whole volume simultaneously, while in the oil-heated tube (right), the contents next to the vessel 
are heated first. 
 
Figure 1.16 Inverted temperature gradients of Microwave (left) versus oil-bath heating (right) after 60 seconds of heating57 
Advantages of microwave irradiation over thermal include efficient and rapid heating, increased rate 
of reactions, higher yields, and environmentally friendly reactions. In organic synthesis the use of 
water as an environmentally benign, cheap, and readily available solvent is appealing. Due to water’s 
ability to polarize, it makes an excellent choice of solvent in microwave mediated synthesis, 
providing it solubilises the reagents. 
The Suzuki reaction is one of the most used and versatile C-C coupling reactions in organic 
synthesis.53 Carrying out high-speed microwave mediated Suzuki reactions has become a regular 
practice. A significant advancement in Suzuki chemistry has been the ability to use water as a solvent 
in microwave facilitated synthesis. Leadbeater and Marco described a very rapid, ligand-free 
palladium-catalysed aqueous Suzuki coupling of aryl halides with aryl boronic acids in the 
microwave. A series of biphenyls were synthesised in the microwave at temperatures between 150-
175 °C for 5 minutes, affording yields between 45-95%, with only 0.4 mol% of Pd(OAc)2 as catalyst. 
Scheme 1.15 shows microwave mediated coupling of bromobenzene and phenylboronic acid, 











Chemical syntheses on a daily basis produce large amounts of waste that are harmful to the 
environment. The term “Green Chemistry” was offered to the scientific community in 1991 with a 
purpose of reducing or eliminating environmentally hazardous substances in synthesis. Greener 
syntheses can be achieved by avoiding toxic and volatile solvents or using solvent-free synthesis, 
reducing the quantity of catalysts, using environmentally benign chemicals, atom-economical 
synthesis, minimising chemical waste/energy, etc. A non-conventional energy source of chemical 
synthesis is mechanochemical mixing.59  
Mechanochemistry is an emerging technique for organic synthesis. With the aid of 
mechanochemistry in synthesis, the use of solvent could be minimised drastically, or even completely 
avoided throughout synthetic routes, from laboratory set-ups to large scale manufacturing. 
Mechanical reactions are chemical reactions that are fostered by the direct absorption of mechanical 
energy. Mechanical methods such as shearing, stretching and grinding, can induce mechanical 
energy. Nobel laureate Wilhelm Ostwald defined mechanochemistry as “a branch of chemistry which 
is concerned with chemical and physio-chemical changes of substances of all stages of aggregation 
due to the influence of mechanical energy”. The mechanistic understanding of mechanochemistry is 
not well studied and remains unclear.60,61  
The technique of ball-milling is derived from the traditional grinding methods using a mortar and 
pestle. For convenient and efficient grinding, various types of electronic milling devices have been 
developed.  
A mixer mill (Figure 1.18) is a type of ball milling device which uses the movement of ball bearings 
to apply mechanical force to the reagents. Reagents are shaken at a chosen frequency in a horizontally 
mounted jar, together with one or more ball bearings. The main mechanical force applied to the 
reagents is impact energy. Other most common type of ball-mill is a planetary mill (Figure 1.19). 
Planetary mill differs in motion to the mixer mill. The jars spin anti-clockwise to the spinning disc 












A major disadvantage related to ball millers is lack of control of temperature. The temperature of a 
reaction run in a mixer mill will only incidentally rise due to the frictional forces experienced during 
the milling process. On the other hand, planetary ball milling can result in the temperature exceeding 
200 °C. Scalability is another concern related to mixer mill, especially in an industrial setting. The 




Figure 1.17: Retsch MM400 mixer mill and different types of jars and balls used for milling62 
 
Figure 1.18: Retsch PM 100 planetary ball mill63 
Traditionally, catalytic hydrogenation is performed in either the gas or liquid phase. Liquid phase 
hydrogenation is more commonly used for small-scale synthesis where, a slurry containing a catalyst 
and a substrate is contacted with gaseous hydrogen.64 Gaseous hydrogen can be generated in situ, 
e.g. by transfer hydrogenation,65  or a balloon filled with hydrogen gas is fed into the reaction. In a 
recent study, it was reported that the hydrogenation of olefins could be accomplished using water as 
a hydrogen source, mediated by mechanochemical energy and stainless steel (SUS304) in a planetary 
ball mill. The study was commenced after observing generation of H2 gas when moistened stainless-
steel balls were exposed to friction. Scheme 1.16 shows hydrogenation of an alkene as well as a nitro 











1.11 Thesis aims 
The increased availability of SF5 containing reagents has promoted the growth of the SF5 group in 
medicinal chemistry. Nevertheless, compared to CF3 in medicinal chemistry, SF5’s presence is only 
imperceptible. Therefore, it is imperative to develop and investigate novel biologically active SF5 
containing compounds. This project aims to explore the effect of SF5 in known drugs (Figure 1.19) 
while comparing it to other functional groups such as halogens, NO2 and CF3. In doing so, the project 
would expand the repertoire of SF5 in medicinal chemistry. In addition, we intended to develop a 
range of SF5 containing building blocks that can be commercialised. For biological studies, 
pentafluorosulfanyl containing compounds such as oxindoles and benzophenones were purchased 
and modified into analogues of known drugs like diazepam. To develop chemicals in an eco-friendly 
manner, we took advantage of microwave and mechanochemistry whenever possible (Scheme 1.17). 
 
 






























































































Purine and pyrimidine nucleotides are the fundamental building blocks of DNA and RNA.63 
Additionally, they play a critical role in membrane lipid biosynthesis and protein glycosylation. 
Biosynthesis of RNA requires two pyrimidine nucleoside triphosphates; uridine-5’-triphosphate 
(UTP) and cytidine triphosphate (CTP), and two purine nucleoside triphosphates; adenosine 
triphosphate (ATP) and guanosine triphosphate (GTP). The nucleosides are generated either via de 
novo synthesis or through utilization of a salvage pathway.64  The de novo biosynthetic pathway for 
the synthesis of UTP and CTP involves five phases and begins with the assembly of the pyrimidine 
ring using simple precursors. At the third phase, dihydroorotic acid (DHO), a precursor for the 
synthesis of pyrimidine, is formed. In phase four, dihydroorotate dehydrogenase (DHODH), the only 
mitochondrial enzyme in pyrimidine biosynthesis catalyses the oxidation of DHO to orotic acid via 
a ‘ping-pong’ mechanism. It is the only enzyme capable of performing this conversion making it 
essential for the cell’s ability to produce uridine monophosphate. Orotic acid is then converted to 
uridine monophosphate (UMP) in two enzymatic steps. Firstly, ribose-5´-phosphate is transferred to 
orotic acid followed by decarboxylation resulting in UMP. Uridine monophosphate synthase 
(UMPS); a bifunctional enzyme consisting of orotate phosphoribosyltransferase and orotidine-5-
monophosphate decarboxylase catalyses the synthesis (Figure 2.1).65 In eukaryotes, DHODH is a 
ubiquitous enzyme located in the inner mitochondrial membrane with ubiquinone as the proximal 
electron acceptor for DHO’s oxidation to orotic acid.66 
 
 








































Lymphocytes are white blood cells that consist of T, B and natural killer cells. B lymphocytes make 
antibodies while T lymphocytes help kill tumour cells and control immune response. Purine and 
pyrimidine are necessary for the development and survival of mature T lymphocytes.68 Lymphocytes 
require eightfold more pyrimidine during proliferation.69 This demand can only be met by using both 
salvage and de novo synthesis pathways. Thus, inhibition of DHODH prevents lymphocytes from 
accumulating sufficient pyrimidines to support DNA synthesis. Pyrimidines are also needed for 
glycosylation of lipids and proteins. DHODH inhibitors therefore demonstrate immunosuppressant 
and anti-inflammatory properties and are effective treatment option for diseases such as multiple 
sclerosis70, rheumatoid arthritis (RA) and cancer.71  
 
In the above oxidation process, there is obviously an accompanying reduction process (Figure 2.2). 
Human DHODH (HDHODH) belongs to the class 2 DHODH family with flavin mononucleotide 
(FMN) as its redox cofactor. DHODH has two binding sites. DHO binds to the first site and is 
oxidised to orotic acid. Initially electrons from DHO are transferred to FMN as part of the redox 
reaction generating dihydroflavin mononucleotide (FMNH2) and orotic acid. After the dissociation 
of orotic acid from the enzyme, FMNH2 is oxidised back to FMN by a second cofactor, called 
coenzyme Q (ubiquinone) that binds to the second site. Ubiquinone is also found in the inner 




Figure 2.2: Ping-pong redox reactions catalysed by DHODH72 
 
Full length HDHODH has 396 amino acid residues. A high-resolution crystal structure (PDB ID: 
1D3H; Figure 2.3) of HDHODH, in complex with teriflunomide  (Scheme 2.1), revealed that the 
long N-terminal extension of the enzyme folds into a helical domain that forms the entrance of a 
tunnel leading to the active site. The helical domain is responsible for the membrane interaction of 
HDHODH. The N-terminal extension contains a small domain that consists of two a helices: a1 and 
a2  and a loop connecting it to the large C-terminal domain. The small N-terminal domain is 
amphipathic i.e. with both hydrophobic and hydrophilic parts. All of the charged and most of the 
polar amino acid residues orient towards the large domain while the hydrophobic side chains project 
away from the large domain. The hydrophobic side chains form a large hydrophobic protruding 
patch. The structure of the small domain provides information about membrane association of the 
enzyme. The hydrophobic patch is able to push into the hydrophobic interior of the membrane while 
the polar and positively charged border interacts with the negatively charged phospholipid head 
groups. An ideal HDHODH inhibitor should address both polar and lipophilic characteristics of the 
binding pocket. The space between the a1 and a2 helices forms a slot in the hydrophobic patch.  The 
hydrophobic tunnel leads to the redox site containing the flavin molecule. Several charged or polar 


























































Ubiquinone that can easily diffuse in the mitochondrial inner membrane uses this channel to approach 
the FMNH2 for a redox reaction.73  
Leflunomide (Aravaâ) is a disease modifying antirheumatic drug (DMARD) with 
immunomodulatory properties. It has been approved for the treatment of rheumatoid arthritis since 
1998 (USA) and 1999 (EU).74,75 However, leflunomide is a prodrug with little or no 
immunomodulatory activity until it is rapidly converted to its active form, teriflunomide, in the 
gastrointestinal tract and plasma (Scheme 2.1). In plasma it is highly protein-bound, >99%, and as a 
consequence, its plasma half-life is approximately 15 days. This can be reduced to 1-2 days by the 
use of cholestyramine, an ion exchange resin, or an activated charcoal washout. The long half-life 
implies significant enterohepatic recirculation. The latter refers to the process by which a drug or its 
metastable metabolite in the liver is secreted into the bile, followed by release into the small intestine 
from where it can be reabsorbed back into circulation and subsequently returned to the liver. This 
can result in significant plasma levels being maintained for up to two years after stopping the 
treatment. In the event of pregnancy, female users of teriflunomide must undergo accelerated 
elimination of teriflunomide until the concentration in plasma falls below 0.02 mg/L which is the 
value predicted to have minimal risk to the foetus, based on animal studies.76 Teriflunomide is 
contraindicated in pregnant women or women planning on getting pregnant as teratogenicity and 
embryo-lethality in the off-spring of teriflunomide treated rats and rabbits are observed. In vitro and 
in vivo studies proved teriflunomide as not mutagenic and clastogenic. Clastogen is a mutagenic 
substance with the ability to alter the structure and number of chromosomes and chromatids.   
Rheumatoid arthritis is an autoimmune and inflammatory disease, where in, the immune system 
attacks healthy cells causing inflammation. B-cells, T-cells and macrophages play important roles in 
RA pathogenesis. B-cells secrete proteins that promote RA such as rheumatoid factor and pro-
inflammatory cytokines. The main function of T-cells in RA is to activate macrophages and 
fibroblasts and transform them into tissue-destructive cells.77 The principal mechanism of action of 
teriflunomide is the inhibition of DHODH. This leads to depletion of ribonucleotide precursors in 
lymphocytes reducing DNA and RNA synthesis and resulting in the arrest of cell proliferation in the 
G1 phase of the cell cycle.78 
 
Teriflunomide (Aubagioâ) is one of the FDA approved treatments for multiple sclerosis, a chronic 
inflammatory disease. It is able to inhibit human DHODH in the low µM range and it binds in the 
same region of the tunnel which is a narrow cleft near the flavin molecule (Figure 2.3).73 As it shares 
affinity for the binding site with ubiquinone,79 it is dubbed as a redox silent coenzyme Q antagonist 
of DHODH.80 Teriflunomide has a polar head consisting of one hydrogen bond donor; enol and two 
hydrogen bond acceptors, a nitrile and a carbonyl group, while the tail of teriflunomide, which 





Scheme 2.1: Isoxazole ring opening under basic conditions 
 
Figure 2.3: Teriflunomide and FMN in complex with HDHODH. PDB ID: 1D3H. FMN: Teal, Teriflunomide: Purple 
2.1.1 Leflunomide and teriflunomide against SARS-CoV-2. 
Viral infections can be addressed as a global crisis endangering our existence on this planet. 
Hundreds of viruses are known to us as pathogenic but fewer than 10 of them can be treated using 
clinically available anti-virals.81 The increasing number of viral infections such as influenza virus, 
SARS-CoV, MERS-CoV, Ebola virus, Zika virus and the very recent SARS-CoV-2, are probably 
lasting global threats. Developing broad spectrum antivirals (BSA) is one way to tackle this issue. 
BSA work by either inhibiting the viral proteins, known as direct-acting antiviral agents (DAA) or 
by targeting the host proteins and processes that facilitate viral replication, known as host targeting 
antivirals (HTAs).81  
A new initiative focused on developing therapeutics for the new coronavirus, identified COVID-19 
virus main protease (Mpro) as a potential target. The genome of COVID-19 comprises approximately 























are required for viral replication and transcription. Mpro is a key enzyme in coronaviruses, which is 
crucial in mediating viral replication and transcription. X-ray crystal structures of the main proteases 
of SARS-CoV-2, SARS-CoV and MERS-CoV revealed high degree of structural similarities and 
conservation of the active site.82 Inhibitors for SARS-CoV-2 Mpro could be adapted from previously 
identified compounds targeting SARS-CoV or MERS-CoV main proteases. 
 
Mpro releases the functional polypeptides from the polyproteins by extensive proteolytic processing. 
It digests the polyproteins at no less than 11 cleavage sites, starting with autolytic cleavage83 and 
exclusively cleaves polypeptides after a glutamine residue. No human host-cell proteases are known 
to possess this substrate specificity.84 
Its functional importance and the absence of closely related homologues in humans, render Mpro as 
an attractive target for antiviral drug design as an example of a DAA.  
Mpro is a cysteine protease with a catalytic dyad; cysteine (Cys145) and histidine (His41), in its active 
centre. Cysteine proteases commonly contain a catalytic triad. Mpro contains a buried water molecule 
in its active site instead of the third catalytic residue.  
The proteolytic process is believed to proceed with extraction of a proton on the cysteine side chain 
(S-H) by the histidine’s imidazole side chain, followed by nucleophilic attack at the amide bond of 
the substrate by the thiolate forming thioester. The N-terminal peptide product is released by proton 
abstraction from histidine before the hydrolysis of thioester to release the C-terminal product and 
regenerate the catalytic dyad (Scheme 2.2).  
  

































Inhibitors of SARS-CoV-285 and MERS-CoV86 have been reviewed comprehensively, reporting 
peptidomimetics and small molecules with affinities in the micro molar to nanomolar range. These 
inhibitors were designed based on a warhead design strategy. Warheads such as Michael acceptors, 
aldehydes, epoxy ketones and other ketones were employed to undergo covalent attack by the 
catalytic cysteine residue. 
 
Previous studies had identified N3 (Figure 2.4, a), a Michael acceptor inhibitor (Figure 2.4, b), to 
inhibit multiple CoVMpros, including those from SARS-CoV and MERS-CoV.87 N3 irreversibly 
modifies Cys145. Molecular docking analysis of N3 (Figure 2.5) in COVID-19 Mpro showed that it 
could fit inside the substrate-binding pocket and a kinetic analysis demonstrated a two-step 
irreversible inactivation of the enzyme. In Vero cells, N3 exhibited anti-SARS-CoV-2 activity. The 
inhibitor initially associates with the enzyme followed by the formation of a stable covalent bond 
between N3 and Mpro.87, 88  
  
Figure 2.4: Potent COVID-19 Mpro inhibitor. (a), structure of N3. (b), N3-Cys 145 adduct 
   
Figure 2.5 shows Mpro in complex with N3. In addition to several non-covalent bonds, a covalent 
bond, Michael addition, between Cys145 and the alpha-beta unsaturated ketone can be seen. The 
structure of SARS-CoV-2 Mpro in complex with N3 was a useful model to identify lead inhibitors to 







































Teriflunomide possesses a Michael acceptor warhead capable of covalently binding with Mpro. 
Therefore, teriflunomide and its analogues were hypothesised to make potential inhibitors of SARS-
CoV-2 Mpro.   
 
Figure 2.5: COVID-19 Mpro in complex with N3 showing interactions with amino acid residues 
One of the main causes of Covid-19 related death is acute lung injury. SARS-CoV-2 spike (S) 
proteins bind to the receptor angiotensin-converting enzyme 2 (ACE2) to enter human cells.89, 90 
ACE2 is a type I membrane protein expressed on cells in the kidney, heart, gastrointestinal tracts, 
blood vessels and type I and II alveolar cells in the lungs.89 ACE2 enzyme catalyses the conversion 
of angiotensin II (AngII), a vasoconstrictor, to angiotensin (1-7). AngII also mediates cell 
proliferation by stimulating various cytokines.  ACE2 regulates the vasoconstrictor and profibrotic 
effects of AngII. Ang (1-7) has vasodilatory and antifibrotic actions. SARS-CoV-2 infection leads to 
downregulation of ACE2 expression, followed by excessive production of AngII by angiotensin 
converting enzyme (ACE) that converts Ang (1-7) to AngII. Once the virus enters and infects the 
host cells, a host immune response and inflammation cascade begin via antigen presenting cells and 
macrophages. Uncontrolled release of pro-inflammation cytokines results in acute lung respiratory 
damage (ARDS). Favalli et al. reported that Covid-19 and rheumatoid arthritis have similar 
pathophysiology. They also suggested that anti-rheumatoid drugs can be used for Covid-19 
treatment.91 Chloroquine and hydroxychloroquine, that are also used to treat RA, were initially used 
to treat Covid-19 pneumonia.91 
Several studies searching for HTAs point towards compounds inhibiting the host’s pyrimidine 
synthetic pathway to impede virus infections, indicating that the replication of viruses is widely 
dependent on the aforementioned pathway.92 Once again, DHODH represents a viable target and 
teriflunomide a potential treatment. In addition, DHODH inhibition provides anti-inflammatory 
effects.93 As leflunomide and teriflunomide are capable of regulating lymphocytes and the release of 
cytokines and chemokines, they can be speculated to be effective against ARDS due to cytokine 
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storm. Several clinical trials to evaluate the potential of leflunomide as Covid-19 treatment are 
ongoing.94  
Independent of our work, a small-scale clinical trial of Leflunomide as a treatment for Covid-19 
revealed that patients treated with leflunomide recovered faster and cleared virus in fewer days than 
the blank-controlled patients. The study was however, conducted on a group of only ten people, 
where, five were administered leflunomide and the other half were not. The control group did not 
receive a placebo either. The study was based on findings, that, DHODH inhibitors are able to rescue 
mice from severe influenza-A-virus infection by antiviral and immune-repression of pathological 
inflammation. Moreover, treating SARS-CoV-2 infected cells with teriflunomide conferred a 
profound antiviral efficacy of EC50 = 6 µmol/L.94 
Following these results, the safety of leflunomide on SARS-CoV-2 infected patients with post-
symptomatic viral shedding, was evaluated and compared with interferon a-2a treatment alone, by 
the same research group. Asymptomatic patients and patients with mild symptoms are known to shed 
virus for a long-term (22.5 days on average).95 Even after resolved symptoms and observed 
improvement in initially abnormal CT imaging, some patients remain viral RNA-positive. A 
combination treatment group received leflunomide and interferon a-2a while the control group only 
received interferon a-2a. Interferon a-2a is a wide biologically activity cytokine.96 It regulates 
several genes involved in antiviral and antiproliferative activities.97 As per their observation, patients 
given a combination of leflunomide and interferon a-2a did not have a substantially shorter length 
of hospital stay than patients treated with interferon alone.98 This result points to a conclusion that 
leflunomide is not a viable treatment for post-symptomatic SARS-CoV-2 viral shedding. 
Another detailed study on the suppression of SARS-CoV-2 by DHODH inhibition was conducted by 
Xiong R. et al92 in Wuhan. According to the study, the inhibition of the DHODH enzyme resulted in 
reduced proliferation of SARS-CoV-2 in cells and, furthermore, this crucial strategy can be used to 
treat Covid-19 disease due to the immune response suppression of DHODH inhibitors.99 From 
280,000 compounds, the group identified two candidates, S312 and S418, with IC50s of 29.2 nM and 
7.5 nM respectively. These compounds are approximately two and seven times more potent than 
teriflunomide (IC50 = 307.1 nM).93 Structures of the identified compounds are not yet released.  
 
An initiative called the COVID Moonshot was launched to accelerate the development of a COVID 
antiviral. The initiative is an open source with no intellectual property constraints where100 scientists 
can submit and view drug designs and experimental data to inspire new ideas.101 We were approached 





In this study we have continued our investigation on the effect of substituting a trifluoromethyl (CF3) 
with pentafluorosulfanyl (SF5) group and applied this to both leflunomide and teriflunomide on 
DHODH inhibition to determine its potential, both as a COVID treatment and an immunomodulator. 
Alliancing with the COVID Moonshot initiative and with the aim of advancing the search for COVID 
antivirals, we tested the effects of teriflunomide analogues, together with several other compounds, 
donated by eMoleculesÒ, on Mpro.   
 
2.2 Results and Discussion 
2.2.1 Comparing HDHODH inhibiting potency of SF5-containing analogues 
against known DHODH inhibitors 
Virtual screening is a useful tool to find ligand hits, and to assist lead optimisation in structure based 
drug discovery. With the help of a computational strategy, and the large number of protein-ligand 
complexes available in the Protein Data Bank (PDB), one could predict the binding affinity of the 
ligands in question towards a receptor site of interest. Using Schrödinger Maestro, a molecular 
modelling software, we docked our ligands in complex with crystal structures of proteins obtained 
from the PDB database. Schrödinger Glide is a scoring functionality that enables you to evaluate 
binding affinity of ligands.102 
Glide finds all the possible binding locations of the ligands in the active site of the receptor and 
produces a set of initial ligand conformations. Different ligand poses can then be generated. Ligand 
pose refers to a complete specification of the ligand; position and orientation relative to the receptor, 
core conformation, and rotamer group conformations.103 Using Glide score, different ligand poses 
can be ranked. Scoring is related to the strength of interaction between the ligand and the protein, 
which is expressed as binding free energy.104 Therefore, more negative values represent tighter 
binders. The binding free energy is described as a sum of the intermolecular interactions between the 
ligand and the protein and the internal steric energy of the ligand.105,106  
 
Liu et al.73 in their paper, disclosed that the carbonyl group on the polar head of teriflunomide forms 
a hydrogen bond with water which in turn is bound to Arg136 while the enolic OH binds to Tyr356. 
In addition, the CF3 containing aromatic ring made several hydrophobic interactions with amino acid 
residues in the tunnel. Leban et al.107 and Davies et al.108 reported that, apart from the direct hydrogen 
bond with Tyr356, there are two hydrogen bond interactions with Arg265 and Gln47 mediated by a 
water molecule. 
 
We performed our own docking studies using the crystal structure of human DHODH in complex 
with teriflunomide obtained from the protein data bank (PDB ID: 1D3H) on Schrödinger Maestro102 
and compared it against literature findings.73 
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Our docking studies show slight variations in the interactions. We obtained 5 poses of teriflunomide 
in the human DHODH binding pocket and scrutinised the pose that gave the best Glide score. We 
observed the carbonyl forming an interaction with Thr360 via a water molecule rather than a direct 
hydrogen bond with Arg136 as mentioned in the literature. The hydroxyl group formed a hydrogen 
bond through the oxygen with Arg136 and with a water which in turn is bound to Thr360 and Gln47. 
The nitrile was found to make two interactions with Tyr356 (Figure 2.6). The trifluoromethyl 
containing aromatic group made several hydrophobic interactions with amino acid residues Pro364 
and Met111. 
A co-crystal structure solved by Liu et al showed that the phenyl group bearing the trifluoromethyl 
phenyl group only partially filled the binding cavity. This justifies the lack of inhibitor-protein 
interactions and low HDHODH potency exhibited by teriflunomide (Figure 2.7).109  
 
 
Figure 2.6: Teriflunomide (blue) in HDHODH binding pocket, docked using Schrödinger Maestro. Hydrogen bonding shown by 









Figure 2.7: Ligand interaction diagram of teriflunomide 
 
According to Erra et al.109 replacing the trifluoromethyl group with a bulkier OSO2CF3 
group (Figure 2.8) improved the in vitro HDHODH activity by an order of magnitude, 
viz. 150 nM vs 1083 nM (teriflunomide), presumably by virtue of having a better fit in 
the aforementioned hydrophobic pocket.  
  
Figure 2.8: Teriflunomide analogue with better potency 
 
Figure 2.9 shows OSO2CF3-teriflunomide analogue (2.1) in the DHODH binding pocket. Figure 2.10 
is a focused image of the OSO2CF3-teriflunomide (2.1) polar head making several hydrogen bond 
interactions as expected. Similar to teriflunomide, the carbonyl oxygen established a water mediated 
bond with Thr360 and the hydroxyl group functioned as a hydrogen bond acceptor bonding with the 































Figure 2.11 clearly displays the interactions formed by the OSO2CF3 moiety and the DHODH pocket. 
The CF3 group on the sulfonate interacts with hydrogens on the Ala59 residue, and the sulfonate 
oxygens form hydrogen bonds with Pro364, Thr63, and Ala59.  
SO2 
CF3 





Figure 2.11: OSO2CF3 group interaction with DHODH. Brown dashes indicate hydrophobic clashes 
A comparison of teriflunomide and OSO2CF3-teriflunomide (2.1) reveals the pronounced 
















The sulfur pentafluoride group is an ideal substitute for the trifluoromethyl group as it is more 
lipophilic as proven by their Hansch hydrophobicity constants; π = 1.51 for SF5 and π = 1.09 for 
CF3.19 Moreover, the SF5 group has superior steric demand than CF3 with van der Waals volumes of 
49.2 cm3mol-1 and 20.5 cm3mol-1 respectively.110,111 Therefore, we proposed the synthesis of a 
Figure 2.12: Ligand interaction diagram of teriflunomide and OSO2CF3-substituted teriflunomide (2.1) 
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pentafluorosulfanyl-containing teriflunomide analogue to augment its binding affinity. To verify this 
hypothesis, we tested the compounds head to head through a commercial assay. 
 
To synthesise SF5-teriflunomide (2.6), we first prepared SF5 -leflunomide (2.5), which when treated 
with sodium hydroxide, provided its teriflunomide equivalent (Scheme 4.3).  
The compounds were synthesised using the same procedure used for preparing teriflunomide.112 
Reacting commercially available 2.4 and 2.3 in isopropyl alcohol (IPA) yielded 2.5. In the absence 
of a base, 2 equivalence of amine (2.4) will be needed to scavenge the hydrochloric acid generated 
as a by-product (Scheme 2.4). However, the aniline is too expensive and too weak a base to be used 
in this manner in a commercial process.   
Use of a base is required to drive the equilibrium towards the product. The reaction between an acid 
chloride and an amine is much faster compared to the hydrolysis of the acyl chloride, as nitrogen is 
a better nucleophile than oxygen. Therefore, an aqueous alkali can be used as base as part of a 
Schotten-Baumann procedure.113,114 Most commonly, sodium hydroxide is the base of choice for this 
procedure. Other bases that are commonly used include piperidine and triethylamine. However, the 
isoxazole ring is base sensitive and in the presence of these strong bases, the isoxazole ring would 
open up to form teriflunomide derivative. To be able to isolate pure SF5-leflunomide, we used a weak 
base; sodium bicarbonate (NaHCO3), which was reported as the most preferred acid scavenger for 
the synthesis of leflunomide. The acid chloride, 2.3, is an expensive reagent (1g = £165)115. However, 
its acid derivative, 5-methylisoxazole-4-carboxylic acid, is  relatively low-priced (1g = £39.20)116 
and the acid can easily be activated using chlorinating agents such as thionyl chloride, oxalyl 
chloride, benzoyl chloride, POCl3, or PCl3 in excess. Formation of the acid chloride can be monitored 
by TLC by taking a small amount of the sample and converting it to the methyl ester by addition of 
methanol. Once the reaction is completed or substantial amounts of acid chloride are formed, excess 
chlorinating agent and by products should be removed. Thionyl chloride and oxalyl chloride make 
ideal chlorinating agents, under fume hoods, as the by-products evolved are gases that can be easily 
removed by evaporation under vacuum at reasonable temperatures. The acyl chloride can then be 
deployed immediately in the amide coupling step. The mechanism of the amide coupling is shown 





Scheme 2.3: Synthesis of SF5-Leflunomide 2.5 and SF5-Teriflunomide 2.6 
 
The acid chloride was added to a suspension of the aniline and NaHCO3 in IPA and the reaction was 
stirred at 60 °C. Dissolution of NaHCO3 is not necessary for the reaction as it can scavenge HCl as 
a suspended solid. It is preferable to carry out the reaction in a relatively highly concentrated solution 
for improved yields. The product precipitates out when cooled to ambient temperature. The isolated 
product 2.5 could be used without further purification for the synthesis of SF5-teriflunomide (2.6).  
3- and 5- unsubstituted isoxazoles are known to be unstable towards alkali and strong bases.117 
Sodium hydroxide is assumed to abstract the C3 proton and the negatively charged species is 
acidified with HCl to obtain the open ring form. The latter can exist in two geometric forms (Z or E). 
The Z-isomer is energetically favoured as an internal hydrogen bond is formed between the hydroxyl 
and the keto group118 (Scheme 2.6). The presence of this bond also helps the compound to penetrate 
through cell membranes. The intramolecular hydrogen bond stabilized conformation is potentially 
less polar while being more lipid soluble due to the hydrogen donor and acceptor not being available 
to form bonds with water, moreover masked H-bonds tend to be effluxed less.119 Removal of one 
hydrogen-bond donor and acceptor atom makes the molecule less recognizable by the P-glycoprotein 
(P-gp), which is an efflux pump involved in multi-drug transport.120 P-gp interacts with substrates by 
forming hydrogen bonds.121 However, such intramolecular interactions could interfere with the 














































Scheme 2.4: Amide coupling mechanism 
   
Scheme 2.5: Base-mediated ring opening of isoxazoles 
 
Studies by Kujawski et al. showed that the presence of the internal hydrogen bond in the Z 
configuration decreases the interaction between teriflunomide and tyrosine or arginine in DHODH. 
It was stated that even the E isomer of teriflunomide provide a stronger teriflunomide-amino acid 
(tyrosine or arginine) interaction.118  










































































Figure 2.13 shows the X-ray structure of Z-SF5-teriflunomide (2.6) that we obtained from soaking it 
in dichloromethane (DCM) proving the configuration of the product as well as an intramolecular H-
bond between the OH and adjacent amide carbonyl group. 
 
 
Figure 2.13: X-ray structure of (Z)-2.6 
 
Figure 2.14 exhibits SF5-teriflunomide (2.6) in the DHODH binding pocket, docked using 
Schrodinger Maestro. Interactions between the ligand and the binding pocket are the same as our 
prior mentioned findings on teriflunomide in the same binding site. The hydroxyl group forms a 
direct bond with Arg136 as well as hydrogen bonds with Gln47 and Thr360 via a water molecule. 
Nitrile bonds with Tyr356. And finally the carbonyl forms a water mediated bond with Thr360. 
Several hydrophobic interaction are formed between the aromatic ring and amino acid residues lining 
the hydrophobic pocket. 
 
 








Figures 2.15 and 2.16 demonstrate the bulkiness of SF5 and that it is able to fill more of the binding 

















Similar analysis was performed comparing SF5-teriflunomide (2.6) and OSO2CF3-teriflunomide (2.1, 
Figure 2.17). Visibly, the OSO2CF3 moiety is bulkier than a SF5 group and therefore, occupies more 
of the binding pocket as well as forming additional hydrogen bonds. While teriflunomide and SF5-
teriflunomide (2.6) embody a polar head and hydrophobic tail; the OSO2CF3 analogue possesses a 
Figure 2.15: Comparing ligand interaction diagrams of SF5-
teriflunomide (2.6) and teriflunomide 








tail that is both polar and hydrophobic. However, any hydrophobic interactions made by the 
compounds are not visible in these molecular docking images.  
 
Figure 2.17: Overlapping of SF5-teriflunomide (2.6) and OSO2CF3-teriflunomide (2.1). Green: OSO2CF3-teriflunomide, salmon pink: 
SF5-teriflunomide 
Following our docking studies, we tested SF5- leflunomide (2.5) and SF5-teriflunomide (2.6) against 
teriflunomide and BAY-2402234 as standard, internal controls. The biophysical tests were carried 
out by Reaction Biology Corp®. 
Bayer developed a novel, potent, and selective DHODH inhibitor, BAY-2402234 (Figure 2.18), that 
inhibits HDHODH enzyme with an IC50 of 1.2 nM. It was developed as a potential treatment for 
acute myeloid leukaemia (AML).122 BAY-2402234 also binds at the ubiquinone binding site. It is a 
notable DHODH inhibitor that is in phase I clinical trials. BAY-2402234 was included in our 
HDHODH inhibition table due to its high affinity and the presence of a trifluoromethyl group.   
 
Figure 2.18: BAY-2402234 
 
Table 2.1 shows a comparison of IC50 and pIC50 of SF5-leflunomide (2.5), SF5-teriflunomide (2.6), 














potent than leflunomide. SF5-teriflunomide has approximately twice as much affinity as 
teriflunomide. 
 
















Table 2.1:HDHODH inhibition table comparing SF5-teriflunomide (2.6), SF5-leflunomide (2.5) and leflunomide against teriflunomide 
and BAY-2402234.  
a In vitro control (n=1). 
b mean (n=2); 29 nM and 25 nM. 
Unless stated otherwise; in vitro fluorescence-based assay run by Reaction Biology.123 
 
A doubling in affinity, when CF3 is exchanged for SF5, is an indication that the SF5 group is forming 
more interactions in the hydrophobic tunnel of the binding pocket and that SF5-teriflunomide (2.6) 



































BAY-2402234 gave the best potency with an IC50 of 1.8 nM in our outsourced assay, which is 
comparable to its literature value, 1.2 nM. As well as the hydrophilic interactions, BAY-2402234 
makes hydrophobic interactions with a large set of non-polar residues such as Leu42, Met43, Leu46, 
etc. With its bigger size, and the combination of hydrophobic and hydrophilic groups, BAY-2402234, 
is able to fill the DHODH active site to a greater degree. Figures 2.19 and 2.20 display the several 
hydrogen bonds and interactions formed by BAY-2402234 in the HDHODH binding pocket.  
 
Figure 2.19: HDHODH in complex with BAY-2402234. Dashed lines indicate hydrogen bonds and aromatic hydrogen bonds. 
 
 
Figure 2.20: Ligand interaction diagram of BAY-2402234 
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The Bayer compound, BAY-2402234, proved to have the most affinity towards HDHODH. We 




2.2.2 Identifying a SARS-CoV-2 Mpro inhibitor  
The N3 inhibitor that irreversibly inhibits CoVMpros contains an a, b unsaturated ester which enables 
it to form a covalent bond with the Cys145 residue (Figure 2.4). It also makes multiple hydrogen 
bonds with amino acid residues in the substrate binding pocket. In addition the amino acid chains 
(Ala, Val and Leu) part of the ligand provide N3 flexibility, which is a favourable aspect for protein-
ligand interaction. 
Through a combination of high throughput screening and structure-based virtual screening, over 
10,000 compounds including drugs, drug candidates and other pharmacologically active compounds 
were assayed as inhibitors of Mpro. Teriflunomide and its SF5 analogue consist of a covalent warhead 
capable of performing a Michael addition with the Sg atom of Cys145. In addition to these two 
compounds, 14 other potential candidates donated by eMoleculesÒ were provided for assays. Out of 
the 16 tested, a singleton hit (compound 2.7, Figure 2.21, Entry 16, Table 2.2) was identified which, 
gave a promising IC50 of 0.23 µM. The other compounds did not show a satisfactory inhibition of 
SARS CoV-2. Due to its singleton nature, we had limited confidence in its suitability as a Mpro 
inhibitor. 
 




















































































































































Figure 2.21:Compound 2.7 with IC50 = 0.23 µM 




Figure 2.22:SARS-CoV-2 Mproin complex with 4.6 
Docking image reveals ligand 2.7, (shown in orange) could covalently bind to the Sg atom of Cys145 
residue (Sg in yellow), following a Michael addition. Besides the covalent bond, two hydrogen bonds 
(yellow dashes) are formed between the O-H and Cys145, as well as the carbonyl and Ser144. In 
addition, hydrogen bonds to aromatic hydrogens (aromatic hydrogen bonds) and several hydrophobic 
interactions are observed. 
 
Once compound 2.7 was identified to have little activity against SARS-CoV-2 Mpro , it was tested 
for HDHODH affinity via a fluorescence assay run by Reaction Biology Corp®. Although it has 
structural similarities to teriflunomide, it was found to be inactive. Upon inspection using the docking 
software, we found that 2.7 occupies the binding pocket differently to teriflunomide. Figure 2.23 
shows both teriflunomide and 2.7 in the HDHODH binding pocket. Evidently, the hydrogen bond 
donors and acceptors on 2.7 lie in the hydrophobic tunnel of HDHODH. Thus, 2.7 is unable to 






                                       Figure 2.23:HDHODH in complex with  teriflunomide (purple) and 4.6 (orange) 
As HDHODH is a druggable target against SARS-CoV-2, we were interested in knowing the 
inhibitory effect of teriflunomide, SF5-teriflunomide (2.6) and 2.7 against SARS-CoV-2. 
The outer surface of coronaviruses contain a spike (S) protein which facilitates its entry into host 
cells. The S1 subunit of S protein attaches to ACE2 receptor which is found on the surface of target 
cells. In addition to this, transmembrane protease, serine 2 (TMPRSS2) processes S protein into its 
constituent subunits, S1 and S2 thus allowing the virus to fuse into the plasma membrane of the host 
cell.  
Cell-based assays were run by Dr M. Derveni from Dr Edward Wright’s group at the University of 
Sussex.  
 
Cytostatic drugs inhibit cell growth and multiplication. Teriflunomide was the most cytostatic with 
effects at concentrations above 0.78 µM and 2.7 the least cytostatic. SF5-teriflunomide (2.6) had 
cytostatic effects at concentrations >3.1 µM and DMSO had no measurable effect. Graph 2.1 shows 







               Graph 2.1: Effect of the teriflunomide compounds on HEK293T/17 viability using a colourimetric (MTS) assay. F-Ph-Cl 
denotes compound 2.7. 
The infection inhibition assay showed that none of the three compounds had an inhibitory effect 
against SARS-CoV-2 infection in the infected cells. Graph 2.2 shows % infection against a range of 
concentrations (log10[compound]) that was found to be non-toxic in the toxicity assay. The 
normalised data show that teriflunomide and SF5-teriflunomide (2.6) have no effect on the efficiency 
of infection while compound 2.7 appears to be acting as an agonist with increased concentration. 
 
 
Graph 2.2: Effect of teriflunomide and its analogues on SARS-CoV-2 infection of HEK293T/17 cells. F-Ph-Cl denotes compound 2.7 
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Work by R. Xiong et al. however shows that teriflunomide has potential to be a covid antiviral 
following an in vivo test. Furthermore, they all showed low toxicity to SARS-CoV-2 susceptible 
Vero E6 cells.92 
 
2.3 Conclusion 
SF5 substituted leflunomide (2.5) and teriflunomide (2.6) have been synthesised and tested for 
affinity towards the HDHODH binding pocket. Biophysical assays conveyed an approximately two-
fold greater affinity for SF5-teriflunomide (2.6) towards HDHODH compared with teriflunomide. 
Molecular binding studies also revealed that the bulky SF5 group fills the binding pocket better than 
the CF3 group. In comparison, OSO2CF3-teriflunomide (2.1, lit IC50 = 150 nM) fills the binding 
pocket better than both 2.6 and teriflunomide from our molecular docking studies. 
A singleton hit (2.7) with structural similarities to teriflunomide was identified to have affinity 
towards SARS-CoV-2 Mpro active site in the low micromolar range. Testing it against HDHODH, 
however, revealed no affinity.  
Teriflunomide, 2.6 and 2.7 did not give satisfactory inhibition of SARS-CoV-2 infection, besides 




4-(Pentafluorosulfanyl)aniline was obtained from Fluorochem and 5-Methyl-4-isoxazolecarbonyl 
chloride was bought from Apollo Scientific. 
Magnesium sulfate and sodium bicarbonate were obtained from Fisher Scientific. Preparative TLC 
was obtained from Analtech. Solvents and reagents were purchased from commercial suppliers and 
were used without purification. All reactions were performed in a fume hood. 
NMR spectra were recorded on Varian 500 MHz or 400 MHz spectrometers and chemical shifts are 
reported in ppm, usually referenced to TMS as an internal standard. LCMS were performed by 
Shimadzu LCMS-2020 equipped with a Gemini® 5µm C18 110Å column and percentage purities 
were ran over 30 minutes in water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-95% over 20 
min, 5 min at 95%) with the UV detector at 254 nm. Mass spectrometry: ESI mass spectra were 
obtained using a Bruker Daltonics Apex III, using Apollo ESI as the ESI source. For EI mass spectra, 
a Fissions VG Autospec instrument was used at 70 eV. All analyses were run by Dr. Iain Goodall at 
the University of Greenwich. Analyses are for the molecular ion peak [M]+ and are given in m/z, 
mass to charge ratio. Melting points were determined using a Stanford Research 
Systems Optimelt and are uncorrected. 





5‐Methyl‐N‐[4‐(pentafluoro‐l6‐sulfanyl)phenyl]‐1,2‐oxazole‐4‐carboxamide (2.5)  
 
4-(Pentafluorosulfanyl)aniline (500 mg, 2.28 mmol, 1.0 equiv.) was dissolved in isopropanol (IPA) 
(4 mL) followed by the addition of NaHCO3 (201 mg, 2.39 mmol, 1.05 equiv.). The mixture was 
heated to 60 °C and 5-methyl-4-isoxazolecarbonyl chloride (0.2 mL, 2.28 mmol, 1.0 equiv.) was 
added dropwise. The reaction was followed by TLC and after 2 hours of stirring, the reaction was 
allowed to cool to ambient temperature. The white precipitate formed was filtered under vacuum and 
washed with water and toluene. The product was dried. A colourless powder was isolated as pure 
product (530 mg, 71%). 1H NMR (600 MHz, CDCl3) δ 8.47 (s, 1H, NH), 7.77 – 7.72 (m, 2H, ArH), 
7.67 (d, J = 8.8 Hz, 2H, ArH), 7.55 (s, 1H, ArH), 2.77 (s, 3H, CH3); 13C NMR (151 MHz, CDCl3) δ 
174.3 (C=O), 159.2 (C=N), 149.7 (C-SF5), 147.3 (ArC), 139.8 (ArC), 127.2 (2C, m, ArC), 119.5 
(2C, ArC), 111.6 (ArC), 12.7 (CH3); 19F NMR (400 MHz, CDCl3) δ 84.62 (p, J = 150 Hz), 63.34 (d, 
J = 150 Hz). LCMS Purity (UV) = 97%, tR  20.1 min; HRMS – ESI (m/z) found 329.0385, calc. for 
[C11H9F5N2O2S][H]+:329.0383; IR (neat) νmax/cm-1: 3366 (N-H), 1663 (C=O), 824 (S-F); mp = 167 
– 168 °C. 
 
(2Z)‐2‐Cyano‐3‐hydroxy‐N‐[4‐(pentafluoro‐l6‐sulfanyl)phenyl]but‐2‐enamide (2.6)  
 
Compound 2.5 (304 mg, 0.93 mmol, 1.0 equiv.) was suspended in a mixture of IPA (2 mL) and water 
(2 mL). To the stirred mixture was added dropwise an aqueous solution of NaOH (39% in water) 
until the solution reached a pH of circa 12. At this point, all of the starting material dissolved in the 
solvent. The solution was filtered and concentrated. Concentrated HCl was added to the filtrate until 
pH 3. Precipitate appeared that was filtered, washed with water and dried under vacuum to obtain 
pure product as colourless powder (283 mg, 93%). 1H NMR (600 MHz, CDCl3) δ 7.79 – 7.74 (m, 
2H, ArH), 7.62 (d, J = 8.8 Hz, 2H, ArH), 2.38 (s, 3H, CH3); N-H and O-H not found; 13C NMR (151 
MHz CDCl3) δ 189.2 (C=O), 167.5 (CN), 150.2 (C-SF5), 138.6 (ArC), 127.3 (2C, ArC, m), 120.2 
(2C, ArC), 116.1(C), 80.6 (C), 22.1 (CH3); 19F NMR (400 MHz, CDCl3) δ 84.82 (p, J = 150.4 Hz), 
63.34 (d, J = 150.4 Hz). HPLC Purity (UV) = 99%, tR  17.9 min; HRMS – ESI (m/z) found 328.0247, 
calc. for [C11H9F5N2O2S][H]+:327.0227; IR (neat) νmax/cm-1: 3312 (N-H), 2219 (CN), 1641 (C=O), 















2.4.2 Toxicity assay and SARS-CoV-2 infection inhibition assay 
HEK293T/17 cells were transiently transfected with human ACE2 and TMPRSS2. The three 
compounds were added to the HEK293T/17 cells in concentrations ranging from 200 to 0.4 µM 
followed by addition of SARS-CoV-2. Control wells included virus and target cell without 
ligands/DMSO and target-cell only wells. Furthermore, a toxicity assay (MTS assay) was carried out 
to assess cell viability. HEK293T/17 at a concentration of 4x105 cells/mL was added to each well 
containing teriflunomide and its analogues (200 to 0.4 µM concentration range) as well as to a control 
well with only DMSO. A cell only control well was also set up. After incubating the wells for 48 
hours in a 37 °C/5% CO2 incubator they were examined microscopically. 20 mL of MTS reagent 
was then added to the wells and incubated for 4 hours. 
Microscopic examination of the cells showed healthy cells at concentrations between 50 – 0.4 µM. 
Cells in DMSO-only wells showed no visible difference to the cell-only control wells. Addition of 






























Chapter 3.0 A Library of SF5 Containing Small molecules  
3.1 Introduction 
Small organic molecules are indispensable as they can be used as powerful tool compounds (chemical 
probes) to explore biological systems and as therapeutics.124 Owing to the relative dearth and high 
cost of commercially available pentafluorosulfanyl containing compounds, we synthesised several 
SF5-comprising small molecules via a simple amide bond construction. The majority of the amides 
in this library were synthesised to increase SF5-containing building block space, which can be useful 
scaffolds for others to expand upon according to their interests. During the process, a couple of 
compounds were synthesised to be analysed as potential Covid-19 antivirals as part of an 
international collaboration.  
 
Jonathan Clayden states in his paper that amide is king in medicinal chemistry.125 Their notable 
stability as well as exceptional polarity make them prevalent in medicinal chemistry. The high 
polarity allows amide-containing drugs to interact with biological receptors and enzymes.125 
Moreover, amide bonds link amino acids to form proteins, therefore, are pivotal for peptide 
synthesis.126 An amide typically consists of a hydrogen bond donor (N-H) and an acceptor (C=O) 
site and possesses a unique ability to form relevant hydrogen bonding interactions.127 This 
characteristic is of particular interest when developing drug-like compounds as it can contribute to 
improved binding affinity. Nevertheless, amide activity can be compromised in vivo by enzymatic 
cleavage resulting in toxic metabolites.128 Amides are also present in industrial materials such as 
detergents, polymers and lubricants. These are adequate reasons as to why amide bond formation is 
one of the most common reactions carried out by medicinal and synthetic chemists.129  
We coupled commercially available 3- and 4-pentafluorosulfanylbenzoyl chlorides with a range of 
amines to build our library. 
Morpholine and piperazine are privileged backbones, due to their versatile binding properties. They 
are often used as substituents in drugs and medicinal chemistry. They have the potential to improve 
pharmacokinetic properties such as water solubility and metabolic stability of molecules although, 
they are not always crucial for direct receptor binding.130 Several drug molecules contain piperazine 
and morpholine viz. moclobemide (antidepressant), gefitinib (anticancer agent), cyclizine (anti-
sickness drug), and amoxapine (antidepressant) (Figure 3.1). Piperazine and morpholine are 
frequently used as handles to modulate lipophilicity while achieving desired pharmaceutical 





Figure 3.1: Piperazine and morpholine containing drugs 
The highly functionalised piperidine core is found in several natural products. It possesses a range of 
biological activities like antibacterial, antimalarial, anti-inflammatory properties, giving it 
tremendous importance in medicinal chemistry. It is considered a privileged structure due to its 
affinity for multiple targets131. Moreover piperidine is one of the most used heterocycles in 
pharmaceutical agents, typically as a linker or to improve a drug’s pharmacokinetic profile, in 
particular, transportation.132 Industrially pyridine is used to synthesise piperidine. Like piperidine, 
pyridine possesses several properties that make it attractive to a medicinal chemist. Similar to 
piperazine and morpholine, piperidine possesses properties like basicity, water solubility, hydrogen 
bond forming ability and its small molecular size makes pyridine an interesting substituent in drug 
discovery. 
 
A novel small molecule library generated by combining the aforementioned privileged scaffolds with 
the sought after SF5 moiety via an amide link can serve useful as part of high-throughput screening. 
A couple of compounds from the amide linked library have been screened against SARS-CoV-2 
main protease (Mpro, also known as 3CLpro) as potential inhibitors as part of the COVID Moonshot 
project, which was mentioned in Chapter 2.0. The Moonshot project obtained several compounds 
through crowdsourcing, which were screened using high throughput crystallography and 
computational chemistry to identify covalent and non-covalent Mpro inhibitors. As discussed in 
Chapter 2.0, Mpro is an essential protease in the life cycle of SARS-CoV-2 that has been recognized 























strategy. Such inhibitors were anticipated to irreversibly modify the cysteine catalytic residue, 
Cys145, resulting in the inhibition of Mpro protease. 
This chapter will discuss non-covalent inhibitors of Mpro. Covalently bound inhibitors that may give 
longer half-life of action but may lead to off-target toxicity and side effects. Research into developing 
non-covalent inhibitors is therefore essential.  
Based on the structure of Mpro, machine learning approaches and insights from past literature on 
SARS and MERS, drug designers across the world have contributed over 10,000 individual molecule 
designs to the COVID Moonshot initiative. Remdesivir is an antiviral that was initially produced to 
combat hepatitis C and a cold like virus called respiratory syncytial virus albeit being ineffective for 
both the diseases. Remdesivir however, showed potency against viruses in the coronavirus family in 
a cell and animals-based study. In SARS-CoV and MERS-CoV it works by interrupting the 
production of the virus by interfering with one of the key enzymes, RNA-dependent RNA 
polymerase (RdRp), which the virus needs to replicate RNA.133,134 Early studies showed that 
Remdesivir accelerated recovery of COVID-19 patients and it was the first drug to be authorised to 
treat hospitalised patients. Following its success, Nguyen et al. investigated Remdesivir’s exact target 
of action.135 In vitro analysis showed that the EC50 value of remdesivir for SARS-CoV-2 is 0.77 
μM.135 By combining a few techniques such as molecular docking, umbrella sampling, and steered 
molecular dynamics they tested Remdesivir’s affinity towards RdRp and Mpro. Their combined 
studies revealed that Remdesivir has affinity towards both the targets mentioned with slightly weaker 
affinity towards Mpro. For example, the work spent on pulling remdesivir from the Mpro binding site 
was calculated to be significantly lower than the amount of work spent on retrieving remdesivir from 
RdRp. The calculated values are 106.2 ± 11.6 kcal/mol for Mpro and 144.6 ± 19.2 kcal/mol for RdRp. 
 
While electrostatic interactions stabilize the RdRp-Remdesivir complex, van der Waals interactions 
dominate in the Mpro-Remdesivir complex. Figure 3.2 shows a few non-covalent warheads identified 
in Mpro as part of Covid Moonshot program. TRY-UNI-714a760b-6 was initially identified and by 
fragment merge, the other two compounds (ADA-UCB-6c2cb422-1 & MAT-POS-b3e365b9-1) 
were synthesised. In an antiviral assay, ADA-UCB-6c2cb422-1 showed antiviral activity (IC50 = 3.1 
µM) similar to Remdesivir (IC50 = 1.7 µM, Figure 3.3). To add to this series, we synthesised a small 
number of compounds by modifying TRY-UNI-714a760b-6 which were analysed in the Mpro 
binding site using Schrodinger Maestro. The synthesised compounds have also been contributed to 





Figure 3.2: Non-covalent warheads showing promising IC50 following fluorescence Mpro  inhibition assay 
 
 
Figure 3.3: Remdesivir, an RNA antiviral 
 
3.2 Results and Discussion 
3.2.1 Synthesis 
Amide couplings were initially attempted by combining amines with 4-pentafluorosulfanylbenzoyl 
chloride in the presence of triethylamine base as an HCl scavenger and dichloromethane (DCM) as 
the solvent (Table 3.1).  
Attempted coupling of 4-pentafluorosulfanyl benzoyl chloride with 1-methyl-piperazine (3.1c) led 
to poor yields and the free benzoic acid was detected in the crude reaction mixture, suggesting acid 
chloride hydrolysis. Hence, the coupling agent HATU (hexafluorophosphate azabenzotriazole 


































3.4). Much to our surprise, even in the absence of a coupling agent, reaction with morpholine and the 
acid chloride delivered excellent yield (93%). 
 
    
 












Table 3.1:Amide coupling products  of 4-SF5-benzoyl chloride  and heterocycles 
 
 
Figure 3.4: Amide coupling agent hexafluorophosphate azabenzotriazole tetramethyl uronium 
HATU is a popular phosphonium based coupling reagent used for simple amide couplings as well as 
long chain peptide synthesis.136 The precise mechanism of HATU mediated coupling is unknown. A 
mechanism proposed by Reszka et al. is shown in Scheme 3.1. An active species a is initially 
generated upon reaction between the carboxylic acid and the benzotriazole species. a Is involved in 
the formation of an ester, b, which exists in equilibrium with its corresponding N-oxide, c.137 The 
































Scheme 3.1: HATU mediated peptide bond formation mechanism136  
Coupling 1-methyl-piperazine and 1-Boc-piperazine with 4-SF5-benzoyl chloride in the presence of 
HATU rendered excellent yields (80% and 91% respectively, Table 3.2) 
  
 



































































































3.1d was successfully deprotected and further functionalised as its amide (3.1e) and sulphonamide 
(3.1f) derivatives (Scheme 3.2 & Table 3.3). 
 











The same reactions were performed on 3-SF5-benzoyl chloride. Only piperidine (3.2a) was coupled 
in the absence of HATU as it gave excellent yield (97%). Yields were generally low in comparison 
with 4-SF5-benzoyl chloride couplings. The carbonyl carbon of 4-SF5-benzoyl chloride is more 








































for the reduction in yields. Yield is significantly low in the case of 1-methyl-piperazine (17%, 3.2b). 
The reduction in yield was mainly due to difficulty in purification (crude yield, 40%). 
   
















Table 3.4: Amide coupling products  of 3-SF5-benzoyl chloride  and heterocycles 
Similar to 3.1(e-f), 3.2(e-f) were synthesised in excellent yields (Scheme 3.3 and Table 3.5).  
  




















































To assist rapid purification of solution phase reactions solid supported scavenger resins are often 
used, especially in peptide syntheses that involve multiple steps.138 In several of our amide couplings, 
we utilised MP-Trisamine (macroporous polystyrene-bound nucleophilic scavenger), which is a 
powerful scavenger for acidic or electrophilic species such as acid chlorides.139,17,18 Simply stirring 
the crude reaction mixture with 3 equivalents of MP-Trisamine for 1-2 hours eliminates the need for 
a base wash. Upon filtration, the reaction mixture is free of the acid chloride. 
 
Compounds 3.3(a-b) are analogues of TRY-UNI-714a760b-6 representing a bioisosteric 
replacement of chlorine with CF3 and SF5 (Figure 3.5) and the 4-methyl chain has been replaced with 
a carboxamide group. The attempted strategy to synthesise 3.3(a-b) did not yield the desired 
products, instead cyclised derivatives 3.3(c-d) were obtained (Scheme 3.4). The hypothesis is that 
3.3(a-b) are formed initially in the presence of ammonia and are rapidly cyclised to 3.3(c-d) under 
reflux conditions (Scheme 3.5). 3.3c was crystallised by diffusion method using hexane and 
dichloromethane to obtain colourless crystals whereby an X-ray structure was obtained (Figure 3.6). 
 
   







3.3a; R = CF3






















   
Scheme 3.4: Unexpected Synthesis of 3.3(c-d) 
  






















3.3c; R = CF3; 23%
3.3d; R = SF5; 25%







3.3a; R = CF3


















3.3i; R = CF3









3.3c; R = CF3; 23%
3.3d; R = SF5; 25%
3.3a; R = CF3





Figure 3.6: X-ray structure of 3.3c 
Attempts to synthesise compounds 3.3(a-b) were futile. However, the synthesis of 3.3e was achieved 
following the hydrolysis of 3.3i by Dr Dan Guest, a Sussex collaborator on this project (Scheme 3.6). 
  
Scheme 3.6: Ester hydrolysis of 3.3i to afford 3.3e 
3.2.2  Modelling 
Molecular docking was performed on 3.3 (c-d) and compared with TRY-UNI-714a760b-6, ADA-
UCB-6c2cb422-1 and 3.3 (a-b). In figure 3.7, we present a ligand interaction diagram of 3.3 (a-b) 
with Mpro of SARS-CoV-2. 3.3a forms hydrogen bonding with His41 and Cys145 residues. A pi-pi 
aromatic interaction is formed by both ligands through respective pyridine rings. 3.3b also forms 
several hydrogen bonds through the amino and carbonyl groups. The hydrophobic heads of the 
ligands must be forming several hydrophobic interactions with amino acid residues such as Leu167, 
Ala191, etc that are in close proximity. Figure 3.8 shows the pose of TRY-UNI-714a760b-6 that has 
the best binding affinity in the Mpro binding pocket, as determined by the software. Orientation of the 
ligand is quite different to that of 3.3 (a-b). The piperidine ring carrying the polar functionalities is 
essentially in the same region as the other two ligands. However, the hydrophobic tail has flipped in 
orientation. The hydrophobic tail is now in proximity with amino acid residues Ser144 and Asn142 
that are non-hydrophobic. Similar to 3.3b, TRY-UNI-714a760b-6 forms a pi-pi interaction with 






































Figure 3.8: TRY-UNI-714a760b-6; HIE denotes histidine 
ADA-UCB-6c2cb422-1 docked in the Mpro binding site is shown in Figure 3.9. The ligand has lost 
the pi-pi interaction between the pyridine ring and His41 residue due to the increased distance 
between the species. However, the ligand is able to contribute hydrophobic interactions as well as a 
hydrogen bond with Cys145 and Glu166, to aid binding. ADA-UCB-6c2cb422-1 has a different 




















ADA-UCB-6c2cb422-1 and 3.3d have similar poses as can be seen in Figure 3.10. The ligand 3.3d 
makes several hydrophobic interactions as well as aromatic hydrogen bonds while the pi-pi stacking 
and hydrogen bond with Cys145 are non-existent. Hydrogen bonds that arise between aromatic 
hydrogens and hydrogen bond acceptors are referred to as ‘aromatic hydrogen bonds’, by 
Schrodinger Maestro. Aromatic hydrogens can acts as hydrogen bond donors  due to partial charges 
















Ligand 3.3c has quite a different orientation when binding compared to the other ligands (Figure 
3.11). It makes one hydrogen bond like 3.3c with Glu166. Unlike 3.3d, 3.3c does not form many 
aromatic hydrogen bonds. It has the potential to form a hydrophobic interaction with Met49.  
 
Figure 3.9: a); Ligand interaction diagram of ADA-UCB-6c2cb422-1, b);ADA-UCB-6c2cb422-1 (blue) and 3.3c(pink) in 
complex with Mpro; blue dashed lines indicate aromatic hydrogen bonds. 
 
Figure 3.10: a) ligand interaction diagram of 3.3d, b) 3.3d (red) overlapped with ADA-UCB-6c2cb422-1 (blue), blue dashed 






Figure 3.11: Ligand interaction diagram of 3.3c 
3.3e interacts with the Mpro binding point through multiple hydrogen bonds including aromatic 
hydrogen bonds and hydrophobic clashes (Figure 3.12). 
 
 
Figure 3.12: Ligand interaction diagram of 3.3e 
Analysis of the ligand interaction diagrams reveals that ligands 3.3 (a-b) are the better predicted 
binders at the Mpro binding site. 
 
A fluorescence assay revealed that ligand 3.3 (e) did not have significant inhibition below 20 µM 




























The figures below demonstrate the dose response curves of TRY-UNI-714a760b-6 and ADA-UCB-
6c2cb422-1 (Figure 3.14).142 Percentage inhibition of ADA-UCB-6c2cb422-1 drops after 10 µM 















Figure 3.13: Dose response curve for ligands 3.3c (a), 3.3d (b) and 3.3e (c). Graphs 
taken from www.covid.postera.ai. 
 
Figure 3.14: Dose response curves of a) TRY-UNI-714a760b-6 and b) ADA-UCB-6c2cb422-1. 
Graphs taken from www.covid.postera.ai 
c) 
  a) b) 
71 
 
Even though, the binding modes of ADA-UCB-6c2cb422-1 and ligand 3.3d were similar from the 
docking studies, 3.3d hardly inhibited the virus. None of the compounds synthesised had superior 
inhibitory effect compared to the original ligands, TRY-UNI-714a760b-6 and ADA-UCB-
6c2cb422-1. Although possible activity of ligands 3.3(a-b) could not be determined, analysing an 
analogue (TRY-UNI-714a760b-20) of TRY-UNI-714a760b-6 with a nitrile in the place of chlorine 
revealed a decrease in inhibition of viral activity (61 µM). On the other hand, adding an electron-
donating group improved the inhibition (4 µM) (Figure 3.15). 
 
 
Figure 3.15: Comparison of TRY-UNI  analogues with electron-donating and withdrawing substituents 
3.3 Conclusion 
To conclude, a library of compounds has been synthesised by coupling N-heterocycles with 3 and 4-
SF5-benzoyl chlorides in order to expand SF5-building block space (Table 3.6). Moreover, two 
compounds [3.3(c-d)] from the library were analysed in vitro (Table 3.7) and in silico for their 

























































Table 3.6: Library of amides synthesised 










Table 3.7: Compounds tested for antiviral activity 
3.4 Experimental 
All reagents were purchased from Merck, Fisher Scientific UK Ltd, SpiroChem AG, Fluorochem 
Ltd, and used without further purification. 1H NMR spectra were recorded on Varian VNMRS 600 
MHz spectrometers, at room temperature, using deuterated solvent for calibration ((CD3Cl at 7.26 
ppm, (CD3)2SO at 2.50 ppm or CD3OD at 3.31ppm). 13C NMR analyses were recorded on Varian 
VNMRS 600 MHz 600 MHz spectrometers, at room temperature, using deuterated solvent for 
calibration (CDCl3 at 77.16 ppm, (CD3)2SO at 39.52 ppm or CD3OD at 49.00 ppm). 19F NMR were 
recorded on Varian VNMRS 376 MHz spectrometers, at room temperature, using deuterated solvent 











































standard, and data reported as s = singlet, d = doublet, t = triplet, q = quadruplet, p = pentet,  ddd = 
doublet of doublets of doublets, m = multiplet; integration. Mass spectrometry analyses were 
conducted by Dr Abdul-Sada. ESI mass spectra were obtained using a Bruker Daltonics Apex III, 
using Apollo ESI as the ESI source; EI mass spectra were obtained using a Fissions VG Autospec 
instrument used at 70 eV. Elemental analyses were conducted by Mr Stephen Boyer from the London 
Metropolitan University. Melting points were determined using a Stanford Research 
Systems Optimelt and are uncorrected. LCMS were performed by Shimadzu LCMS-2020 equipped 
with a Gemini® 5µm C18 110Å column and percentage purities were ran over 30 minutes in 
water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-95% over 20 min, 5 min at 95%) with the 





Triethylamine (247.4 mg, 2.44 mmol, 1.3 equiv.) was added to piperidine (176.0 mg, 2.07 mmol, 1.1 
equiv.) dissolved in dichloromethane (2 mL) followed by dropwise addition of 4-
(pentafluorosulfanyl) benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv.). The reaction mixture was 
stirred at room temperature overnight. It was then diluted with dichloromethane (5 mL) and washed 
with 2M HCl (10 mL x 3). The aqueous layers were extracted with dichloromethane (15 mL x 3), 
dried over MgSO4, filtered and concentrated in vacuo. The crude was purified over a column of silica 
(dichloromethane:methanol, 9:1) to obtain a colourless solid as the title compound (451.0 mg, 76%). 
1H NMR (600 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 2H, ArH), 7.43 (d, J = 8.4 Hz, 2H, ArH), 3.66 (m, 
2H, CH2), 3.24 (m, 2H, CH2), 1.63 (m, 4H, (CH2)2), 1.47(m, 2H, CH2). 13C NMR (151 MHz, CDCl3) 
δ 168.0 (C=O), 154.1(p, J = 17.8 Hz, ArC-SF5), 139.9 (ArC), 127.1 (2ArC), 126.2 (m, 2ArC-CSF5), 
48.6 (C), 43.1 (C), 26.4 (C), 25.4 (C), 24.3 (C); 19F NMR (400 MHz, CDCl3) δ 83.75 (m, F), 62.53 
(d, J= 150.0 Hz, 4F); LCMS Purity (UV) = 95%, tR 19.5 min; HRMS – ESI (m/z) found 316.0789, 
calc. for [C12H14F5NOS][H]+:316.0789; IR (neat) νmax/cm-1: 2945, 1627, 817; mp 84.5 - 86.7 °C. 
 
[4-(Pentafluorol-l6-sulfanyl)phenyl)](morpholino)methanone  (3.1b) 
 
To morpholine (180.3 mg, 2.07 mmol, 1.1 equiv.), dissolved in dichloromethane (2 mL) was added 
triethylamine (247.0 mg, 2.44 mmol, 1.3 equiv.), followed by dropwise addition of 4-
(pentafluorosulfanyl) benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv). The reaction mixture was 










mL) and the organic layer was washed with 2M HCl (10 mL x 3). The combined aqueous layers were 
extracted with dichloromethane (15 mL x 3). The organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified over a column of silica 
(dichloromethane:methanol, 9:1) to afford a colourless solid as the title compound (556.0 mg, 93%). 
1H NMR (600 MHz, CDCl3) δ 7.58 (d, J= 8.1 Hz, 2H, ArH), 7.30 (d, J= 8.1 Hz, 2H, ArH), 3.33 (m, 
8H, ((CH)2)4); 13C NMR (151 MHz, CDCl3) δ 168.1 (C=O), 154.2 (p, J = 17.7 Hz, ArC-SF5), 138.7 
(ArC), 127.4 (2ArC), 126.3 (m, 2ArC), 66.5 (2C, N-(CH2)2, 47.9 (CH2), 42.4 (CH2); 19F NMR (400 
MHz, CDCl3) δ 83.40 (p, J = 150.3, F), 62.39 (d, J = 150.3 Hz, 4F); LCMS Purity (UV) = 95%, tR 
18.3 min; HRMS – ESI (m/z) found 340.0394, calc. for [C11H12F5NO2S] [Na]+: 340.0401. IR (neat) 




To 1-methyl piperazine (188.0 mg, 1.88 mmol, 1.0 equiv.), dissolved in dichloromethane (2 mL) was 
added triethylamine (190.3 mg, 1.88 mmol, 1.0 equiv.), followed by dropwise addition of 4-
(pentafluorosulfanyl) benzoyl chloride (250.0 mg, 0.94 mmol, 0.5 equiv.) and HATU (391.2 mg, 
0.94 mmol, 0.5 equiv.). The reaction mixture was stirred at room temperature overnight and then 
diluted with dichloromethane (10 mL). The reaction mixture was filtered and the organic filtrate was 
washed with water (10 mL x 3) and the aqueous layer extracted with dichloromethane (10 mL x 3). 
The organic layer was then dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was purified over a column of silica (dichloromethane:methanol, 9:1) to afford a yellow solid as the 
title compound (257 mg, 83%). 1H NMR (600 MHz, CDCl3) δ 7.78 (m, 2H, ArH), 7.52 (m, 2H, 
ArH), 3.78 (m, 2H, CH2), 3.39 (m, 2H, CH2), 2.50  (m, 4H, (CH2)2), 2.30 (s, 3H, CH3). 13C NMR 
(151 MHz, CDCl3) δ 168.0 (C=O), 153.9 (m, ArC-SF5), 136.6 (ArC), 130.1 (ArC), 129.1 (ArC), 
127.1 (m, ArC-CSF5),124.9 (m, ArC-CSF5), 54.8 (2C), 47.6 (C), 45.9 (CH3), 42.2 (C); 19F NMR 
(400 MHz, CDCl3) δ 83.50 (m, F), 62.67 (d, J = 150.3 Hz, 4F); LCMS Purity (UV) = 98%, tR 11.6 
min. HRMS – ESI (m/z) found 331.0901, calc. for [C12H15F5N2OS][H]+:331.0898. IR (neat) νmax/cm-
















To N-Boc piperazine (385.5 mg, 2.07 mmol, 1.1 equiv.), dissolved in dichloromethane (3 mL) was 
added triethylamine (247.0 mg, 2.44 mmol, 1.3 equiv.) and the mixture was stirred for a few minutes. 
HATU (787.1 mg, 2.07 mmol, 1.1 equiv) was added to this solution followed by dropwise addition 
of 4-(pentafluorosulfanyl) benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv.). The reaction mixture 
was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane 
(5 mL) and the precipitate formed was discarded after gravity filtration. MP-Trisamine scavenger 
resin (520.0 mg, 3.0 mmol, 1.6 equiv.) was added to the filtrate and after 3 hours, the scavenger was 
removed by gravity filtration. The crude material was purified over a column of silica 
(dichloromethane:methanol, 9:1) to obtain a white solid as the title compound (352.0 mg, 76%). 1H 
NMR (600 MHz, CDCl3) δ 7.67 (m, 2H, ArH), 7.37(m, 2H, ArH), 3.78 –3.49 (m, 4H), 3.40 –3.32 
(m, 4H), 1.32 (s, 9H, (CH3)3); 13C NMR (151 MHz, CDCl3) δ 168.4 (C=O), 154.6 –153.9 (m, 2C, 
C=O, ArC-SF5), 138.8 (ArC), 127.4 (2ArC), 126.5 (2ArC), 80.5 (C), 47.4 (2C), 42.1 (2C), 28.3 (3C); 
19F NMR (400 MHz, CDCl3) δ 83.32 (p, J = 150.2 Hz, F), 62.47 (d, J = 150.2 Hz, 4F); LCMS Purity 
(UV) = 97%, tR  21.5 min; HRMS - ESI (m/z) found: 439.1078, calc. for [C16H21F5N2O3S][Na]+: 






Compound 3.1d was dissolved in dichloromethane (2 mL) and treated with HCl in dioxane (4M, 6.0 
equiv.) overnight to remove the Boc group. The reaction was monitored by TLC. Following the 
completion of the reaction, it was concentrated in vacuo to obtain the HCl salt (4‐[4‐(pentafluoro‐l6‐
sulfanyl)benzoyl]piperazinyl hydrochloride, 3.1d’), as a colourless solid. Compound 3.1d’ was used 
without purification in the following step. 
To 3.1d’ (80.0 mg, 0.2 mmol, 1.0 equiv.), dissolved in THF (1.0 mL), was added triethylamine (20.0 
mg, 0.2 mmol, 1.0 equiv.). The reaction mixture was stirred for 30 minutes, followed by which, acetic 
anhydride (20 mg, 0.2 mmol, 1.0 equiv.) was added to the mixture and this was stirred at room 
temperature overnight. The crude was dissolved in dichloromethane (5 mL) and passed through a 
hydrophobic frit, to collect the organic layer. Afterwards, the crude material was purified over a 
column of silica (dichloromethane:methanol; 7:3) to obtain the pure product as a colourless solid (59 
mg, 82%). 1H NMR (600 MHz, CDCl3) δ 7.81 (d, J = 8.4 Hz, 2ArH), 7.49 (d, J = 8.4 Hz, 2ArH), 
3.89 –3.64 (m, 4H, piperazine), 3.56 (s, 3H, CH3), 3.47 –3.30 (m, 4H, piperazine); 13C NMR (151 








126.6 (2ArC), 47.3 (bs, C), 46.1 (bs, C), 42.1 (bs, C), 41.3 (bs,  C), 21.4 (CH3) 19F NMR (400 MHz, 
CDCl3) δ 83.32 (p, J = 150.4 Hz, 1F), 62.96 (d, J = 150.4 Hz, 4F); HPLC Purity (UV) = 95%, tR 
13.3 min; HRMS – ESI (m/z) found 381.0665, calc. for [C13H15F5N2O2S][Na]+ :381.0667; IR (neat) 
νmax/cm-1 2917(C-H), 1633 (C=O), 1625(C=O), 820 (S-F); mp 158 – 160 ºC. 
 
(4-Pentafluoro-l6sulfanyl phenyl)(4-(methylsulfonyl)piperazin-1-yl)methanone (3.1f) 
 
To crude 3.1d’ (82.0 mg, 0.23 mmol, 1.0 equiv.) dissolved in THF (3.0 mL) was added triethylamine 
(23.0 mg, 0.23 mmol, 1.0 equiv.) and the mixture was stirred for 30 minutes. Methanesulfonyl 
chloride (32.0 mg, 0.28 mmol, 1.2 equiv.) was added to the reaction mixture, which was stirred 
overnight at room temperature. The reaction mixture was quenched with dichloromethane (5 mL) 
and water (5 mL) then passed through a hydrophobic frit. 
The crude was purified over column of silica (dichloromethane:methanol; 3:2) to get the pure product 
as a colourless solid (43 mg, 48%). 1H NMR (600 MHz, CDCl3) δ 7.83 (d, J = 8.2 Hz, ArH, 2H), 
7.50 (d, J = 8.2 Hz, ArH, 2H), 3.90 (m, CH2, 2H), 3.52 (m, CH2, 2H), 3.34 (m, CH2, 2H), 3.18 (m, 
CH2, 2H), 2.81 (s, CH3, 3H); 13C NMR (151 MHz, CDCl3) δ 168.4 (C=O), 154.8 (m, C-SF5), 138.1 
(ArC), 127.5 (ArC, 2C), 126.7 (ArC, 2C), 47.2 (CH2), 46.0 (CH2), 45.5 (CH2), 41.8 (CH2), 35.1 
(CH3); 19F NMR (376 MHz, CDCl3) δ 82.99 (p, J = 150.3 Hz, 1F), 62.51 (d, J = 150.3 Hz, 4F); 
HRMS - ESI (m/z) found 417.0342, calc. for [C12H15F5N2O3S2][Na]+:417.0349; Anal. calc (%) for 
C12H15F5N2O3S2: C, 36.55; H, 3.83; N, 7.10; found (%): C, 36.65; H, 3.69; N, 6.98. IR (neat) νmax/cm-





This was made as for its 3.1a-analogue, from piperidine (175.8 mg, 2.07 mmol, 1.1 equiv.), 
triethylamine (247.0 mg, 2.44 mmol, 1.3 equiv.), and 3-(pentafluorosulfanyl)benzoyl chloride (500.0 
mg, 1.88 mmol, 1.0 equiv.). It was obtained as a colourless solid (572.0 mg, 97%).1H NMR (600 
MHz, CDCl3) δ 7.72 (m, 2H, ArH), 7.47 (m, 2H, ArH), 3.46 (m, 4H, 2CH2), 1.63 (m, 4H, 2CH2), 
1.47 (m, 2H, CH2). 13C NMR (151 MHz, CDCl3) δ 167.9 (C=O), 153.7 (C-SF5, p, 2JF,C = 17.5 Hz), 
137.3 (ArC), 129.8 (ArC), 128.9 (ArC), 126.6 (ArC-CSF5, m), 124.6 (ArC-CSF5, m), 48.6 (N-CH2), 











(d, J = 150.0 Hz); LCMS Purity (UV) = 96%, tR 21.0 min; HRMS – ESI (m/z) found 316.0785, calc. 
for [C12H14F5NOS][H]+: 316.0789; IR (neat) νmax/cm-1: 3680, 1633, 820; mp 88 – 90 °C. 
 
 
(3-(Pentafluoro-λ6-sulfanyl)phenyl](4-methylpiperazin-1-yl)methanone  (3.2b) 
 
To N-methylpiperazine (207.0 mg, 2.07 mmol, 1.1 equiv.), dissolved in dichloromethane (2 mL) was 
added triethylamine (247.4 mg, 2.44 mmol, 1.3 equiv.) together with HATU (787.0 mg, 2.07 mmol, 
1.1 equiv.) and, finally, 3-(pentafluorosulfanyl)benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv.) 
was added dropwise. The reaction mixture was stirred at room temperature overnight, then filtered 
and the filtrate was stirred with MP Trisamine (3 equiv.) for 3 hours to remove the unreacted acid 
chloride. The crude product was purified over a column of silica (dichloromethane:methanol; 9:1) to 
give a colourless gum as the title compound (107 mg, 17%).1H NMR (600 MHz, CDCl3) δ 7.79 
(ArH, m, 2H), 7.53 (ArH, m, 2H), 3.80 (CH2, bs, 2H), 3.41 (CH2, bs, 2H), 2.50 (CH2, bs, 2H), 2.36 
(CH2, bs, 2H), 2.32 (CH3, s, 3H); 13C NMR (151 MHz, CDCl3) δ 168.1 (C=O), 153.9 (ArC-SF5, p, 
2JFC= 17.8 Hz), 136.6 (ArC), 130.1 (ArC), 129.1 (ArC), 127.1 (ArC, p, 2JFC= 4.4 Hz), 124.9 (ArC, 
p, 2JFC= 4.4 Hz), 55.0 (C), 54.5 (C), 47.6 (C), 45.8 (C), 42.2 (C); 19F NMR (376 MHz, CDCl3) δ 
83.45 (1F, p, J = 150.1 Hz), 62.83 (4F, d, J = 150.1 Hz); LCMS Purity (UV) = 97%, tR 7.1 min; 
HRMS - ESI (m/z) found:331.0896, calc. for [C12H15F5N2OS][H]+:331.0898; IR (neat) νmax/cm-1- 





To morpholine (180.30 mg, 2.07 mmol, 1.1 equiv.), dissolved in dichloromethane (2 mL), was added 
triethylamine (246.90 mg, 2.44 mmol, 1.3 equiv.) and the mixture was stirred for a few minutes. 
HATU (787.10 mg, 2.07 mmol, 1.1 equiv.) was added to this solution followed by dropwise addition 
of 3-(pentafluorosulfanyl)benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv.). The reaction mixture 
was stirred at room temperature overnight then diluted with dichloromethane (5 mL) and the 
precipitate formed was discarded after gravity filtration. MP-Trisamine (520.0 mg, 3.00 mmol, 1.6 
equiv.) was added to the filtrate and stirred for 3 hours after which the scavenger was removed by 











obtain a colourless solid as the title compound (317.0 mg, 53%). 1H NMR (600 MHz, CDCl3) δ 7.75 
– 7.71 (m, 2H, ArH), 7.50 –7.43 (m, 2H, ArH), 3.75 –3.63 (m, 4H, (CH2)2), 3.57 –3.26 (m, 4H, 
(CH2)2); 13C NMR (151 MHz, CDCl3) δ 168.0 (C=O), 153.8 (p, J= 17.7 Hz, ArCSF5), 136.2 (ArC), 
130.1(ArC), 129.1 (ArC), 127.2 (p, J = 4.5 Hz, (ArC-CSF5)), 124.9 (p, J = 4.5 Hz, ArC-CSF5), 66.6 
(4C); 19F NMR (376 MHz, CDCl3) δ 84.29 – 82.21 (m), 62.66 (d, J = 150.4 Hz); LCMS Purity (UV) 
= 97%, tR 18.3 min; HRMS – ESI (m/z) found 340.0384, calc. for [C11H12F5NO2S][Na]+: 340.0401; 





tert-Butyl 4-(3-pentafluoro-l6-sulfanyl benzoyl)piperazine-1-carboxylate (3.2d) 
 
To N-Boc piperazine (385.5 mg, 2.07 mmol, 1.1 equiv.), dissolved in dichloromethane (3 mL) was 
added triethylamine (247.0 mg, 2.44 mmol, 1.3 equiv.) and the mixture was stirred for a few minutes. 
HATU (787.2 mg, 2.07 mmol, 1.1 equiv.) was added to this solution followed by dropwise addition 
of 3-(pentafluorosulfanyl)benzoyl chloride (500.0 mg, 1.88 mmol, 1.0 equiv.) and the reaction 
mixture was stirred at room temperature overnight. After completion of the reaction, it was diluted 
with dichloromethane (10 mL) and the precipitate formed was removed by filtration. MP Trisamine 
(520 mg, 3 mmol, 1.6 equiv.) was added to the filtrate then removed by gravity filtration after 3 hours 
of stirring. The crude material was purified over a column of silica (dichloromethane:methanol, 9:1) 
to obtain a colourless solid as the title compound (573.0 mg, 73%). 1H NMR (600 MHz, CDCl3) δ 
7.81(m, 2H, ArH), 7.53 (m, 2H, ArH), 3.51 (m, 4H, (CH2)2), 3.39 (m, 4H, (CH2)2), 1.45 (s, 9H, 
(CH3)3); 13C NMR (151 MHz, CDCl3) δ 168.4 (C=O), 154.5 (C=O), 154.0 (ArC-SF5), 136.3 (ArC), 
130.1 (ArC), 129.2 (ArC), 127.4 (ArC-CSF5), 125.0 (ArC-CSF5), 80.5 (C), 47.5 (2C, m), 42.9 (2C, 
m), 28.3 (3C); 19F NMR (376 MHz, CDCl3) δ 83.20 (m, F), 62.67 (d, J = 150.1 Hz, 4F); LCMS 
Purity (UV) = 99%, tR 20.4 min. HRMS – ESI (m/z) found 439.1078, calc. for 

















Compound 3.2d (573 mg, 1.38 mmol, 1.0 equiv.) in dichloromethane (2 mL) was treated with HCl 
in dioxane (4M, 5.0 equiv.) overnight. The reaction mixture was concentrated in vacuo to afford the 
HCl salt, 3.2d’ (4‐[3‐(pentafluoro‐l6‐sulfanyl)benzoyl]piperazin hydrochloride) as a colourless solid 
(376 mg, 92%). 
To 3.2d’ (0.100 g, 0.28 mmol, 1.0 equiv.), dissolved in THF (3 mL) was added triethylamine (0.028 
g, 0.28 mmol, 1.0 equiv.) and stirred for 30 minutes. Acetic anhydride (0.028 g, 0.28 mmol, 1.0 
equiv.) was added to the mixture and stirred overnight at room temperature. The reaction mixture 
was concentrated in vacuo and purified by flash chromatography (dichloromethane:methanol; 9:1) 
to obtain the pure product as a colourless oil (47.0 mg, 47%). 1H NMR (600 MHz, CDCl3) δ 7.84 –
7.81 (m, 1H, ArH), 7.80 –7.79 (m, 1H, ArH), 7.57 –7.51 (m, 2H, ArH), 3.88 –3.28 (m, 8H, ArH), 
2.11 (s, 3H, CH3); 13C NMR (151 MHz, CDCl3) δ 169.3 (C=O, MeCO), 168.4 (C=O), 154.0 (t, 2JFC 
= 18.0 Hz, ArC), 136.0 (ArC), 130.2 (ArC), 129.3 (ArC), 127.7 – 127.4 (m, ArC), 125.0 (ArC), 47.4 
(bs, CH2), 45.9 (bs, CH2), 42.4 (bs, CH2), 41.4 (bs, CH2), 21.3 (CH3); 19F NMR (376 MHz, CDCl3) 
δ 83.19 (p, J = 150.3 Hz, F), 62.78 (d, J = 150.3 Hz, 4F); LCMS Purity (UV) = 96%, tR 13.5 min; 
HRMS - ESI (m/z) found 381.0662, calc. for [C13H15F5N2O2S][Na]+: 381.0667; IR (neat) νmax/cm-1 
2917 (C-H), 1633 (C=O), 1322 (S=O), 821 (S-F). 
 
(3-Pentafluoro-λ6-sulfanyl phenyl)(4-(methylsulfonyl)piperazin-1-yl)methanone (3.2f) 
 
To crude 3.2d’ (75 mg, 0.21 mmol, 1.0 equiv.), dissolved in THF (3 mL) was added triethylamine 
(21 mg, 0.21 mmol, 1.0 equiv.) and stirred for 30 min. Methylsulfonyl chloride (24 mg, 0.21 mmol, 
1.0 equiv.) was added to the reaction mixture and stirred overnight at room temperature. The reaction 
was followed by TLC. After completion of the reaction, it was separated over dichloromethane (5 
mL) and water (5 mL). The biphasic layers were passed through a hydrophobic frit to obtain the 
organic phase which was concentrated in vacuo. The crude was then purified over a column of silica, 
(dichloromethane:methanol; 3:2) to obtain the title compound as a colourless solid (66mg, 80%). 1H 
NMR (600 MHz, CDCl3) δ 7.86 –7.82 (m, 1H, ArH), 7.82 –7.80 (m, 1H, ArH), 7.57 –7.54 (m, 2H, 
ArH), 4.03 –3.47 (m, 4H, CH4), 3.38 –3.14 (m, 4H, (CH2)2), 2.81 (s, 3H, CH3); 13C NMR (151 MHz, 
CDCl3) δ 168.4 (C=O), 154.2 –153.8 (m, C-SF5), 135.7 (ArC), 130.2 (ArC), 129.4 (ArC), 127.8–
127.6 (m, ArC), 125.2 –125.0 (m, ArC), 47.4 (CH2), 45.5 (2C, (CH2)2), 42.0 (CH2), 35.0 (CH3); 19F 
NMR (376 MHz, CDCl3) δ 83.32 (p, J = 150.4 Hz, 1F), 62.96 (d, J = 150.4 Hz, 4F); LCMS Purity 
(UV) = 98%, tR 15.6 min; HRMS - ESI (m/z) found 417.0349, calc. for 
[C12H15F5N2O2S][Na]+:417.0342; IR (neat) νmax/cm-1 2007 (C-H), 1616 (C=O), 1342 (S=O), 826 (S-














To methyl 3-aminopyridine-4-carboxylate (100.0 mg, 0.66 mmol, 1.0 equiv.) in dichloromethane (5 
mL) was added triethylamine (134.0 mg, 1.32 mmol, 2.0 equiv.) followed by dropwise addition of 
3-(trifluoromethyl)phenyl acetyl chloride (220.0 mg, 0.99 mmol, 1.5 equiv.). The reaction mixture 
was stirred at room temperature for 48 h and monitored by TLC. After 48 h, it was diluted by 
dichloromethane (10 mL), washed with 2M HCl (10 mL x 3) and the aqueous layer was extracted 
with dichloromethane (25 mL). Combined organic layers were washed with sodium bicarbonate (25 
mL), brine (15 mL x 3), dried over MgSO4, filtered and concentrated in vacuo. The crude material 
was purified over a column of silica (dichloromethane:methanol; 19:1) to obtain a colourless solid, 
3.3i, (144 mg, 65%). The product was then refluxed with 7M ammonia in methanol (10 mL) for 48 
hours. The crude was diluted with dichloromethane (15 mL) and washed with 2M HCl (10 mL x 2). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
was purified over a column of silica (dichloromethane:methanol; 97:3) to obtain the title compound 
as a colourless solid (30 mg, 23%). The pure product was crystallised using diffusion method 
(hexane:dichloromethane). Crystallization of 3.3c was achieved by soaking it in minimum amount 
of dichloromethane.  
1H NMR (600 MHz, (CD3)2SO) δ 12.79 (s, 1H, NH), 8.94 (s, 1H, ArH), 8.59 (d, J = 5.1 Hz, 1H, 
ArH), 7.89 (d, J = 5.1 Hz, 1H, ArH), 7.77 (s, 1H, ArH), 7.67 (d, J = 7.8 Hz, 1H, ArH), 7.62 (d, J = 
7.8 Hz, 1H, ArH), 7.58 – 7.52 (m, 1H, ArH), 4.08 (s, 2H, CH2 ); 13C NMR (151 MHz, CD3OD) δ 
161.5 (C=O), 158.1 (ArC), 149.8 (ArC), 145.1 (ArC), 143.9 (ArC), 136.7 (ArC), 132.5 (ArC), 130.6 
(q, 2JFC = 32.0 Hz, ArC-CF3), 129.2 (ArC), 126.4 (ArC), 125.5 (q, 3JFC = 4.0 Hz, ArC), 124.2 (q, 1JFC 
= 271.4 Hz, ArC), 123.7 (q, 3JFC = 4.0 Hz, ArC), 118.4 (ArC), 40.5 (CH2); 19F NMR (376 MHz, 
CDCl3) δ -62.71 (s, 3F); HRMS – ESI (m/z) found 306.0845, calc. for [C15H10F3N2O][H]+:306.0869; 
LCMS Purity (UV) = 90%, tR 14.9 min; IR (neat) νmax/cm-1: 2769 (NH), 1704 (C=O), 1329 (CF3).  
 
 
















To 2‐[3‐(pentafluoro‐l6‐sulfanyl)phenyl]acetic acid (120.0 mg, 0.46 mmol, 1.0 equiv.) was added 
thionyl chloride (201.0 µL, 2.76 mmol, 6 equiv.) and 2 drops of DMF. The reaction was refluxed 
under argon overnight. The reaction was followed by LCMS and following completion of the 
reaction, it was concentrated in vacuo to obtain 3.3d’ (2‐[3‐(pentafluoro‐l6‐sulfanyl)phenyl]acetyl 
chloride). The crude was taken through to the following steps without purifications (115 mg, 0.4 
mmol). 
To methyl 3-aminopyridine-4-carboxylate (41.0 mg, 0.27 mmol, 1.0 equiv.) in dichloromethane (5 
mL) was added triethylamine (55.0 mg, 0.54 mmol, 2.0 equiv.) followed by dropwise addition of 
3.3d’ (115.0 mg, 0.40 mmol, 1.5 equiv.). The reaction mixture was stirred at room temperature for 
48 h and monitored by TLC. After 48 h, it was diluted with dichloromethane (10 mL), washed with 
2M HCl (10 mL x 3) and aqueous layer extracted with dichloromethane (25 mL). Combined organic 
layers were washed with sodium bicarbonate (25 mL), brine (15 mL x 3), dried over MgSO4, filtered 
and concentrated in vacuo. The crude was purified over a column of silica 
(dichloromethane:methanol; 19:1) to obtain a colourless solid, 3.3ii, (144 mg, 65%). 3.3ii was then 
refluxed with 7M ammonia in methanol (10 mL) for 48 hours. The crude was diluted with 
dichloromethane (15 mL) and washed with 2M HCl (10 mL x 2). The combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude was purified over a column of 
silica (dichloromethane:methanol; 97:3) to obtain the title compound as a colourless solid (9 mg, 
25%). 1H NMR (600 MHz, CDCl3) δ 11.85 (s, 1H, NH), 9.20 (s, 1H, ArH), 8.76 (d, J = 5.1 Hz, 1H, 
ArH), 8.05 (d, J = 5.1, 1H, ArH), 7.97 (dd, J = 8.0 Hz, 1.9 Hz, 1H, ArH), 7.71 – 7.67 (m, 1H, ArH), 
7.64 (d, J = 7.7 Hz, 1H, ArH), 7.49 – 7.44 (m, 1H, ArH), 4.19 (s, 2H, CH2); 13C NMR (151 MHz, 
CDCl3) δ 161.7 (C=O), 156.0 (ArC), 154.3 – 153.7 (m, ArC-SF5), 151.1 (ArC), 146.3 (ArC), 143.5 
(ArC), 136.2 (ArC), 132.3 (ArC), 129.2 (ArC), 126.8 (m, ArC), 126.0 (ArC), 125.1 (m, ArC), 118.1 
(ArC), 41.5 (C). 
19F NMR (376 MHz, CDCl3) δ 87.64 – 85.94 (p, J = 148.4 Hz, 1F), 65.21 (d, J = 148.4 Hz, 4F); 
HRMS-ESI (m/z) found 364.0543, calc. for [C14H10F5N3OS][H]+:364.0527; LCMS Purity (UV) = 














            
Chapter 4.0 SF5-Substituted Oxindole Scaffolds as Kinase Inhibitors 
 
4.1 Introduction 
The oxindole scaffold is ubiquitously found in the tissues and body fluids of mammals, as well as in 
many natural products and biologically active compounds.143 One of its many applications comprises 
antitumor activity by inhibiting tyrosine receptors such as PDGFR (platelet-derived growth factor 
receptor), VEGFR (vascular endothelial growth factor receptor), etc.144 	
Protein kinases are enzymes that catalyse the transfer of a g-phosphate of adenosine triphosphate 
(ATP, Figure 4.1) often to a hydroxyl residue of a protein leading to a structural change in the protein 
and an intracellular signal.145 They are part of a huge superfamily and many kinases and isoforms 
exist. The human kinome contains 518 protein kinases that are classified according to the amino acid 
residue they phosphorylate.146 Most kinases recognise serine/threonine residue known as 
serine/threonine kinases (STK). Another major class of kinases are tyrosine kinases (TK) and as the 
name implies, they phosphorylate tyrosine specifically. However, tyrosine phosphorylation is 
relatively rare (1.8 %) compared to serine (86.4%) and threonine (11.8%) phosphorylation.147 A few 
kinases, known as dual-specificity tyrosine phosphorylation-regulated kinases (DYRK), 
phosphorylate on both tyrosine and serine/threonine amino acid side residues.148  
Oxindole scaffolds are widely used as protein kinase inhibitors as the NH-C=O groups form 
hydrogen bonds with the backbone of the hinge segment of the kinase ATP binding domain.149 Of 
these oxindoles, 3-pyrrolylmethylidene oxindoles are of particular interest as they inhibit receptor 
tyrosine kinases (Figure 4.1).150,151 
Tyrosine kinases are cell surface receptors with receptor tyrosine kinase (RTK) part of the larger 
family of protein tyrosine kinases.152 These consist of epidermal growth factor receptor (EGFR), 
nerve growth factor receptor (NGFR), platelet-derived growth factor receptor (PDGFR), vascular 
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), insulin 




Figure 4.1:ATP binding mode 
All RTKs consist of an extracellular domain encompassed with a ligand-binding site, a 
hydrophobic transmembrane a-helix, and a cytosolic domain containing a protein-tyrosine kinase 
activity region (Figure 4.2).153 Most RTKs dimerise in response to growth factor ligand binding. A 
protein kinase of each receptor monomer phosphorylates a distinct set of tyrosine dimer pairs. This 
process is termed autophosphorylation. Protein domains, Src homology-2 (SH2) and 
phosphotyrosine-binding (PTB) domains recognise phosphotyrosine and bind to them. Binding of 
these protein domains to an activated RTK allows simultaneous activation of multiple intracellular 









RTK activation regulates various biological processes like cell growth and cell survival. 
Dysregulation of RTKs caused by mutation is related to development and progression of many 
human cancers. Therefore, RTKs are an attractive therapeutic target. Small molecule RTK inhibitors 
can modify the dysregulated functions of the receptors by directly inhibiting the tyrosine kinase 
activity. They achieve inhibition by mimicking the binding mode of the ATP molecule.  
Growth factors are signalling proteins that regulate cell growth and survival from conception to 
death. Some growth factors are considered hormones and those that regulate cell growth are classified 
Figure 4.2: RTK autophosphorylation 






















as growth factors. They act in three ways: mitogens induce cell proliferation, trophic factors promote 
growth and survival factors inhibit apoptosis. Growth factors can have multiple effects in the same 
cell or different roles in different cells.  Abnormalities in growth factor signalling is the basis of many 
types of cancers. Major growth factor families that will be mentioned in this chapter and their 
biological activity are summarised in Table 4.1 
















Table 4.1: Growth factor families and their biological activity 
 
Prominent oxindole based small molecule kinase inhibitors include nintedanib, which acts as triple 
kinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR), fibroblast 
growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) kinases 
resulting in angiogenesis inhibition, suppressed vascularization and proliferation of tumour tissues 
causing starvation and death of tumour cells. Other triple kinase inhibitors of VEGFR, FGFR and 
PDGFR kinases are orantinib (SU 6668) and SU4984. The latter specifically inhibits FGFR1 with an 
IC50 of 10-20 µM.156 Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits VEGFR-1, 
VEGFR-2, c-KIT (stem-cell factor receptor), FLT3 (FMS like tyrosine kinase 3), PDGFRa and 
PDGFRb in both biochemical and cellular assays. It is an FDA approved treatment for advanced 
renal cell cancer and imatinib-resistant gastrointestinal stromal tumours. Semaxanib was the first 
pyrrole indoline-2-one to be tested clinically as a potent inhibitor of VEGFRs and PDGFRs for anti-
angiogenesis properties. It selectively inhibits VEGFR. It had proceeded to clinical studies but was 
halted due to toxicity issues (Figure 4.3). 
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Angiogenesis is the development of new blood vessels from the existing vascular system157 whereas 






                                                                               Figure 4.3: Oxindole-based RTKIs 
The C5 and C6 carbons of the oxindole moiety on the pyrrole indoline-2-one derivatives occupy a 
hydrophobic pocket, hydrophobic pocket II, in the ATP binding site. Therefore, modification of 
highly active pyrrole indoline-2-one derivatives at these positions is common.  
In 2017, Sansook. et al159, from the Spencer group, published their work on oxindole-based kinase 
inhibitors containing a pentafluorosulfanyl moiety at positions C5 and C6. Their compounds were 
tested against a panel of protein kinases following which a few compounds showing low nM potency 
against bone morphogenic protein-2 inducible gene (BMP2K), PDGFR2, PDGFRa, and VEGFR3 
were identified. The structures and respective IC50 are shown in Figure 4.4. BMP-2 comes under the 
transforming growth factor-b (TGF-B) superfamily and binds to serine-threonine kinase receptor 


















































                                         Figure 4.4: Oxindole-based kinase inhibitors with IC50 values 
 
In addition to being potent RTK inhibitors, oxindoles and spirooxindoles are credited to have a wide 
range of applications in medicinal chemistry.160,161  Spirocyclic compounds are both 
conformationally rigid and flexible. Their rigidity make them an ideal substituent when absorption 
and permeability of a molecule is restricted.162 On the other hand they are more flexible compared to 
flat aromatic heterocycles and can adapt to many a variety of proteins.162 Spirooxindoles are found 
as core structures of many naturally occurring alkaloids such as mitraphylline, horsfiline, etc with 
encouraging pharmacological activity (Figure 4.5). 
  








































BMP2K = 452 nM PDGFR2 = 98 nM
VEGFR3 = 230 nM
PDGFRα = 3.1 nM
VEGFR3 = 18 nM


















Besides antiproliferative activity, they possess antiviral, antifungal, antibacterial and 
antihypertensive activities.143 In this study we synthesised five more SF5 containing oxindoles and a 
nitro-substituted analogue, to widen the range of SF5 containing biologically active scaffolds. In 
addition biological activity of Semaxanib was compared with two novel SF5-analogues of 
Semaxanib. 
 
4.2 Results and discussion 
 
4.2.1 Synthesis 
Figure 4.6 demonstrates the oxindoles synthesised by a microwave assisted Knoevenagel reaction. 












1 150 Ethanol 30 4.2a (80) 
2 150 Ethanol 30 4.2b (50) 
3 100 Acetone 20 4.2c (90) 
4 100 acetonitrile 20 4.2d (66)  









































Sansook. et. al.’s microwave-mediated Knoevenagel condensation conditions (Figure 4.4) were 
followed to synthesise compounds 4.2a and 4.2b. For entries 3 and 4, the conditions were slightly 
modified. Compound 4.2c was synthesised with an excess of acetone to dissolve the reaction 
components. In this case acetone acted both as a solvent and a reagent. Soon after combining the 
oxindole, acetone and piperidine, product was observed, which precipitated out of the solution as an 
orange solid. Nevertheless, the reaction mixture was microwave irradiated until completion of the 
reaction, i.e. 20 min, as monitored by TLC. Following a simple work-up, the pure product was 
obtained at 90% yield and was crystallised in acetone, affording single crystals suitable for X-ray 
structure determination (Figure 4.7). 
 
                                                                            Figure 4.7: X-ray structure of 4.2c 
 
Upon realising that simple Knoevenagel products could be recrystallised using acetonitrile, 4.2d was 
synthesised in acetonitrile and the crude was recrystallised in the same solvent, yielding pure product 
in 68% yield. A quick search in the literature revealed the same reaction carried out in acetone by 
stirring for 14 hours at room temperature to obtain 86% yield.163 The purity of the compound was 
not reported. We then attempted the synthesis of 4.1c in acetonitrile at 100 °C for 20 minutes in the 
microwave as opposed to the initial synthesis in ethanol at 150 °C by Sansook et al. Purification of 
4.1c was not as simple as the prior mentioned compounds. When synthesised in acetonitrile, we 
observed both Z and E isomers in the 1H NMR spectrum of the crude mixture in an approximate 9:1 
ratio. However, the E-isomer could not be isolated from the mixture. The crude product was subjected 
to reverse phased column chromatography followed by normal phased column to obtain pure Z 
isomer in 77% yield. The 1H NMR spectrum of the product was compared with the reported literature 
spectrum to confirm its configuration. Equilibrium between Z and E isomers has been reported in 
polar solvents or in the presence of light.164 E isomers of pyrrole indoline-2-one derivatives are 
known to convert back into their respective Z isomers in the dark, perhaps due to the intramolecular 
hydrogen bonding between the carbonyl oxygen and NH group of the pyrrole ring.165 Pyrrole 
indoline-2-one derivatives predominantly exists as Z isomers due to this intramolecular hydrogen 
bonding. A NOESY experiment would confirm the configuration by showing interaction between 
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the proton at C4 position and the vinyl proton.166 A study which investigated isomerisation of 3-
substituted indolin-2-ones revealed that pyrrole indoline-2-ones with no N-substitution on the pyrrole 
are isolated as  Z-isomers and are converted to E-isomers after exposure to fluorescent light.165 As 
occurrence of isomerisation is also reported while in solution, we came to a conclusion that part of 
4.1c isomerised into its E-isomer while in solution in the NMR tube (exposed to light) rather than 
the method of synthesis producing a mixture of isomers. Another drawback of using acetonitrile as 
the solvent is that it could potentially react with the ketone or aldehyde to give an additional 
Knoevenagel condensation product.167 
The synthesis of 3-pyrrolylmethylidene oxindoles in acetonitrile using the aforementioned conditions 
were not considered favourable as two column purifications were needed to obtain the pure product. 
Sansook et al’s conditions provided pure 4.1c in 74% yield following a normal phase column. 
Therefore compounds 4.2a and 4.2b were synthesised following the said method. 
 
Mechanochemical synthesis is another attractive method that is an environmentally friendly 
alternative for traditional routes. It provides mild/short reaction conditions, simplicity and often 
solvent-free conditions.168 Mechanochemical Knoevenagel condensation is a known method of 
synthesis.169,170 We attempted the synthesis of 4.2d in a vibratory ball mill (VBM, Scheme 4.1). Table 
4.4 shows various conditions utilized for the synthesis. Reactions were attempted in steel jars (SST) 
and zirconium oxide jars (ZrO2); with and without catalyst, and for various reaction times. Under 
mechanochemical conditions, reactions performed in the absence of catalyst did not yield any 
product. Zirconia jars were best suited for mechanochemical Knoevenagel condensation as opposed 
to steel jars. Zirconia is extremely hard171 and chemically inert.172 These jars provide high impact 
and iron free milling. Steel jars are also able to provide high impact milling. However, grinding in 
steel jars can result in iron contaminated product. The 1H NMR spectra of crude reaction mixtures 
from steel jars tend to be highly noisy due to the presence of paramagnetic iron particles.173   
 

















Table 4.3: Various conditions used for mechanochemical Knoevenagel synthesis 
 
4.2d synthesised via ball milling under conditions in entry 5, yielded 78% of pure product (by 1H 
NMR) as a brown solid without further purifications. Figure 4.8 shows the proton NMR of 4.2d in 
DMSO following mechanochemical synthesis. As expected the NMR shows three aromatic protons 
between 6.98 ppm and 8.27 ppm, two aliphatic peaks between 2.41 and 2.54 ppm with each peak 
integrating to three protons and an NH peak at 11.14 ppm. 
 
 
                                    Figure 4.8: Proton NMR of 4.2d from ballmill experiment (entry 5) 
 
Scheme 4.2 shows the reaction steps of mechanism of the piperidine catalysed Knoevenagel 
condensation. Ellen V. Dalessandro et. al. proposed a mechanism for the piperidine catalysed 
Knoevenagel condensation reaction which proceeds via deprotonation of acetyl acetone (pKa 8.93) 
by piperidine (pKaH 11.28) to generate the nucleophile which attacks the respective iminium.174 In 
Entry Jar No of balls Time 
(min) 
Catalyst % conversion by 1H NMR 
(product:starting material) 
1 SST (10 mL) 1 180 - - 
2 SST (10 mL) 1 60 Piperidine 16:84 
3 SST (10 mL) 1 90 Piperidine 44:56  
4 ZrO2 (25 mL) 1 90 - - 
5 ZrO2 (25 mL) 1 90 Piperidine 100:0 
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the following mechanism, we have proposed the formation of an enolate which would serve as the 
nucleophile. The keto-enol tautomerisation occurs readily in solvent and when combined with simple 





























































































Subsequently, the synthesis of 4.1c was also attempted under mechanochemical conditions in a 
zirconia jar. However the reaction did not yield any product (Scheme 4.3). Unlike the aforementioned 





                                                             Scheme 4.3: Mechanochemical synthesis of 4.1c 
 
 
Often, solids clump together preventing proper mixing of the reagents. Introducing a liquid additive 
in µL amounts; known as liquid assisted grinding (LAG) can circumvent this issue.56,175 The solvent 
acts as a lubricant and enhances overall mixing and reaction kinetics.56 We reasoned that Liquid 
assisted grinding (LAG) could be a better option for Knoevenagel condensations when the starting 
materials are in the solid state. Temperature might have been another factor that impeded the 
formation of 4.1c. Temperature cannot be controlled while using a vibratory ball miller. It is solely 
dependent on the energy released during the milling process. For reagents with high melting points 
such as 5-pentafluorosulfanyl-2-oxindole (mp: 179–181 °C)176, higher temperatures might be 
required to activate mixing. 
Further investigation on the mechanochemical Knoevenagel synthesis was not carried out due to time 
limits. Regardless, the synthesis of 3-substituted oxindoles via a mechanochemical route has proven 

























Synthesis of the spirocyclic oxindoles 4.4a and 4.4b proceeded via different routes to the above 
mentioned oxindoles (Scheme 4.4). 
  
  
                                          Scheme 4.4: Synthesis and N-methylation of spirocyclic oxindole  
Compound 4.4a was synthesised adopting a method published for the synthesis of non-substituted 
spirooxindole.177 Condensation of 5-SF5-2-oxindole and 2-bromoethyl ether was performed in the 
presence of an organic base, LiHMDS, in THF to obtain 4.4a in 33% yield. Figure 4.9 shows the 
crystal structure of 4.4a.  The latter was subsequently methylated by MeI in the presence of NaH to 




                                                             Figure 4.9: Crystal structure of 4.4a 
 
 
4.2.2 Modelling (performed using Schrodinger Maestro Version 12.6.144) 
Protein kinases share a common three dimensional folding that consists of two lobes; N-terminal and 
C-terminal lobe. Between these two lobes is the ATP-binding site, which is a flexible hinge region, 
that connects the two lobes (Figure 4.10). The active site consists of several structural elements 
required for enzymatic activity. The activation loop which is typically 20 to 30 residues begins with 
a conserved DFG motif (Asp-Phe-Gly, Figure 4.11) which extends to an APE motif (usually Ala-
Pro-Glu). In an active kinase, this loop forms a cleft that binds substrate. The Asp residue of the DFG 
motif in an active conformation binds to a magnesium ion that interacts directly with an oxygen atom 





























(hydrophobic pocket II) by fitting into a hydrophobic pocket between one residue from the N-lobe 
and one from the C-lobe. The Asp residue orientates and conceives a position which allows 
interaction with Mg2+. Once the above mentioned interaction takes place a conserved Glu residue of 
the C-helix forms a salt bridge with a Lys residue. After the formation of the salt bridge, the lysine 
side chain forms hydrogen bonds with oxygen atoms of the a and b phosphates of ATP. 
 
 




























Most small molecule kinase inhibitors bind in the region of the ATP binding site. In this study, we 
integrated SF5 on to carbons C5 and C6 of Semaxanib, which is an experimental stage drug that 
specifically inhibits VEGFR2. SF5 moiety is hypothesised to form hydrophobic interactions in the 
hydrophobic pocket II. 
Indoline-2-one of Semaxanib binds in a similar fashion to the ATP’s purine ring. The pyrrole forms 
van der Waals interaction with the hydrophobic pocket I located outside the ATP binding pocket 
(Figure 4.12). The indoline-2-one moiety forms two hydrogen bond interactions with Glu917 and 
Cys919 residues in the adenine pocket and an aromatic pi-pi interaction with the phenylalanine of 







Figure 4.12: Semaxanib (yellow) in complex with VEGFR2. a) Highlights adenine pocket and solvent region. Blue dashed line 
indicates aromatic pi-pi interaction. Hydrogen bonds shown as yellow dashes. b) Hydrophobic interaction between pyrrole and 













When docking 4.2b in VEGFR-2 we observed that the indoline-2-one is no longer able to occupy the 
adenine pocket (Figure 4.13). The bulkiness of the SF5 pushes the oxindole ring into the hydrophobic 
pocket and the pyrrole into the solvent region. The aromatic pi-pi bond between Phe (DFG motif) 
and the oxindole endures. However, hydrogen bond interactions with Glu917 and Cys919 disappear. 
The oxygen of the oxindole forms a (solvent region) hydrogen bond interaction with a water 
molecule.  SF5 moiety must be forming van der Waals interactions with Lys868 and Ala866 in the 
hydrophobic binding pocket. 
 
The same analysis was performed on 4.2a. Incorporating SF5 at position 5, forces the compound 
further away from the DFG motif and the adenine pocket resulting in no interaction between the 
oxindole and the adenine pocket except for an aromatic hydrogen bonding with the Cys919 residue 






Figure 4.13: 4.2b (pink) in complex with VEGFR-2. Dashed lines indicate hydrogen bonds (yellow), aromatic interactions 
(light blue) and pi-pi interactions (dark blue)  





We compared our modelling analysis with a crystal structure of Sunitinib bound to VEGFR-2. 
Sunitinib contains a fluorine at position C5. Therefore, it seemed logical to compare SF5-substituted 
Semaxanib and Sunitinib to understand the role of a halogen at the site. 
The oxindole and pyrrole moieties of Sunitinib and Semaxanib overlap perfectly in the binding 
pocket (Figure 4.15). Consequently, Sunitinib forms interactions similar to those in Semaxanib, in 
the adenine pocket and the hydrophobic pocket. In addition, Sunitinib forms multiple water mediated 
hydrogen bonds in the solvent region. Fluorine is in close proximity to the b-carbon of phenylalanine, 
favouring van der Waals interactions. The fluorine atom is also a bio-isostere of proton which slows 
down metabolism of the drug. As fluorine and proton are similar in size, it does not affect the 
orientation and positioning of the drug in the binding pocket. These findings also apply to PDGFR-




                               Figure 4.15 a) Sunitinib in complex with VEGFR-2. b) An overlap of Sunitinib and Semaxanib 
 
From our docking studies, it is apparent that a bulky ligand in the adenine pocket is not favourable 





or CF3 at positions C5 and C6 are undesirable. Alternatively substitution of electron donating and 
polar groups enhance binding affinity. A para substitution of an electron withdrawing group weakens 
the oxindole N-H bond. Subsequently the hydrogen bond interaction between the NH and amino acid 
residues becomes weaker. 
Out of interest we modelled compounds 4.4a and 4.4b to get similar results to that of 4.2a and 4.2b. 
The spiro cycle was expected to form interactions in the solvent region through the oxygen but none 




4.2.3 In Vitro Analysis 
 
A biochemical assay showed Semaxanib to inhibit VEGFR2 giving an IC50 of 1.5 µM (lit. 1.04 ± 
0.53 µM).178  Compounds 4.2a and 4.2b did not show any satisfactory inhibition to generate IC50 
values. At 10 µM, 4.2a exhibits 27% inhibition of VEGFR2 while 4.2b only gives 23% inhibition at 
the same concentration. 
 
Entry Compounda IC50 (µM) 
1 Semaxanib 1.5 
2 4.2a -b 
3 4.2b -b 
Table 4.4: Biochemical kinase assay of Semaxanib and its SF5 counterparts. an = 1; 10-dose IC50 mode with 2-fold serial dilutions, 
starting at 10 µM. b % inhibition at 10 µM; 4.2a (27%); 4.2b (23%) 
 
4.3 Conclusion  
To conclude, SF5 and NO2-substituted oxindoles were modified by substituting at position-3 via 
Knoevenagel condensation, in the microwave. Knoevenagel condensation was also explored by 
means of mechanochemistry. Modification of oxindole includes synthesis of a spirocyclic compound 
and N-methylating it. An in silico study of SF5-counterparts of Semaxanib, 4.2a and 4.2b, in the 
VEGFR-2 active site and comparing them with Semaxanib, revealed that SF5 is too bulky a 
substituent that impedes the ligands’ interaction with the adenine pocket. A radioactive assay carried 
out showed 4.2a and 4.2b to have no inhibition activity validating our in silico observation. 
 
4.4 Experimental 
All reagents were purchased from Merck, Fisher Scientific UK Ltd, SpiroChem AG, Fluorochem 
Ltd, and used without further purification. The milling treatments were carried out in a Retsch 
MM400 vibratory ball mill (VBM) operated at 30 Hz. 1H NMR spectra were recorded on Varian 
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VNMRS 600 MHz spectrometers, at room temperature, using deuterated solvent for calibration 
((CD3)2CO) at 2.05 ppm, (CD3)2SO at 2.50 ppm, or CD3OD at 3.31ppm). 13C NMR analyses were 
conducted by Rémi Legay from the University of Caen, and spectra recorded on Bruker Avance III 
600 MHz spectrometers, at room temperature, using deuterated solvent for calibration ((CD3)2CO) at 
29.84, 206.26 ppm, (CD3)2SO at 39.52 ppm, or CD3OD at 49.00 ppm). 19F NMR were recorded on 
Varian VNMRS 376 MHz spectrometers, at room temperature, using deuterated solvent for 
calibration. Chemical shifts are reported in ppm, usually referenced to TMS as an internal standard, 
and data reported as s = singlet, d = doublet, t = triplet, q = quadruplet, p = pentet, ddd = doublet of 
doublets of doublets, m = multiplet; integration. Mass spectrometry analyses were conducted by Dr 
Abdul-Sada. ESI mass spectra were obtained using a Bruker Daltonics Apex III, using Apollo ESI 
as the ESI source; EI mass spectra were obtained using a Fissions VG Autospec instrument used at 
70 eV. Elemental analyses were conducted by Mr Stephen Boyer from the London Metropolitan 
University. Melting points were determined using a Stanford Research Systems Optimelt and are 
uncorrected. LCMS were performed by Shimadzu LCMS-2020 equipped with a Gemini® 5µm C18 
110Å column and percentage purities were ran over 30 minutes in water/acetonitrile with 0.1% 





In a 10 mL microwave vial equipped with a stirrer bar was added 5-(pentafluorosulfanyl )-1,3-
dihydro-indol-2-one (0.096 g, 0.37 mmol, 1.0 equiv.), 3,5-dimethyl-1H-pyrrole-2-carbaldehyde 
(0.062 g, 0.5 mmol, 1.3 equiv.), ethanol (2.5 mL) and 3 drops of piperidine. The vessel was then 
sealed using a rubber microwave septum and placed into the microwave cavity. The reaction mixture 
was subjected to microwave irradiation by ramping to 150 °C with 200 W of power. It was held at 
that temperature for 30 min. The vessel was then cooled to ambient temperature and solvent removed 
in vacuo. The crude was purified over a column of C18 silica (100% acetonitrile) to obtain the pure 
product as a red solid (0.137 g, 80%). 1H NMR (600 MHz, (CD3)2CO) δ 13.46 (s, NH), 10.15 (s, 
NH), 8.21 (s, ArH), 7.91 (s, ArH), 7.60 (d, J = 8.6 Hz, ArH), 7.10 (d, J = 8.6 Hz, ArH), 6.06 (s, 
C=H), 2.38 (3H, s, CH3), 2.35 (3H, s, CH3); 13C NMR (151 MHz, (CD3)2CO) δ 169.8 (C=O), 147.7 
(m, ArC-SF5), 140.0 (ArC=C), 138.0 (ArC), 134.4 (ArC), 127.4 (ArC), 126.6 (ArC), 125.4 (m, ArC-
CSF5), 123.0 (ArC), 115.5 (ArC), 113.3 (m, ArC-CSF5), 110.5 (C=C), 108.5 (ArC), 12.9 (CH3), 







axial); LCMS Purity (UV) = 100%, tR 23.6 min; HRMS – ESI (m/z) found 365.0737, calc. for 




1H‐indol‐2‐one  (4.2b) 
 
In a 10 mL microwave vial equipped with a stirrer bar was added 6-(pentafluorosulfanyl)-1,3-
dihydro-indol-2-one(0.100 g, 0.4 mmol, 1.0 equiv.), 3,5-dimethyl-1H-pyrrole-2-carbaldehyde (0.062 
g, 0.5 mmol, 1.3 equiv.), ethanol (2.5 mL) and 3 drops of piperidine. The vessel was then sealed 
using a rubber microwave septum and placed into the microwave cavity. The reaction mixture was 
irradiated with 200 W of power. When at 150 °C it was held by moderation of power for 30 min. The 
vessel was then cooled to room temperature and solvent removed in vacuo. The aqueous layer was 
extracted using ethyl acetate (3 x 20 mL), washed with brine (3 x 20 mL), dried over MgSO4, filtered 
under gravity and concentrated in vacuo. The crude was purified over a column of C18 silica (100% 
acetonitrile) (70 mg, 50%) to get an orange solid. 1H NMR (600 MHz, (CD3)2CO) δ 13.52 (1H, s, 
NH), 10.02 (1H, s, NH), 7.82 (1H, d, J = 8.5 Hz, ArH), 7.79 (1H, s, ArH), 7.48 (1H, d, J = 8.5Hz, 
ArH), 7.41 (1H, s, ArH), 6.08 (1H, s, C=H), 2.36 (3H, s, CH3), 2.38 (3H, s, CH3). 13C NMR (151 
MHz, (CD3)2CO) δ 169.6 (C=O), 138.7 (ArC-SF5), 137.3 (ArC=C), 135.0 (ArC), 130.2 (ArC), 127.7 
(ArC), 126.0 (ArC-CSF5), 118.6 (ArC), 117.0 (ArC), 113.6 (ArC-CSF5), 110.0 (ArC), 106.8. (ArC), 
54.1 (C=C), 12.9 (CH3), 10.7 (CH3). 19F NMR (376 MHz, (CD3)2CO) δ 86.32 (1F, m), 63.74 (4F, d, 
J = 148.1 Hz); LCMS Purity (UV) = 100%, tR 23.7 min; HRMS – ESI (m/z) found 389.2959, calc. 




In a 10 mL microwave vial equipped with a stirrer bar was added 5-(pentafluorosulfanyl)-1,3-
dihydro-indol-2-one (0.096 g, 0.37 mmol, 1.0 equiv.) in acetone (2 mL) followed by 3 drops of 
piperidine. The vessel was then sealed using a rubber microwave septum and placed into the 
microwave cavity. The reaction mixture was irradiated with 200 W of power. When at 100 °C, it was 













reaction mixture was extracted with ethyl acetate (3 x 20 mL), washed with water (20 mL), dried 
over MgSO4, filtered under gravity and concentrated in vacuo. Orange solid was obtained as pure 
compound without further purification (0.100 g, 90%). Crystallization by mixed solvents, 
dichloromethane and hexane, provided orange crystals. 1H NMR, (600 MHz, (CD3OD) δ 2.39 (3H, 
s, CH3), 2.59 (3H, s, CH3), 6.94 (1H, d, J = 8.5 Hz, ArH), 7.65 (1H, d, J = 8.5 Hz, ArH), 7.87 (1H, 
s, ArH); N-H not observed. 13C NMR (600 MHz, CD3OD) δ 21.9 (CH3), 24.0 (CH3), 108.2 (C=C), 
120.7 (C, ArC-CSF5, m), 121.8 (ArC), 123.6 (ArC), 125.6 (ArC-CSF5, m), 142.5 (ArC), 147.6 (ArC-
SF5, m), 159.0 (C=C), 169.6 (C=O); 19F NMR, (376 MHz, CD3OD) δ  62.9 (4F, d, J = 147.8 Hz, 
equatorial), 85.3(1F, p,  J = 147.8, axial); LCMS Purity (UV) = 99%, tR 18.5 min; HRMS – ESI (m/z) 
found 322.0285, calc. for [C11H10F5NOS][Na]+:322.0295; IR (neat) νmax/cm-1 3062 (N-H), 2925 (C-





In a 10 mL microwave vial equipped with a stirrer bar was added 5-nitro-2-oxindole (0.50 g, 2.9 
mmol, 1.0 equiv.), acetone (0.25 mL, 3.4 mmol, 1.2 equiv.), acetonitrile (5 mL) and 3 drops of 
piperidine. The vessel was then sealed using a rubber microwave septum and placed into the 
microwave cavity. The reaction mixture was irradiated with 200 W of power and heated to 100 °C 
in a CEM Explorer. When at 100 °C it was held by moderation of power for 20 min. The vessel was 
then cooled to ambient temperature and the reaction mixture was concentrated in vacuo. The crude 
was recrystallized in acetonitrile to obtain a brown solid as pure product (0.411g, 66%).  
Solventless reaction: 
5-nitro-2-oxindole (242.0 mg, 1.36 mmol, 1.0 equiv.), acetone ( 200.0 µL, 2.71 mmol, 2.0 equiv.) 
and piperidine (40.2 µL) were mechanically activated in a Retsch MM400 vibratory ball-mill for  90 
minutes at 30 Hz in 25 mL zirconia jar with one, 1.2 cm dia. ball. The product was suspended in 
acetone (10 mL) and filtered to obtain the pure product as a brown solid (229.0 mg, 78%). 
1H NMR (600 MHz, (CD3)2SO ) δ 10.96 (1H, s, NH), 8.21 (1H, s, ArH), 8.11 (1H, dd, J = 8.6, 2.0 
Hz, ArH), 6.94 (1H, d, J = 8.6 Hz, ArH), 2.52 (3H, s, CH3), 2.38 (3H, s, ArH). 13C NMR (151 MHz, 
(CD3)2SO ) δ 169.0 (C=O), 160.0 (ArC), 146.6 (ArC), 141.9 (ArC), 125.0 (ArC-H), 124.1 (ArC-
NH), 121.5 (C=ArC), 118.9 (ArC-H), 109.4 (ArC-H), 25.5 (CH3), 23.2 (CH3); HRMS – ESI (m/z) 
found 241.0584, calc. for [C11H10N2O3][Na]+:241.0584; IR (neat) νmax/cm-11694 (C=O), 1509 (N-O 










5-(Pentafluorosulfanyl)-1,3-dihydro-indol-2-one (0.500 g, 1.93 mmol, 1.0 equiv.) dissolved in 
tetrahydrofuran (10 mL) was added to LiHMDS (1M) in tetrahydrofuran (5.80 mL, 5.80 mmol, 3.0 
equiv.) at -78 ºC. After an hour of stirring, 1-bromo-2-(2-bromoethoxy)ethane (0.448 g, 1.93 mmol, 
1.0 equiv) was added to the mixture and warmed to ambient temperature. The reaction was stirred 
for 46 hours and quenched with water. The reaction mixture was extracted with ethyl acetate (3 x 20 
mL), washed with brine (3 x 20 mL), dried over MgSO4, filtered under gravity and concentrated in 
vacuo. The crude material was purified over a column of silica (hexane:ethyl acetate; 4:1) to get a 
pink solid as the title compound (210 mg, 33%). 
1H NMR (600 MHz, CD3OD) δ 7.82 (1H, s, ArH), 7.71 (1H, d, J = 8.6 Hz, ArH), 7.01 (1H, d, J = 
8.6 Hz, ArH), 4.22 (2H, m, OCH2), 3.88 (2H, m, OCH2), 1.95 (2H, m, CH2), 1.82 (2H, m, CH2); 13C 
NMR (151 MHz, (CD3)2CO) δ 180.7 (C=O), 147.8 (m, ArC-SF5), 144.3 (ArC), 135.2 (ArC), 126.7 
(m, ArC-CSF5), 121.2 (m, ArC-CSF5), 109.0 (ArC), 62.0 (2C), 44.6 (C), 32.5 (2C);19F NMR (376 
MHz, (CD3)2CO) δ 86.41 (4F, m), 64.09 (F, d, J = 148.1 Hz); LCMS Purity (UV) = 98%, tR = 20.2 
min; HRMS – ESI (m/z) found 329.0535, calc. for [C12H12F5NO2S]: 329.0509; IR (neat) νmax/cm-1 




Sodium hydride (11 mg, 0.45 mmol, 1.5 equiv ) was added to a round bottomed flask and purged 
with argon. Dry dimethyl formamide (15 mL) was then added to the flask followed by compound 
4.4a (0.1g, 0.30 mmol, 1.0 equiv) and stirred for 1 hour. To this mixture was added methyl iodide 
(0.213 g, 1.50 mmol, 5.0 equiv) and stirred overnight at room temperature. The reaction mixture was 
quenched with water (10 mL), extracted with ethyl acetate (10 mL x 3), washed with brine (20 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified over a column 
of silica (hexane:ethyl acetate; 4:1) to get a yellow solid as the title compound(68 mg, 66%). 
1H NMR (600 MHz, CDCl3) δ 7.71 (ArH, dd, J = 8.6, 1.9 Hz, 1H), 7.68 (ArH, d, J = 1.9 Hz, 1H), 
6.86 (ArH, d, J = 8.6 Hz, 1H), 4.25 (CH2, ddd, J = 12.0, 9.5, 3.0 Hz, 2H), 3.89 (CH, dt, J = 12.0, 4.3 
Hz, 2H), 3.22 (s, 3H), 1.91 (ddd, J = 13.4, 9.5, 4.3 Hz, 2H), 1.82 (dt, J = 13.4, 3.0 Hz, 2H).13C NMR 












126.7 (ArC-H, p, 3JFC = 4.7 Hz), 120.9 (ArC-H, p, 3JFC = 4.7 Hz), 107.3 (ArC-H), 62.6 (2C), ((CH2)2), 
44.4 (C), 32.7 (2C, (CH2)2), 26.3 (CH3).19F NMR (376 MHz, CDCl3) δ 86.61 – 84.84 (p, J = 150.1 
Hz), 64.42 (d, J = 150.1 Hz); HRMS – ESI (m/z) found 344.0743, calc. for [C13H14F5NO2S][H]+: 
344.0744; IR (neat) νmax/cm-1 2947 (C-H, st), 1727 (C=O), 1258 (N-C, methyl), 828 (S-F); LCMS 































Since their discovery in the late 1950s,179 benzodiazepines (BZDs or 1,4-diazepams) have been 
widely employed to treat a broad spectrum of neurological disorders such as anxiety, insomnia, 
seizure disorders and certain kinds of spasticity.180,181,182,183 The first 1,4 diazepam to be 
discovered, chlordiazepoxide (Librium®, Figure 5.1)184, was fundamentally purposed to treat 
anxiety disorders. In 1963, diazepam (Valium®)185 was revealed as an even more potent BZD. Its 
therapeutic benefits were not limited to anxiety; several other CNS disorders including epilepsy 
and alcohol withdrawal were treated with diazepam.186,187,180 Since then several drugs with the 1,4-
BZD nucleus have been developed and used.  
 
Figure 5.1: Chlordiazepoxide 
 
For around 15 years after their discovery, BZDs were widely prescribed without significant 
knowledge of their mode of action. Although, each BZD differs in its structure activity relationship 
(SAR), in general all BZDs produce a clinical effect by enhancing the actions of g-aminobutyric 
acid (GABA, Figure 5.2). GABA is a major neurotransmitter of the nervous system,188 found in 
high concentrations in the cortex and limbic system.189  
 
Figure 5.2: g-Aminobutyric acid 
During a synaptic neuronal process, GABA binds to GABA receptors found in the plasma 
membrane. This allows ion channels to open and negatively charged chloride ions to enter the 
neuron.190 The overall negative change in the transmembrane potential limits other 
neurotransmitters from binding, thus reducing the excitability of neurons. There are three known 













sites for BZDs, barbiturates, general anaesthetics and picrotoxin (Figure 5.3) other than GABA. 
GABAB and GABAC receptors are resistant to drugs that modulate GABAA.191,192,193 
 
Figure 5.3: Barbiturate & Picrotoxin 
 
GABAA receptor is a chloride ion channel typically formed by 5 subunits, each with multiple 
isoforms. There are 19 known GABAA subunit families: α1–6, β1–3, γ1–3, δ, ε, θ, π, and ρ1–3.194 
Most commonly they are constructed of 2 copies of  an α1 subunit, 2 copies of β2 and a single γ2 
subunit. This composition can vary depending on age, brain region as well as subcellular 
distribution. The benzodiazepine binding sites form in a specific pocket at the intersection of α and 
γ subunits (Figure 5.4). BZDs only have affinity towards the α subunit and in particular towards 
isoforms 1, 2, 3, and 5, as they possess a histidine residue: H101, H101, H126, and H105, 
respectively.195,196 The histidine residue is small enough to accommodate BZDs in the binding 
pocket. Isoforms 4 and 6 possess arginine residue. These larger side chains would sterically clash 














































      




There are two types of drugs on the market, classified based on their inhibition: orthosteric and 
allosteric.197 Orthosteric drugs bind at the active site and allosteric ones bind elsewhere on the 
protein surface.198  
BZDs, barbiturates and general anaesthetics are positive allosteric modulators (PAM) of GABA 
receptor, while picrotoxin is a negative allosteric modulator. A PAM works by binding to an 
allosteric site while modifying the conformation of the orthosteric site to cause boosting of a signal 
or increased activity. When BZDs and other PAM bind to their binding sites, they allosterically 
change the conformation of the GABAA receptor site, altering the ion channels and allowing 
increased chloride ion flow into the cell by increasing the permeability of the central pore to 
chloride ions.199 
BZDs enhance the effectiveness of GABA in a unique way by lowering the concentration required 
for opening the channel. Unlike barbiturates and other GABAA modulators, BZDs do not act 
directly to open chloride ion channels. This notable difference makes BZDs a safer set of drugs in 
comparison.200 An overdose of non-BZD drugs is lethal due to their direct action on the chloride 
ion channels.201  
 
As mentioned, 1,4-BZDs are successful drugs in treating several CNS disorders. Figure 5.5 





Figure 5.5: Pharmacologically active 1,4-benzodiazepines 
 
Figure 5.6 shows the basic structure of a 1, 4-BZD. Early SAR studies identified the 7-membered 
imino ring B, as an essential structure for binding affinity towards the BZD binding site on the 
GABAA receptor. Additional SAR and quantitative SAR (QSAR) studies revealed that the 
lipophilicity of several BZDs has contributed in improving binding affinity.203 
 
Figure 5.6: 1,4 benzodiazepine skeleton 
Moreover, the carbonyl group at position 2 and the C=N double bond are crucial for high binding 
affinity. Removal of the carbonyl group results in a decrease of binding affinity by two orders of 
magnitude and saturation of the 4,5 double bond results in a complete loss of in vitro affinity.202  
SAR studies by Sternbach et al. revealed that positions 7, 2' and 1 are key regions in the molecule, 
and functionalising them can potentially improve binding affinity.204 The most important being 




































































improved receptor affinity whereas having electron donors at the same position had the opposite 
effect. Having an electrophilic and bulky substituents (mainly halogens; F and Cl) at position 2', 
enhanced the binding affinity of the BZD analogues, e.g. flunitrazepam, and clonazepam. A methyl 
group on position 1 improved the activity. Substituting the 1- and 2-positions with an imidazo- or 
triazolo-ring could heighten the binding affinity for 1,4-BZDs with low affinity. However, 
modifying 1,4-BZDs that have high binding affinity in this manner, does not appear to boost ligand 
binding affinity.205 Another spot of interest is position 3. Position 3 is often substituted with a 
hydroxy group which accelerates elimination of the drug.  
 
Benzodiazepines are titled ‘privileged scaffolds’ owing to their affinity for multiple receptor 
sites.206 Other than GABA receptor, BZDs bind to CCK receptors (cholecystokinin receptor), 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor), gastrin receptors etc. 
Apart from CNS activity, BZDs are researched for their antitumour, anti-HIV, anti-inflammatory, 
anti-viral, anti-malarial and anti-bacterial properties.202,207,208,209,210 
 
The modification of benzodiazepines at position 7 by the incorporation of an SF5 seemed, at first 
sight, to be an ideal research endeavour. It is intriguing to discover how SF5’s enhanced 
lipophilicity and electronegativity211 would alter the fate of the resulting compound in the BZD 
binding site of the GABAA receptor.  
The prevailing lack of SF5 containing biologically active compounds in the literature111 is another 
matter that is addressed as part of this synthesis. Besides, there were no known SF5 containing 
benzodiazepines, to the best of our knowledge, at the onset of this study. 
Convinced by the vast pharmacological profile of BZDs and with the aim of studying the effect of 
a SF5 vs e.g. Cl group on the GABAA receptor, we synthesized some 1,4-BZDs functionalized with 
an SF5 group.  
As position 7 is the most important position in terms of ligand binding affinity, we incorporated 
SF5 here, which is comparable to nordiazepam. The nordiazepam analogue was further modified at 
position 1 by N-methylation to obtain a diazepam analogue, and finally we modified a BZD 
derivative at position 2' via C-H activation (Figure 5.7). 
 
  


















5.2 Results and Discussion 
5.2.1 Synthesis 
The original synthesis of 1,4-BZDs was described when L.H. Sternbach and E. Reeder212 attempted 
to prepare secondary amino derivatives of quinazoline 3-oxides as part of a project to develop new 
tranquilizers. 6-Chloro2-chloromethyl-4-phenylquinazoline 3-oxide (5.2, Scheme 5.1) was treated 
with primary amines to obtain the expected products in a few cases (5.2a). In addition to this, they 
observed a different compound in all the reactions. The infrared and ultraviolet absorption spectra 
indicated a structural change in these compounds; to be specific, a ring enlargement (Scheme 5.2). 
In, fact these compounds were 2-amino derivatives of 7-chloro-5-phenyl-3H-l,4-benzodiazepine 4-
oxide (5.2b).212 
  





































Scheme 5.2: Mechanism showing formation of chlordiazepoxide213 
 
To investigate the unfamiliar side products formed, Sternbach and Reeder reacted 6-chloro-2-
chloromethyl-4-phenylquinazoline 3-oxide with methylamine. The reaction only generated the 
rearranged 7-membered ring also in high yields (Scheme 5.3). 
 
  














































































Later they realised that 1,4-BZDs possessed much more pronounced pharmacological activity than 
benzodiazepine 4-oxides of the type 5.2c.204 Hence, a large number of 1,4-BZDs were synthesised. 
Scheme 5.4 shows the earliest methods to synthesise diazepam, developed by Leo. H. Sternbach 
and colleagues. 2-Aminobenzophenones were treated with glycine ethyl ester hydrochloride in 
pyridine to yield 1,4-BZDs in a single step, generally in yields of about 50%.214 
 
 
Scheme 5.4: Routes to diazepam developed by Hoffmann-La Roche Inc. 
 
In 1971 Sternbach et.al. devised an improved multi-step route to synthesise 1,4-BZDs, which 
furnished the desired products in overall yields frequently exceeding 70%. An example of this 






























































Scheme 5.5: A multi-step route to synthesise 1,4-BZDs215 
Other approaches utilised N-protected, such as benzoxycarbonyl, phthaloyl, or azido, glycine 
derivatives, to first synthesise the intermediate (5a) followed by deprotection and cyclisation 
(Figure 5.8).204  
  
Figure 5.8: N-protected glycine derivatives. 
 
Subsequently in 1976, Hoffmann-La Roche Inc., published an approach that utilises 
hexamethylenetetramine to synthesise 5-phenyl-1,4-benzodiazepines (Scheme 5.6).216 It was stated 
that this approach gives good yields when the nitrogen on 5a is substituted, especially methylated. 









































Scheme 5.6: Preparing 1,4-BZD with hexamethylenetetramine 
In 2011,  a one pot, microwave mediated synthesis of 1,4-BZDs of the type 5.4a was reported by 
Mwande-Maguene et al.217 The reactions were reported to give good yields (80-86%), in less than 
an hour.  
Microwave mediated reactions are preferred over conventional heating methods because, they 
generally produce clean and high yielding reactions in minimum time.218 For this reason, we opted 
for a one pot microwave route to synthesise SF5-substituted BZD analogues. 
Commercially available 2-amino-5-pentafluorosulfanyl-benzophenone was coupled under 
microwave irradiation with Boc-Gly-OH, and DCC as the coupling agent, in toluene at 150 °C for 
30 min, followed by Boc-deprotection with TFA.42,219 However, the attempt was unsuccessful and 
one speculation for the failure was the poor nucleophilicity of the aniline. To validate this 
hypothesis, we attempted the same reaction with 2-amino-5-nitrobenzophenone as the nitro group 
has an electronic effect fairly close to that of the SF5 group (sp = 0.68211 for SF5 and sp = 0.78220 
for NO2). The result was, as postulated, unsuccessful.  
Although position-8 on the BZD ring was not a region of interest in terms of biological activity, we 
were curious about the electronic effect a pentafluorosulfanyl group would lead to at this position. 
Again, we used the microwave approach for the attempted synthesis of 5.5b (Scheme 5.7).  
The reaction was moderately successful with 5.5b formed in 13% yield with a purity of only 88% 
by LCMS. The unsubstituted benzodiazepine 5.5a was synthesised in 65% yield.  
 
  
















X = Cl, CF3, NO2, Br, CH3, H
R = lower alkyl group: MeOH, EtOH
5.4 5.4a
ONH2 i) Boc-Gly-OH, EEDQ, toluene
µW, 150 oC, 0.5 h





5.5a; R1, R2 = H; 65%
5.5b; R1 = SF5, R2 = H; 13%
5.5c; R1 = H, R2 = SF5; no reaction








Unperturbed in this approach, we next attempted the microwave mediated route, utilizing 5.5 and 
Boc-Gly-OH but with EEDQ as the coupling agent (Table 5.1). Moreover, the coupling reaction 
mixture was worked up and the anticipated intermediate was isolated and purified before 
continuing to the next step, viz.  Boc-group deprotection. This would enable us to establish whether 
this initial coupling step was responsible, or the cyclisation step, for the poor overall yield. We 
found that the coupling step was very low yielding for the reaction of 5.6b and the reaction was 
also, disappointingly, again, unsuccessful for 5.6c. 
 










Table 5.1: Boc-Gly-OH coupling reactions 
As the microwave approaches on the SF5 derivatives were unsuccessful, yet worked on a standard 
1,4-BZD core (entry 1),  it was decided to synthesise the desired products using other approaches. 
 
As above, a method published by Hoffmann-La Roche, using hexamethylenetetramine with 
ammonia as a reagent, was reported to be successful even for starting materials with electron-
withdrawing substituents. This method was also reported to give good yields although none were 
stated. Accordingly, this was our next method of choice.  
ONH2 Boc-Gly-OH, EEDQ 
CH2Cl2

























Scheme 5.8 shows the multi-step route to synthesise a SF5-substituted nordiazepam analogue 
(5.5c). 5.7 was acylated using chloroacetyl chloride then aminated with hexamethylenetetramine in 
the presence of ammonia (Scheme 5.8). Analysis of the crude mixture, gratifyingly, showed the 
presence of the expected product as well as a similar by-product, which we tentatively assigned the 
structure (5.7b), notably by the similarity of its 1H NMR spectrum to that of its 4-chloro-derivative 
(5.8, Figure 5.13). The two products could be separated after a normal phase and a reverse phase 
column chromatographic purification. Formation of side products221 of the type 5.7b has been 
reported in Sternbach’s paper but as a rare occurrence. 214 5.7b was observed each time this 
reaction was carried out. A similar side reaction was observed when 2-amino-4-
pentafluorosulfanyl-benzophenone was reacted. 
 
 
Scheme 5.8: Multi-step synthesis of SF5 substituted nordiazepam 
  
The 1H NMR and 13C NMR spectra of 5.5c and 5.7b are very similar. The obvious difference 
between these structural isomers would be the absence of a CH2 in the case of 5.7b. However, the 
NH2 peak appears around the same region as the CH2 on 5.5c. Another notable difference is the 
distinct chemical shifts of the two NH peaks; NH on 5.7b appears around d= 12.2 ppm, whereas the 
NH peak of 5.5c appears around d = 10.5 ppm. The presence of NH2 at d= 3.19 as well as the 
second aromatic ring that is closer, further deshields the NH proton, and so, the chemical shift is 
shifted more downfield (d= 12.2 ppm). Figure 5.9 shows the proton NMR spectrum of the mixture 
of the two compounds in deuterated methanol and Figure 5.10 highlights the NH2 and CH2 peaks of 

































Figure 5.9:1H NMR spectra of 5.5c and 5.7b mixture in CD3OD 
 
 
Figure 5.10: Comparing NH2 and CH2 peaks of 5.5c and 5.7b from 1H NMR mixture 
 
Compound 5.5c was crystallised by diffusion method using hexane and DCM to obtain colourless 
crystals and this confirmed both the regiochemistry of the SF5-substituent and the formation of the 







We were not successful in growing a crystal of compound 5.7b. A 1H NMR sample of the latter, in 
CD3CN, was subjected to a D2O shake (Figure 5.12) and, as expected, the NH2 peak significantly 
diminished, after hydrogen exchange for deuterium, with its integration reducing from around 2H 
to 0.18H. At the same time the NH peak at d =10.28 ppm disappeared. 




Figure 5.12: Comparing 1H NMR of 5.7b before and after  D2O shake in CD3CN 
 
The 1H NMR spectrum of 5.7b was comparable with that of a similar Cl-substituted compound, 
from the literature (5.8, Figure 5.13).  
 

















Tables 5.2 and 5.3 show proton NMR assignment of compounds 5.8 in CDCl3222 and 5.7b in 






















A mechanism proposed by Nikola Blazevic et al. in 1979223 for the formation of 1,4-BZD in the 
presence of hexamethylenetetramine is shown in Scheme 5.9. It also shows the formation of the 
side product when two equivalence of a base is present.  
The initial step of the mechanism shows a nucleophilic substitution which proceeds via SN2. 
However, the carbonyl used is too poor a nucleophile and is unlikely to react in an SN2 fashion 
therefore, we believe the reaction would rather proceed via an SN1 (Scheme 5.10). In addition the 
carbocation generated can be stabilized by the a nitrogen, and the reaction is in polar protic 
condition which favours SN1. 
According to the proposed method (Scheme 5.9), after the formation of 5.21, it undergoes 
alcoholysis to give the desired 1,4-BZD. Nikola Blazevic et al. reported that the formation of side 
product is due to the presence of base in the reaction. They refluxed the hexaminium salt in ethanol 
without any ammonia present and reported 1,4-BZD as the only product formed and in good yields, 
unless the equivalence of alcohol used for the solvolysis was insufficient. We propose a different 
Chemical shift 
(ppm) 




12.11 s 1  NH 
    7.61-7.20 m 7  ArH 
7.03 d 1 2.1 ArH 
4.44 s 2  NH2 
Table 5.2: 1H NMR assignment of 5.8 
Chemical shift 
(ppm) 




10.28 s 1  NH 
7.64-7.60 m 3  ArH 
7.56-7.52 m 1  ArH 
7.39-7.35 m 3  ArH 
7.31 d 1 2.5 ArH 
4.69 s 2  NH2 
Table 5.3: 1H NMR assignment of 5.7b 
121 
 
route towards the formation of the side product in Scheme 5.11. In the presence of ammonia, an 
enolate is generated which undergoes an aldol condensation followed by alcoholysis of 


















































































Scheme 5.11: Proposed mechanism for the formation of the side product 
 
 
Hexamethylenetetramine can hydrolyse to ammonia and formaldehyde. Formaldehyde is capable 
of reacting with 2-chloroacetamidobenzophenone to form imidazolidinones.224 In 1976, a patent 
published by Hoffmann-La Roche216 states that reacting compound of type 5.7a (Scheme 5.8) with 
hexamethylenetetramine in the presence of ammonia gives improved yields compared to their prior 
art which utilizes hexamethylenetetramine alone to synthesise benzodiazepines. Ammonia assisted 
reactions were said to be good especially when position 1 of BZD is substituted. When position 1 is 
non-substituted, the hydrogen and oxygen forms a hydrogen bond and the electron withdrawing 
capability of group X determines the strength of this bond. Highly electron withdrawing groups 
weaken the N-H bond, thus making the hydrogen bond stronger. This favours reaction with 













































































formaldehyde formed, preventing imidazolidinone formation. Other side products such as 
quinazolines were reported by G.M. Clarke et al. although these were not observed in our 
experiments.224   
In the above mentioned patent, the characteristic of solvent was stated as inert organic. The only 
requirement of the solvent is to dissolve the starting materials. Some of the solvents that could be 
used as reported were any lower alcohols such as methanol, ethanol, propanol, etc.216  
According to G.M. Clarke et al., formation of the side product proceeds via an epoxide 
intermediate (Figure 5.15). They also conveyed a dubiety towards the mechanism proposed by 
Nikola Blazevic et al as the intermediates from the proposed mechanism were not observed in their 
hands.  
From a crude 1H NMR spectrum of our reaction mixture, we only observed formation of 1,4 
benzodiazepine and phenylquinolone together with 2-aminoacetamidobenzophenone. No epoxide 
was observed in our reactions.  
 
 
Figure 5.14: Intermolecular hydrogen bonding between N-H-O that favours the formation of imidazolidinone  
  
   
Figure 5.15: 3,4-epoxyquinolone Intermediate  
 
After the success with synthesising a SF5 containing nordiazepam analogue, we moved on to 
addressing the methylation of it to form the diazepam counterpart. A standard N-methylation route 



















   
Scheme 5.12: N-methylation to form SF5-diazepam 
The reaction was low yielding, again attributed to the electron poor ring. The yield calculated on 
recovered starting material is, however, 92%. 
 
Functionalisation at position 2' with bulky and electrophilic substituents is desirable, as previously 
mentioned. Functionalised aromatic rings could make a good choice of substituent at this position. 
The aromatic ring can be made bulky and/or electrophilic. Introducing an aryl group at the 2'- 




Scheme 5.13: Multi-step route to arylate at position 2' 
The above route requires cryogenics, dry conditions and an acidic work up to yield the desired 
benzophenone. Having a bulky and electrophilic group on the benzophenone might also negatively 
affect the yield of the repetitive coupling, cyclisation steps to follow. When a range of ortho-
substituted BZDs need to be generated, the above approach seems inefficient as these groups need 
to be coupled early on in the reaction. In addition, commercially available SF5 containing aromatic 
building blocks are limited and expensive. 
A better route to synthesise compounds of type 5.10c would be to arylate in the last step. This 
would add atom and step economy. Late stage C-H activation to functionalise BZDs is an explored 
and established method within the Spencer group.225,226,227 We were also interested in knowing if 





































Our initial approach was to use visible-light catalysed procedure mediated by a Ru photocatalyst 
and Pd catalysis, as well as involving an available diazonium salt; 4-methoxy-benzenediazonium 
tetrafluoroborate.226 The reaction was refluxed for 12 hours in methanol and the light source used 
was a 26W bulb (Scheme 5.14). However, the desired product was not obtained. To our surprise, 
instead of the arylated product we isolated 5.7. The product was characterised by 1H NMR 




Scheme 5.14: Photocatalyzed Pd-mediated route for C-H activation 
Sternbach et al. has reported mild acidic hydrolysis of 2-aminonitrobenzodiazepinones into 2-
aminonitrobenzophenones. Heating 5.5c for prolonged time (12 h) in the above conditions yielded 
5.7. 
We were curious to learn if the desired product could be synthesised with a short period of heating 
under the same conditions. Therefore, 5.5c was refluxed in MeOH for only 2 hours as shown in 
Scheme 5.15. 
  
Scheme 5.15: Photocatalyzed synthesis of arylated BZD 
Formation of product 5.11 was observed by LCMS (Figure 5.8). A peak with a retention time (tR) 
of 20.8 min showed a molecular mass for 5.11 at m/z = 468. The peak at tR 18.6 min indicated the 












































photocatalyzed C-H activation works on SF5 substituted 1,4-BZDs. Due to the expensive nature of 
the SF5 substituted amino benzophenone and the low yielding cyclisation step, we were reluctant to 




Figure 5.16: LCMS data showing the m/z of the desired product. 
 
The Spencer group have previously published another Pd mediated C-H activation involving 
microwave chemistry and iodonium salts.225 This method was appealing to us as it only used one 
metal catalyst and the work up was much simpler than the photocatalyzed method. An unoptimized 
attempt at Pd-catalysed C–H activation with iodonium salts, using our previously described 
conditions, involving microwave chemistry afforded the expected ortho-aryated product 5.12 
(Scheme 5.16). This illustrates that catalytic C–H activation chemistry is now amenable to the 
synthesis of polyfluorinated BZDs and 5.12 was now available for biological assay. 
  





5.2.2  Modelling 
The compounds were docked into the cryo-EM structure (PDB ID: 6HUP)193 of the α1β3γ2L 
GABAA receptor at the interfacial benzodiazepine binding site between the principal (+) α and 
complementary (−) γ subunit using Schrödinger Glide102,228. We evaluated their apparent binding 





















binding site of the receptor and produces a set of initial ligand conformations. However, the task of 
accurately estimating protein ligand binding affinities is beyond the capabilities of docking scoring 
functions and, hence Glide scores are not always congruent with experimental data. 
 
A Glide score was determined for compounds 5.5c, 5.5e and 5.12 and was compared against 
diazepam and the metabolite, nordiazepam (Table 5.4). Diazepam showed similar binding in 
comparison with the SF5-substituted diazepam (5.5e) analogue. The SF5-substituted nordazepam 
analogue (5.5c), however gave a better Glide score suggesting it binds stronger than diazepam in 
the binding site. The Glide score of the ortho C-H activated analogue (5.12) was (-3.98 kcal/mol) 
very poor in comparison. 










































Table 5.4: Glide score of diazepam versus SF5-substituted BZDs 
Figure 5.17 shows diazepam interacting with the amino acid residues in the α1β3γ2L receptor. The 
dashed lines indicate hydrogen bonds and p-p interactions. The chlorine atom interacts with the 
αHis102 side chain. The distance between the chlorine atom and the nitrogen on the αHis102 was 
measured as 2.89 Å. According to the literature, the polarized N-methyl group forms hydrogen 
bonds with Thr206, Tyr209 and the backbone of Tyr159 in a C-H----O fashion.229 However, no 
such hydrogen bond interactions were observed in our modelling study. 
 
Poses of 5.5c, 5.5e as well as their superpositions with diazepam and nordiazepam with the best 
Glide score docked in the α1β3γ2L receptor are shown in Figure 5.18.  
The images show that there is no interaction between SF5 and the amino acid side chains. 
A direct comparison of 5.5e and diazepam can be made. We calculated the distance between SF5 
and αHis102 to be 5.34 Å. This was calculated between the closest fluorine to αHis102, and 
αHis102. This distance is almost double the distance between chlorine and αHis102 on diazepam 
(2.89 Å). This could explain the lack of interaction between SF5 and the αHis102. This applies to 
5.5c and 5.12, as well (Figure 5.18 and 5.19).  
The interaction of the chlorine in diazepam with the ring nitrogen on the histidine side chain can be 
defined as a halogen bond. The IUPAC definition of a halogen bond is: “a halogen bond occurs 
when there is evidence of a net attractive interaction between an electrophilic region associated 
with a halogen atom in a molecular entity and a nucleophilic region in another, or the same 
molecular entity.”230 In a halogen bond the distance between the halogen and the nucleophile is less 
than the sum of the van der Waals radii of the atoms. The sum of van der Waals radii between 
chlorine and nitrogen = 3.34 Å and the distance calculated between them = 2.89 Å.  
In contrast sum of the van der Waals radii between a F atom and nitrogen = 2.89 Å which is less 
than the distance between F on SF5 and nitrogen (5.34 Å). 
A halogen bond can also be described as a direct, non-covalent interaction between a nucleophilic 
region of a Lewis base with a halogen atom as a Lewis acid where the halogen atom is involved in 
a covalent bonding in an R-X manner (Figure 5.20, X = halogen). Anisotropic distribution of 
electronic charge around halogen atoms allows them to act as both a Lewis acid and base. Many 
covalently bonded halogens have positive electrostatic potential on their outer surface known as a s 









addition, they possess negative charge on their equatorial sides due to the lone pairs. As per s hole 
concept, fluorine lacks a positive s hole on the outer surface as its charge distribution is spherical 







Careful inspection of Figure 5.18d which shows an overlap of nordiazepam and 5.5c in the GABAA 
receptor site, reveals that due to the bulky size of SF5, the positioning of SF5-nordiazepam is 
slightly different to that of nordiazepam and the SF5 group is not oriented toward the nitrogen on 




























Figure 5.17: α1β3γ2L receptor in complex with 






Figure 5.18: Benzodiazepines in complex with α1β3γ2L receptor a) Brown dashed lines show hydrophobic clashes between diazepam’s (purple) 
chlorine and amino acid residues, His102, Val203, and Tyr210. b) diazepam (purple) overlapped with SF5-diazapam (5.5e, red). c) Interactions 
between nordiazepam (blue) and the benzodiazepine binding pocket and d) superposition of nordiazepam and SF5-nordiazapam (5.5c, pink). Yellow 
dashed lines indicate hydrogen bonds. Pi-pi interactions are indicated by blue dashed lines. SF5-diazapam and SF5-nordiazapam do not interact with 




Figure 5.19: 5.12 (Violet) in complex with α1β3γ2L receptor shows no interaction with His102. Aromatic hydrogen bonds are indicated 
by blue dashed lines. 
 
 
Figure 5.20: Demonstration of halogen bonding 
With the benzodiazepines to hand and predictive docking studies, our next obvious step was to test 
out compounds in an assay. Biological studies were performed by Dr Trevor Smart at UCL. 
To access functionality of the BDZ ligands, whole-cell patch-clamp recording from human 
embryonic kidney cells expressing recombinant α1β2γ2L GABAARs were used. The analogues, 
5.5c, 5.5e and 5.12 were compared to diazepam for their ability to potentiate 2μM GABA-induced 
currents (~EC6.5). The three SF5-diazepam analogues showed much lower potencies than diazepam 
(60- (5.5c), 70- (5.12), and 190-fold lower (5.5e)). The relative extent of potentiation  was very low 
for 5.12, ~half that of diazepam for 5.5e, or near equivalent with diazepam for 5.5c (Graph 5.1; 
Table 5.5). For 5.12, the efficacy level of the potentiation was reduced at the highest concentration 
of 100 μM (Graph. 5.1). Such inhibition has been reported before for benzodiazepines like 
diazepam and flurazepam and could reflect increased desensitization of GABAARs. From these 
data, it is clear that substituting Cl on the benzo ring for SF5 has a deleterious effect primarily on 
BDZ potency and to a large extent, also on their relative efficacy at GABAA receptors. This is 
likely to be due to disruption of the Cl – αH102 interaction, which is known to be critical for BDZ 























Graph 5.1: Whole-cell voltage-clamp tests of diazepam and the sulphur-pentafluoride diazepam analogues, 5.5c, 5.5e and 5.12 on 
α1β2γ2L GABAA receptors expressed in HEK cells 
 
 
Diazepam 5.5e 5.5c 5.12 
Maximum 
Potentiation 
133 ± 15 %  77 ± 20 %  138 ± 19 %  28 ± 2.5 %  
Potency 
pEC50 ± SEM 
(EC50) 
7.518 ± 0.067 
(30 nM)  
5.247 ± 0.121 
(5.7 μM)  
5.780 ± 0.043 
(1.7 μM)  
5.697 ± 0.076 
(2.0 μM)  
Number of cells 5 5 5 5 





Three SF5-substituted 1,4-BZDs were synthesised and were evaluated in silico and in vitro. 
Multiple approaches were tried before successfully synthesising the desired product; 5.5c. While 
synthesising the mentioned compound, we isolated compound 5.7b as a by-product. Synthesis of an 
Concentration-response curves of the potentiation effects by  diazepam, 5.5e, 

































































SF5 meta-substituted BZD (5.5b) was attempted but failed due to separation issues from the by-
product. N-methylated benzophenones when treated with hexamethylenetetramine gave 1,4 BZDs 
in good yields as reported by Blazevic and Sternbach. This may be a desirable approach for the 
synthesis of both the meta and para-SF5-substituted BZDs in the future. 
 
In silico calculations of the BZDs predicted that the SF5-substituted diazepam and nordazepam 
analogues are better or equivalent in activity in comparison with diazepam. However, in vitro 
binding studies showed the three SF5-diazepam analogues to have much lower potencies than 
diazepam. It can be appreciated that although Glide scoring is an ideal function for generating a 
library of compounds with potential biological activity by estimating binding affinity, it is not an 




5.4.1 Organic Chemistry 
 
All commercially purchased materials and solvents were used without further purification unless 
specified otherwise. NMR spectra were recorded on a Varian VNMRS 600 (1H 600 MHz, 13C 126 
MHz) and VNMRS 400 (19F 376 MHz, 2H 61 MHz and 31P 162 MHz) spectrometer and prepared 
in deuterated solvents such as CDCl3 and DMSO-d6. 1H and 13C chemical shifts were recorded in 
parts per million (ppm). Multiplicity of 1H-NMR peaks are indicated by s – singlet, d – doublet, dd 
– doublets of doublets, t – triplet, pt – pseudo triplet, q – quartet, m – multiplet and coupling 
constants are given in Hertz (Hz). Electronspray ionisation – high resolution mass spectra (ESI-
HRMS) were obtained using a Bruker Daltonics Apex III where Apollo ESI was used as the ESI 
source. All analyses were conducted by Dr A. K. Abdul-Sada. The molecular ion peaks [M]+ were 
recorded in mass to charge (m/z) ratio. LC-MS spectra were acquired using Shimadzu LC-MS 
2020, on a Gemini 5 m C18 110 Å. column. All X-ray analyses were performed at the UK National 
Crystallography Services, Southampton. Purifications were performed by flash chromatography on 












Triethylamine (188 mg, 1.86 mmol, 2.0 equiv.) was added to a solution of 2-benzoyl-4-
(pentafluoro-λ6-sulfanyl)aniline (0.300 g, 0.93 mmol, 1.0 equiv.) in dichloromethane (1 mL) and 
the mixture was stirred at room temperature. After an hour the mixture was cooled in an ice bath, 
and chloroacetyl chloride (0.210 g, 1.86 mmol, 2.0 equiv.) dissolved in dichloromethane (1 mL) 
and cooled in an ice bath was added dropwise to the reaction mixture. The reaction was stirred 
overnight at room temperature. The reaction was monitored by TLC and the crude was 
concentrated in vacuo and purified by flash chromatography (petroleum ether: ethyl acetate; 7:3) to 
obtain pure N-[2-benzoyl-4-(pentafluoro-λ6-sulfanyl)phenyl]-2-chloroacetamide as a clear solid 
(0.301 g, 0.75 mmol, 81%). Ammonium carbonate (0.360 g, 3.75 mmol, 5.0 equiv.) was suspended 
in a solution of ammonia (2M) in ethanol (5 mL) and stirred. Hexamethylenetetramine (0.531 g, 
3.75 mmol, 5.0 equiv.) was added and refluxed. After 5 minutes of refluxing, a solution of N-(2-
benzoyl-4-sulfur penta-fluoro phenyl)-2-chloroacetamide (0.301 g, 0.75 mmol, 1.0 equiv.) in 
dichloromethane (3 mL) was added and the reaction mixture was refluxed overnight. After cooling, 
the latter was concentrated in vacuo and dissolved in toluene (5 mL). p-Toluene sulfonic acid (6 
mg, 0.03 mmol, 0.04 equiv.), was added to the solution and the mixture was refluxed for 1 hour. 
The crude was concentrated in vacuo and purified over a column of silica (hexane:ethyl acetate; 
3:7), followed by a reverse phased column (C18, acetonitrile:water, 1:3) to obtain the pure product 
as a colourless solid (83 mg, 31%, 72 mg, 26% of N-(2-benzoyl-4-sulfur penta-fluoro phenyl)-2-
chloroacetamide recovered). 1H NMR (600 MHz, Chloroform-d) δ 9.40 (s, 1H, NH), 7.87 (dd, J = 
8.9, 2.6 Hz, 1H, ArH), 7.74 (d, J = 2.6 Hz, 1H, ArH), 7.53 – 7.50 (m, 2H, 2ArH), 7.50 – 7.47 (m, 
1H, ArH), 7.41 (m, 2H, 2ArH), 7.25 (d, J = 8.9 Hz, 1H, ArH), 4.37 (s, 2H, CH2); 13C NMR (600 
MHz, Chloroform-d) δ 172.1 (C=O), 169.8 (C=N), 148.1 (t, 1JF,C = 18.9 Hz, ArC-SF5), 141.0 
(ArC), 138.2 (ArC), 131.1 (ArC), 129.6 (2ArC), 129.5 (m, ArC), 129.1 – 129.01 (m, ArC), 128.5 
(2ArC), 126.8 (ArC), 121.5 (ArC), 56.7 (CH2); 19F NMR (376 MHz, Chloroform-d) δ 83.51 (q, J = 
150.5 Hz), 63.32 (d, J = 150.5 Hz); LCMS Purity (UV) = 96%, tR 18.1 min; HRMS - ESI (m/z) 
found 385.0404, calc. for [C15H11F5N2OS] [Na]+: 385.0404; IR (neat) νmax/cm-1: 3089 (N-H), 1687 




Sodium hydride (0.023 g, 0.94 mmol, 2.0 equiv.) was added to a solution of 5.5c (0.170 g, 0.47 
mmol, 1.0 equiv.) in dry THF (1 mL) and the mixture was stirred for 1 hour. Methyl iodide (0.133 







overnight. Crude product was washed with water (3 x15 mL), extracted with ethyl acetate (3 x15 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude was purified over a column 
of silica (hexane:EtOAc; 7:3) to obtain a colourless solid as the title compound (0.066 g, 37%). 1H 
NMR (600 MHz, Chloroform-d) δ 7.93 (dd, J= 9.1 Hz, 2.6 Hz, 1H, ArH), 7.73 (d, J= 2.6 Hz, 1H, 
ArH), 7.61 (m, 2H, ArH), 7.52 (m, 1H, ArH), 7.45(m, 3H, ArH), 4.90 (d, J= 11.0 Hz, 1H, CH), 
3.79 (d, J= 11.0 Hz, 1H, CH), 3.44 (s, 3H, CH3); 13C NMR (600 MHz, Chloroform-d) δ 169.8 
(C=O), 168.8 (C=N), 148.4 (C-SF5), 146.1(ArC), 137.7 (ArC), 131.1 (ArC), 129.4 (2ArC), 128.7 
(4ArC), 128.6(ArC), 121.2 (ArC), 56.9 (CH2), 34.9 (CH3); 19F NMR (400 MHz, Chloroform-d) δ 
83.10 (p, J= 150.4 Hz), 63.23 (d, J= 150.4 Hz); LCMS Purity (UV) = 96%, tR 19.5 min; HRMS -
ESI(m/z) found 377.0749, calc. for [C16H13F5N2OS][H]+:377.0742; IR (neat) νmax/cm-1: 1682 





5.5c (86 mg, 0.24 mmol, 1.0 equiv.), bis(2‐fluorophenyl)iodonium tetrafluoroborate (145 mg, 0.36 
mmol, 1.5 equiv.) and glacial acetic acid were combined in a 10 mL microwave vial. The vial was 
degassed and purged with argon before adding palladium (II) acetate (7 mg, 0.0089 mmol, and 0.01 
equiv) and stirring at 125 °C in the microwave for 1 hour. Thereafter, the cooled reaction mixture 
was filtered through celite, washed with dichloromethane (50 mL) and concentrated in vacuo. The 
residue was dissolved in dichloromethane (15 mL), washed with sodium bicarbonate (20 mL) and 
the aqueous layer extracted with dichloromethane (20 mL x 3), dried over MgSO4, filtered and 
concentrated in vacuo. The bright red oil was purified over a column of silica (hexane:EtOAc; 1:4) 
to obtain a colourless solid as pure product (0.024 g, 22%). 1H NMR (600 MHz, Chloroform-d) δ 
9.49 (s,1H, NH), 7.82 –7.74 (m, 1H, ArH), 7.58 –7.53 (m, 2H, 2ArH), 7.50 (dd, J= 8.9, J=2.5 Hz, 
1H, ArH), 7.34 –7.30 (m, 2H, 2ArH), 7.07 –7.01 (m, 1H, ArH), 6.92 –6.84 (m, 2H, ArH), 6.78 (d, J 
= 8.9 Hz, 1H, ArH), 6.75 (pt, J = 9.0 Hz, 1H), 4.32 (s, 2H, CH2);13C NMR (600 MHz, Chloroform-
d) δ 171.1 (C=O), 170.9 (C=N), 158.7 (ArC-F, d, 1JF,C= 247.6 Hz), 148.6 –148.0(ArC-SF5), 139.5 
(ArC), 138.9 (ArC), 135.7 (ArC), 131.3 (ArC), 131.0 (ArC),130.4 (ArC), 130.2 (ArC), 129.5 (ArC, 
d, 3JF,C= 7.9 Hz), 128.5 (2ArC), 128.2 (ArC), 127.8 (ArC, d, 2JF,C= 15.6 Hz), 127.6 (ArC), 123.7 
(ArC), 120.5 (ArC), 115.0 (ArC, d, 2JF,C= 22.0 Hz), 56.5 (CH2); 19F NMR (376 MHz, Chloroform-
d) δ 83.40 (p, J= 150.7 Hz, axial F), 63.07 (d, J= 150.7 Hz, equatorial F); LCMS Purity (UV) = 









(neat) νmax/cm-1: 3064 (N-H), 1704 (C=O), 1616 (C=N), 1336 (C-F), 836 (S-F); mp = 190 – 191 
°C. 
 
5.4.2 Computational ligand docking  
Docking was performed using the solved cryo-EM structure of the α1β3γ2L receptor in complex 
with GABA and diazepam obtained from PDB (ID: 6HUP). The software used was Schrodinger 
Glide. 
 
5.4.3 Cell culture and recombinant GABAAR expression 
HEK cells were maintained at 37°C, 95% CO2 / 5% O2 in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% v/v fetal bovine serum and 100 U/ml penicillin/100 μg/ml 
streptomycin. Cells were transfected with cDNAs encoding enhanced green fluorescent protein 
(EGFP) and murine α1, β2, γ2L GABAAR| subunits in a 1:1:1:1 ratio using a standard calcium-
phosphate precipitation method. 
 
5.4.4 Electrophysiology experiments 
Whole-cell patch clamp recording from HEK cells was used to study GABAA receptor currents as 
described previously231 using an Axopatch 200B Axon Instruments amplifier. Patch pipettes 
(resistance 3-5MΩ) were filled with a solution containing (mM): 120 KCl, 1 MgCl2, 11 EGTA, 30 
KOH, 10 HEPES, 1 CaCl2, and 2 adenosine triphosphate; pH 7.11. The cells were continuously 
perfused with Krebs recording solution containing (mM): 140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.52 
CaCl2, 11 Glucose and 5 HEPES; pH 7.4. diazepam and SF5-analogues were first dissolved in 
DMSO (stock), and for functional electrophysiology experiments subsequently diluted at least 
1000-fold in Krebs solution. Drug solutions were applied to recording cells via a Y-tube 
application system[30].  
 
The potentiating effects of diazepam, and analogues 2c, 5c and 6c were evaluated in the presence 
of 2 µM GABA which was equivalent to a current approximately 6.5% of the GABA maximum 
response (EC6.5). The efficacy and potency for the potentiation by each ligand was established by 
fitting curves to the GABA current response-concentration relationship data points from each of the 
five individual experiments using the Hill equation, I / Imax pot = (1 / (1 + (EC50 / [L])n). The ligand 
potency, EC50, represents the concentration of the ligand ([L]) inducing 50% of the maximal 
potentiation current (in the presence of 2 µM GABA), and n is the Hill slope. 
Since concentration response EC50 data are distributed on a logarithmic scale, we converted these 
to pEC50 values (pEC50 = -log(EC50)) which are distributed on a linear scale. From pEC50 values we 
calculated mean values ± sem, and to facilitate data-interpretation we re-transformed these mean 
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pEC50 values into mean EC50 values (Table 2). The relative efficacy for GABA current potentiation 




































Chapter 6.0 Conclusion, Future Directions and Thesis Outcome 
 
The importance of halogen containing fragments, and in particular, fluorine’s role in medicinal 
chemistry was described in Chapter 1.4,232–234 Recent years have seen a rise in molecules substituted 
with pentafluorosulfanyl (SF5) groups,22,235 as direct access to aryl- and alkyl-SF5 building blocks 
has been achieved.31,236 Despite their popularity, SF5 containing arenes remain an underdeveloped 
class of compounds in medicinal chemistry, mainly due to difficulty accessing the respective building 
blocks. Therefore, this thesis aimed to expand the repertoire of SF5 in medicinal chemistry while 
exploring SF5 as a bioisostere. In accord with the project’s aim, a series of SF5-substituted aromatic 
compounds have been synthesised, some of which are SF5 analogues of known drugs (teriflunomide, 
leflunomide, semaxanib, diazepam, and nordiazepam), while utilizing microwave and 
mechanochemistry when possible. 
 
Chapter 2 discussed the scope of SF5 as a bioisosteric replacement in leflunomide and it’s active 
form, teriflunomide (Figure 6.1). Compounds 2.5 and 2.6 (mentioned in Chapter 2) were synthesised 
and a biophysical assay conveyed an approximate two-fold greater affinity for 2.6 towards HDHODH 
compared with teriflunomide. Molecular binding studies also revealed that the bulky SF5 group fills 




Figure 6.1: Leflunomide, teriflunomide and their SF5 analogues 
 
Johnson et al.108 screened a series of compounds similar to teriflunomide, against P. falciparum 
DHODH (PfDHODH) as well as the human DHODH (HDHODH). The series revealed that having 
a cyclopropane (compound 6.1) in the place of the methyl group enhances binding affinity (Figure 
6.2). Furthermore, replacement of CF3 on teriflunomide with a phenyl significantly improved binding 
























Figure 6.2: Teriflunomide vs cyclopropane analogue (6.1) 
 
 
Figure 6.3: Binding affinity of 6.2 towards PfDHODH & HDHODH 
 
Future studies on this work could involve synthesis and analysis of compound 6.3 and 6.4 for their 
HDHODH binding affinity (Figure 6.4). 
 
Figure 6.4: Compounds 6.3 and 6.4 
Chapter 3 discussed the synthesis of a library of SF5-comprising small molecules via a simple amide 
bond construction. The synthesis involved coupling of amines such as morpholine, piperazine, 
piperidine, and pyridine with 3 and 4-SF5-benzoyl chlorides. To aid coupling of hydrolysed acid 
chlorides, HATU (hexafluorophosphate azabenzotriazole tetramethyl uronium), was used. In order 
to ease purification, solid supported scavenger resin, MP-Trisamine (microporous polystyrene-bound 
nucleophilic scavenger), was used to remove unreacted acid chloride from the reactions.237  
A collaboration with the Covid Moonshot Consortium which is an open source initiative, lead to the 
synthesis of a couple of compounds related to TRY-UNI-714a760b-6. TRY-UNI-714a760b-6 is a 
non-covalent Mpro inhibitor. Compounds 3.3c and 3.3d were synthesised and analysed for their 
affinity towards Mpro binding site (Figure 6.5). A fluorescence assay revealed that compounds 3.3c 
and 3.3d does not satisfactorily inhibit Mpro. Analysis of similar compounds, TRY-UNI-714a760b-
20 (Figure 6.6), indicated that replacing chlorine on TRY-UNI-714a760b-6 with electron 








Teriflunomide, R1; = Me, IC50; PfDHODH = 190.1 µM, HDHODH = 0.261 µM


























Figure 6.5: TRY-UNI-714a760b-6 and related compounds 3.3(c-d) 
 
 
Figure 6.6: Comparing IC50s of TRY-UNI-714a760b-6 & TRY-UNI-714a760b-20 
 
Chapter 4 described the synthesis of a series of SF5 substituted oxindoles to expand the repertoire 
of pentafluorosulfanyl chemistry in medicinal chemistry. Included in the series were two SF5 
cognates of Semaxanib.165 Using molecular modelling and a radioactive kinase assay we compared 
activities of Semaxanib  and its SF5 counterparts in the VEGFR2 binding pocket to learn that SF5 is 
too bulky a substituent to occupy the ATP-binding site, and in particular, it impedes the ligand’s 
ability to interact with the adenine pocket. In addition,  a NO2-substituted oxindole, and SF5-
substituted spirooxindoles were synthesised via Knoevenagel condensation. The reaction was 
performed using microwave chemistry as well as mechanochemistry. Synthesis via 
mechanochemistry was successful when one of the reagents used was a liquid. Liquid assisted 
grinding could be employed to facilitate Knoevenagel condensation where, all the reagents are of 
solid state. 
Analysis of SF5 as a bioisostere was accomplished by replacing chlorine and nitro groups in Chapter 
5 through developing SF5-substituted analogues of nordiazepam and diazepam (5.5c and 5.5e). 
Benzodiazepine was functionalised at positions 1, 7 and 2’ (Figure 6.7). Late stage C-H activation 
was performed on SF5-substituted nordiazepam (5.5c) via a microwave route as well as a visible-
light catalysed procedure, while refluxing in methanol, to modify at position 2’. Both routes would 
yield the desired product however, heating 5.5c for a prolonged time under the condition described 







3.3c; R = CF3






















Figure 6.7: Benzodiazepine 
In vitro binding studies showed the three SF5-diazepam analogues (5.5c, 5.5e, & 5.12) to have 
much lower potencies than diazepam. Substituting Cl on the benzodiazepine ring for SF5 has a 
damaging effect on BZD potency as well as on their relative efficacy at GABAA receptors. The Cl - 
αH102 interaction is known to be critical for BZD modulation at GABAA receptors. This 
interaction has been disrupted when substituted with SF5 due to its bulkiness. The distance between 
F and αH102 is too big for forming interactions.  
As substitution of a bulky and electrophilic group at position 2' is known to improve the activity of 
the ligand, we propose synthesis of compound 6.5 (Figure 6.8).  
 
 
Figure 6.8:SF5-substituted at position 2’ 
 
The distance calculated between chlorine of compound 6.5 and His102 is 2.71 Å which is smaller 
than the distance between chlorine and His102 in diazepam (2.89 Å) and the Glide score obtained 
for this docking is -5.21 kcal/mol which is more negative than the one obtained for diazepam. This 
suggests that this compound might serve to be an adequate binder in the GABAA receptor, 
however, it is not conclusive and synthesis of the compound in question is required. Unfortunately, 
the SF5-containing starting material required to synthesis this compound is not commercially 
available, moreover, an expensive Home Office Scheduled Drugs License would probably be 




























Figure 6.9: Compound 6.5 in complex with GABAA receptor 
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